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Abstract 
 
In recent decades more soldiers are being mobilized to conflict areas, such as the 
over 2 million service members, who have been deployed to Iraq and Afghanistan since 
October 2001, which includes but is not limited to Operation Enduring Freedom (OEF) 
and Operation Iraqi Freedom (OIF); or the 700,000 service veterans deployed to the 
Persian Gulf War in 1990-91 in the US. The UK mobilized over 46,000 military 
personnel to Iraq, 9,500 British troops to Afghanistan and 50,000 troops to the Gulf War. 
Soldiers are being exposed to traumatic events such as physical and psychological 
trauma, as well as chemical exposure and therefore service members are at risk of post-
deployment health-related issues, associated commonly with post-traumatic stress 
disorder (PTSD) and traumatic brain injury (TBI) among OEF/OIF veterans, as well as 
Gulf War Illness (GWI) among the Persian Gulf War Veteran population.  
Although progress has been made in identifying underlying pathology for TBI and PTSD 
and acute as well as sub-acute biomarkers have been identified, with commercially 
available tests on the horizon, the work presented here addresses a critical but under-
investigated issue, the need for chronic biomarkers for these conditions, as they can go 
undetected for an extended period of time. Additionally, more evidence has surfaced that 
discusses how symptoms related to mild TBI (mTBI) can last for years after the insult, 
emphasizing the importance of investigatjng biomarkers at a late timepoint after injury 
as, owing to the mild nature of the injury, the condition was often undiagnosed at the 
time. PTSD itself still lacks an objective measure that can capture its complexity, 
whereas co-morbidity of PTSD with TBI further complicates the issue. The other 
mentioned militarily relevant condition, termed GWI, faces similar issues. Veterans 
 7 
deployed to the Persian Gulf War in 1991 suffer from a disease that has shown to exhibit 
persistent multisymptom complexity. No biomarker has been identified for this particular 
population thus making objective diagnosis difficult. 
Besides the identification of clinical biomarkers, much research has been done in 
preclinical models, yet there is still a need to verify and validate such animal models in 
order to demonstrate their utility. Once the validity of a preclinical model has been 
confirmed, investigation of pathogenic mechanisms in those models has the potential to 
reveal therapeutic targets of relevance to the human condition. 
Chapter 1 will discuss epidemiology, current clinical diagnosis and 
pathophysiology of TBI, PTSD and GWI as well as the status of biomarker research in 
each of these three areas. The thesis then focuses on the identification of plasma 
biomarkers in human patient populations, specifically in military populations suffering 
from TBI, PTSD or both at chronic time points post traumatic exposure (Chapters 2 & 3). 
In Chapter 4, we then explore whether or not such changes are present in our established 
animal model of TBI.  In Chapter 5 we investigate peripheral biomarkers in plasma 
samples from Gulf War veterans and in two animal models of GWI. Given the 
complexity of TBI, PTSD and GWI clinical presentation and pathogenesis and their 
heterogeneity in human populations, it is anticipated that a valid biomarker for broad 
application will in fact require assessment of many markers to create a panel that can 
support diagnosis.  The lipidomic and proteomic analyses I employed in this work are 
approaches with the required breadth and lack of bias to be successful in such an 
undertaking, and I hope that the work described in this thesis provides a foundation for 
future development of such biomarker panels. 
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POMS Profile of Mood States  
PSQI Pittsburgh Sleep Quality Index  
PTSD Posttraumatic Stress Disorder 
PUFA Polysaturated fatty acid 
PVN paraventricular nucleus  
r-mTBI repeated mild TBI 
RAC Research Advisory Committee  
RB Resuspension Buffer 
ROC Receiver Operating Curve 
ROS Reactive Oxygen Species  
S100β S100 Calcium-Binding Protein β 
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SBDP Spectrin breakdown product 
SCID In-source collision induced dissociation  
SDC Sodium deoxycholate  
SDS-
PAGE 
Sodium odecyl sulfate polyacrylamide gel 
electrophoresis 
SEM Standard Error of the Mean  
SF-36V MOS Short Form 36-veteran version 
SFA Saturated fatty acid 
SM Sphingomyelin  
SNTF α-spectrin N-terminal fragment  
SOP Standard Operation Procedure 
SPECT Single Photon Emission Tomography  
TBA Thiobarbituric Acid  
TBARS Thiobarbituric Acid Reactive Substances  
TBI Traumatic Brain Injury 
TCEP Tris(2-carboxyethyl)phosphine  
TEAB Triethylammonium Bicarbonate  
TGF  Transforming growth factor 
TMB 3,3′,5,5′-Tetramethylbenzidine  
TMT Tandem Mass Tag 
TNF Tumor Necrosis Factor  
UCH-L1 Ubiquitin C-terminal hydrolase  
USAAARL United States Army Aeromedical Research Laboratory 
VA Veterans Affairs 
VAS Visual Analog Scale  
VEGF Vascular endothelial growth factor  
VLDL Very low-density lipoprotein  
WHO World Health Organization  
ZAS Zung Anxiety Scale  
ZDS Zung Depression Scale  
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Chapter 1 Introduction 
1.1 Epidemiology of TBI and PTSD and their comorbidity 
 
Traumatic brain injury (TBI) is a major cause of disability and death among 
young adults in the US and worldwide, and its prevalence is increasing 1,2. In 2008 the 
Center for Disease Control and Prevention estimated over 1.7 million occurrences of TBI 
in the US per year 3 and 214,000 in the UK 4 with 5.3 million Americans (1 million in the 
UK) living with long-term severe disabilities as a result of brain injury. Moreover, in the 
US up to 275,000 hospitalizations and 1,365,000 emergency department visits are due to 
TBI 3,6.  
Besides its importance for the civilian population, TBI has been termed the  
"signature injury" of the wars in Iraq and Afghanistan with over 19% of returning service 
members diagnosed with a deployment-related TBI 7.   
Economic costs of TBI account for 10% of the annual health care budget 
amounting to approximately US$ 76.3 billion 8,9. Furthermore, each veteran affected by a 
TBI creates an average annual cost of $11,700 in medical treatment 10. Additionally, the 
World Health Organization (WHO) estimates that, by 2020, TBI will become the third 
leading cause of disability and mortality worldwide, further raising costs in the future 11. 
 Faul et al, defined TBI as the “silent epidemic”, due to the fact that complications 
from mild injury may not be readily apparent 3. Furthermore, awareness about TBI 
among the general population is still limited, although the recent case reports of a distinct 
neurodegenerative disease in American football players, termed “chronic traumatic 
encephalopathy” (CTE), has increased awareness of the consequences of exposure to a 
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history of repetitive concussions 12–15. Other popular sports, including boxing, ice hockey, 
soccer, rugby, the martial arts, cycling, motor racing, equestrian sports, rodeo, skiing and 
roller skating also contribute to increasing numbers of TBI 16. These together underscore 
the vital need to understand the underlying neurobiological mechanisms in TBI and to 
identify new novel biomarkers and therapeutic targets for objective diagnosis and 
treatment.  
Severity of injury in TBI correlates with cognitive and motor function limitations. 
A study by Colantonio and colleagues, which investigated long-term outcomes after 
moderate to severe TBI, revealed that among the 306 patients evaluated up to 24 years 
post-injury, only 29% had returned to full-time employment and still experienced 
limitations in daily life 17.  Most TBIs are categorized as mild (~80%), which is the most 
challenging to diagnose, monitor and treat 18. In the majority of mTBI patients 
neurocognitive impairment is temporary, with resolution within days to weeks post-injury 
and no visible evidence of degenerative changes from brain imaging tests 19. Although 
studies have shown that most patients make a full recovery within 3 months of injury, 
additional research indicates long-term molecular and cellular damage that may persist 
for years with approximately 15%–25% of mTBI cases experiencing ongoing symptoms, 
which could cause significant disability 19,20. These somatic, cognitive, emotional, motor, 
or sensory symptoms ascribed to a concussion (or following TBI) are termed post 
concussion syndrome (PCS).  
In 2004 The World Health Organization published a detailed review of the 
literature consisting of 120 studies on the prognosis after mTBI. Symptoms usually fall 
into three categories: somatic (e.g., headache, dizziness, weakness, sensitivity to light and 
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sound), cognitive (e.g., difficulties with attention, memory, and language), and 
psychological/ behavioral (e.g., irritability, depression, anxiety, personality changes)21. 
Several factors have been suggested to be predictors of prolonged symptoms after the 
initial TBI insult. These include demographic factors, such as gender and age, as well as 
psychosocial factors, such as an inability to sustain relationships and existence of 
previous psychiatric disorders. External stressors, pre-existing TBI and other neurological 
disorders are also thought to influence the recovery process 19,22. Especially in military 
settings, comorbidities can further make identification of TBI symptoms more difficult. 
Military TBI patients are particularly at risk for the development of more severe, 
long-term psychiatric disturbances, including personality change, post-traumatic stress 
disorder (PTSD), anxiety, mania, substance abuse, psychosis and depression 23,24. Due to 
the wars in Iraq and Afghanistan, attention has been brought to the importance of TBI in 
its complex relationship with PTSD, owing to their common comorbid appearance in 
veterans 7,25,26. PTSD is a debilitating consequence of witnessing severe or life-
threatening trauma 27 and is associated with a number of symptoms that interfere with 
neurological functioning and quality of life, often resulting in social withdrawal, anger 
and aggression, and sleep disturbance 28.  
The RAND 2008 Report recorded that 14% of troops, returning from Operation 
Iraqi Freedom (OIF, 2003-2011) and Operation Enduring Freedom (OEF, 2001-2014), 
met criteria for PTSD or major depression, 19% sustained a TBI and 5% had been 
diagnosed with co-morbid TBI and PTSD or depression 7,25.  
A national sample of all OEF/OIF Veterans who received care for TBI through 
the Veterans Affairs (VA) system during the year 2009 revealed in this TBI group, 89% 
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had a concomitant mental health disorder, with the most frequent diagnosis being PTSD 
(73%) 29. Especially in the military population, PTSD and TBI often coexist because 
brain injuries are often sustained during traumatic events and experiences.  
It has been estimated that, within the military, proper care of each veteran affected 
by TBI creates annual costs of $11,700, whereas a PTSD veteran creates an average 
annual cost of $8,300, in medical treatment 10. Of note, patient care for comorbid TBI and 
PTSD costs are estimated at $13,800 in the first year.  
Furthermore, PTSD is often complicated by other mental health problems 30,31. 
Epidemiological studies have documented that subjects with a given diagnosis of PTSD 
show elevated risk for a broad spectrum of disorders, including depression, anxiety 
disorder, panic disorder, conduct disorder, personality disorders, and multiple types of 
substance abuse 32. Returning service members often present common clinical symptoms 
which can be attributed to either PTSD or TBI or both 33. A cluster of overlapping 
symptoms can be found in Figure 1-1, which include depression/ anxiety, insomnia, 
irritability/anger, trouble concentrating, fatigue, hyperarousal and avoidance. The 
presence of overlapping (and heterogeneous) clinical symptoms in both TBI and PTSD 
can make it extremely challenging for physicians to precisely diagnose both conditions 
either individually or if they occur together in comorbid cases. This emphasizes the need 
to identify an objective biomarker that can distinguish between those two conditions. 
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Figure 1-1: Overlapping persistent symptoms of PTSD and TBI (adapted from Stein & 
McAllister, 2009). 33 
 
1.2. Clinical diagnosis  
1.2.a TBI 
Due to the heterogeneous presentation of TBI, specific diagnoses for different 
severities is of importance in order to determine suitable treatments for the patient’s 
needs, including rehabilitation programs 34. As such, accurate identification of those TBI 
patients is a major challenge in clinical settings. The Department of Defense and 
Veteran’s Affairs define a TBI as a traumatically induced structural injury and/or 
physiological disruption of brain function. This injury is the result of an external force 
that leads to a new onset/worsening of clinical signs, which can be described as the 
following35:  
1) LOC: Any period of loss of or a decreased level of consciousness 
2) PTA: Any loss of memory for events immediately before or after the injury (post-
traumatic amnesia) 
PTSD  
 
Reexperiencing symptoms 
 Nightmares 
Flashbacks 
Hypervigilance 
Avoidance 
 
TBI 
 
Headache  
Sensitivity to light (and 
sound)  
Dizziness 
Vision problems 
Nausea & Vomiting 
Depression 
Anxiety  
 Insomnia  
 Irritability 
 Cognitive deficits 
Fatigue 
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3) AOC: Any alteration of consciousness/mental state at the time of the injury 
(confusion, disorientation, etc.)  
4) Neurological deficits (weakness, loss of balance, change in vision, praxis, 
paresis/plegia, sensory loss, aphasia, etc.) 
5) Intracranial lesion 
 
 
The presence and duration of TBI symptoms defines the severity level, which 
range from mild to moderate to severe TBI. The different severity levels of TBI are 
associated with different durations of loss of consciousness (LOC), length of 
posttraumatic amnesia and alteration of consciousness, as well as normal/abnormal 
structural imaging. The joint Veterans Health Administration/Department of Defense 
clinical practice guidelines classify TBI severity on the basis of the American College of 
Rehabilitation Medicine (ACRM) definitions 36. Table 1-1 presents the guidelines for TBI 
severity classification.  The pathophysiology for mild TBI is different than for moderate 
and severe TBI, mostly distinguishable through the absence of structural/anatomical 
damage, whilst similar bimolecular process are activated in the brain in all cases of TBI 
(see below, pathophysiology of TBI). Overall, TBI classification is based of cause and 
symptomology, as well as existence of comorbid disorders (see above), rather than 
underlying biological mechanisms.  
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 Glasgow 
Coma 
Scale 
37  
Loss of 
Consciousness 
Posttraumatic 
Amnesia 
Alteration of 
Consciousness 
Structural 
Imaging 
Mild TBI 13-15 0-30 minutes 0-1 day <24 hours Normal 
Moderate 
TBI 
9-12 30min - 24 
hours 
1-7 days >24 hours Normal/ 
Abnormal 
Severe 
TBI 
<9 >24 hours >7 days >24 hours Normal/ 
Abnormal 
 
Table 1-1 Severity level of TBI defined on the bases of the ACRM definition. Mild 
TBI is defined by LOC of 0-30min, posttraumatic amnesia for up to 1 day, alteration of 
consciousness under 24hours, normal structural imaging and a score of 13-15 in the 
Glasgow Coma Scale (GCS; described below). Moderate TBI is defined via LOC of 
30min-24hours, alteration of consciousness over 24hours, 1-7 days posttraumatic 
amnesia and a GCS score of 9-12. Severe TBI shows LOC over 24hours, alteration of 
consciousness over 24hours and posttraumatic amnesia over 7 days with GCS below 9. 
Both moderate and severe injury can show normal or abnormal structural imaging. 
Glasgow Coma Scale  
Among clinicians, the GCS is the most common test used for TBI. It is a 15-point 
test, 3 being the worst score, which evaluates injury severity and level of consciousness 
after TBI.  The GCS tests eye, verbal and motor responses, immediately after hospital 
admission and during the acute phase of examination and care. The three broad categories 
as shown in Table 1-1 classify TBI into: severe TBI (GCS 3-8), moderate TBI (GCS 9-
13) or mild (GCS 14-15) 38 (Table 1-2 (adapted from http://glasgowcomascale.org)). 
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Criterion Response Score 
Eye Opening Response Spontaneous 4 
To sound 3 
To pressure 2 
None 1 
Verbal Response Oriented/normal conversation 5 
Confused/disoriented conversation 4 
Words 3 
Sounds 2 
None 1 
Motor Response Obeys commands 6 
Localizing (to pain) 5 
Normal flexion (withdraw to pain) 4 
Abnormal flexion 3 
Extension 2 
None 1 
Table 1-2: Glasgow Coma Scale scoring 
 
Although the GCS is widely used, it has several drawbacks relating to the scoring 
process itself. For example, eye response is difficult to test if eyes are swollen shut from 
the injury, a person's verbal responses cannot be scored if the person drank alcohol before 
his injury as alcohol may make his speech hard to understand or motor response might 
decline if an injury causes pain with movement, or makes the person unable to move. 
Additionally, the GCS does not check if a person can learn and remember new things, 
which is an important factor helping caregivers predict recovery after a TBI. Moreover, 
medical sedation, paralysis, intoxication through drugs, as well as other injuries that 
distract from TBI, can confound the resulting score of the GCS 38,39. Multiple 
epidemiological studies have shown that those confounders are increasing, which leads to 
a decrease in the value of the GCS 40. It also has been shown that the GCS is most precise 
in the severe TBI population, however has poor performance for mTBI, which is 80-90% 
of all TBI cases 39. A low GCS score is associated with acute mortality and morbidity, but 
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higher scores lack the prediction of long term outcome, providing no information about 
underlying neurological deficits 41.  
 Overall the GCS was introduced for clinical monitoring following TBI, 
but was then adapted to diagnose TBI severity. Although it is widely recognized that the 
GCS lacks adequacies for this purpose, no real alternative exists. There is no consensus 
for the selection of clinical features or standardized test for TBI diagnosis and severity 
grading and TBI subtype definition, which often is bases on findings from brain imaging 
studies, history and clinical features42. 
Neuroimaging techniques have been used for the assessment of more severe TBI 
to add to the value of GCS and gather information about structural and functional 
pathological mechanisms. Examples include detection of skull fractures and hematomas 
through computed tomography (CT), visualization of macroscopic areas of white matter 
damage via magnetic resonance imaging (MRI) and identification of functional metabolic 
changes via functional MRI, positron emission tomography (PET), single-photon 
emission computed tomography (SPECT) and diffusion tensor imaging (DTI), just to 
name a few. Diffusion tensor imaging in particular has shown promising and consistent 
findings for sports-related mild TBI in older adolescents and young adults in the post-
acute period and decreases in the integrity of white matter microstructure have shown to 
occur 3 or more months after mild to severe pediatric TBI 43. Overall, neuroimaging 
techniques allow partial diagnosis of TBI severity and play an important role in 
determining the presence and extent of the injury and guide surgical planning that require 
a minimum of invasive interventions.  
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However, the techniques also come with general drawbacks, such as high cost, poor 
availability and the lack of ability to perform a secondary scan in short term follow up. 
Especially in military settings, such equipment is often not available on site. Using brain-
imaging techniques for diagnosis of TBI is especially challenging in cases of mTBI. 
It is of importance to note that these Department of Veterans Affairs (VA) and the 
Department of Defense (DoD) guidelines were designed to provide information and assist 
in decision-making. They are not intended to define a standard of care. The classification 
of the severity of a TBI helps guide acute management and establishes selection criteria 
for admission to intensive care units. Furthermore, whilst it has been shown that severe 
TBI (and mostly moderate TBI) is related to long-term cognitive defects there is 
insufficient evidence to determine a relationship between as single, mild classified TBI 
and long-term consequences, although studies of post concussive syndrome have 
increased. It has been shown that TBI severity classification such as LOC, PTA, AOC, 
the GCS-score and abnormalities on CT scanning in the acute stage predict short term 
outcome rather than long term outcome44. 
Various clinical trials have been conducted on neuroprotective agents for TBI, 
usually in randomized controlled trials. Yet, up till now, all multi-center trials have failed 
to successfully produce results. The commonly used categorization of TBI via the 
“artificial” GCS has been named as an error introducing factor, separating injury into 
categories, instead of using the fact that clinical severity is based on a pathophysiological 
continuum. Underlying biochemical mechanisms occur across the spectrum of clinical 
severity, but might differ in frequencies or strength of biological signals. Furthermore, as 
mentioned above, patients with the same GCS can have different types of injury. 
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Therefore a new gold standard needs to be implemented for the diagnosis of TBI and its 
pharmaceutical outcome measures (Glasgow outcome scale) that allows for a more 
precise categorization of TBI in clinical trials. Objective biomarkers or mechanistic 
targeting is based on the identification of occurrence/time of pathophysiological 
mechanisms. Additionally, individualized personal treatment in a clinical trial, instead 
not depended on the used clinical diagnosis45. Overall, diagnostic measures need to be 
improved in order to validate clinical trial outcome. 
 
1.2.b PTSD 
Post-traumatic stress disorder criteria and symptoms have been defined in the 
latest Diagnostic and Statistical Manual (DSM)-Fifth Edition-Text Revised (DSM-5)46 
and reviewed by Kennedy et al. 47. It is a trauma and stressor-related disorder, which 
requires exposure or witness to a traumatic or stressful event as a diagnostic criterion, 
which is threatening to safety, and one must respond to this event with fear, horror, or 
helplessness. The DSM-5 diagnosis of PTSD requires four major symptom criteria: (1) 
Intrusion (re-experiencing of the trauma, e.g. as nightmares or intrusive memories), (2) 
Avoidance, (3) negative alterations in Cognition and Mood (persistent and distorted 
blame of self or others, and persistent negative emotional state), and (4) alterations in 
Arousal and Reactivity (reckless or destructive behavior). In the case of avoidance, 
patients must present at least three avoidance symptoms (active avoidance of thoughts, 
feelings, or reminders of the trauma, inability to recall some aspect of the trauma, 
withdrawal from others, or emotional numbing). Lastly, arousal must be present in form 
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of insomnia, irritability, difficulty concentrating, hypervigilance or heightened startle 
response 47.  
Like the GCS for the diagnosis of TBI, the DSM 5 diagnostic criteria for PTSD 
rely on observation rather than an objective measure, leading to limitations that mirror 
those of the GCS. Besides the DSM5 criteria listed above, which focus on behavioral 
presentation, functional neuroimaging techniques have been used to investigate PTSD, 
such as functional MRI (fMRI), SPECT and PET. Measures such as blood oxygenation 
level for fMRI, or regional cerebral blood flow/regional cerebral metabolic rate for 
glucose for PET, evaluate regional activity in the brain 48. Although sensitivities in spatial 
resolution have increased for imaging techniques, the high comorbidity between PTSD 
and other anxiety disorders (e.g. depression) makes diagnosis difficult and leads to a lack 
of sensitivity. As such a more objective method/biomarker is needed for more precise 
diagnosis 48. 
For military populations the Post-Deployment Health Assessment (PDHA), the 
Brief Traumatic Brain Injury Screen (BTBIS), Neurobehavioral Symptom Inventory 
(NSI), as well as the PTSD Checklist-Military Version (PCL-M) are, among others, the 
standard for TBI and PTSD assessment. A copy of the questionnaires can be found in the 
Appendix. 
A downside commonly exhibit to psychiatric diagnostic categories is the considerable 
symptom heterogeneity. PTSD shows symptom overlap with generalized anxiety disorder 
(GAD) and major depressive disorder (MDD), as well as a wide range of fear and anxiety 
disorders, such as panic disorder, social anxiety disorder, and specific phobias. In order to 
reduce heterogeneity in PTSD, mechanisms responsible for subtypes of symptoms need 
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to be investigated, as well as longitudinal data needs to be acquired, collected after the 
traumatic event to enable early prediction and classification of these conditions allowing 
to identify targets for prevention. 
 
1.3 Pathophysiology of TBI 
Traumatic brain injury has been defined as a brain injury caused by an external 
mechanical force, e.g. a bullet or blow 49, significantly disrupting brain function as 
indicated by any of the following: a period of loss of consciousness or alteration in 
consciousness (e.g., confusion, disorientation); loss of memory (amnesia) for events 
immediately before or after the injury; neurological deficits (e.g., weakness, loss of 
balance, change in vision); or intracranial lesion 50.  
Damage caused by TBI is the result of a contact and/or acceleration/deceleration 
injury type mechanism 51. Contact injury, which is usually associated with focal brain 
injury, is a result of an object hitting the head, the consequences of which can include 
skull fractures, intracranial hematomas, lacerations, contusions, penetrating wounds and 
increased intracranial pressure (ICP) 52,53. Acceleration/deceleration brain injury, which 
leads to tensile, shear and compressive strain, results from unrestricted head movement. 
These injury mechanisms are associated with diffuse brain damage, such as ischemic 
brain injury, diffuse brain swelling and axonal damage 51,54. 
Pathology of the injury is dynamic and can be divided into 2 subcategories. It 
begins with the mentioned (1) primary injury (mechanical), which occurs at the moment 
of trauma. Following primary insult (2) a secondary phase of TBI is initiated; a cascade 
of biochemical changes, that is attributable to further cellular damage from the effects of 
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primary injuries and develops over hours and days. This includes elevated 
neurotransmitter release and subsequent activation of receptors and subsequently to early 
ionic changes in postsynaptic membranes, calcium-mediated damage, mitochondrial 
dysfunction, free-radical generation and inflammatory responses as well as mechanical 
damage 55. The result of the described metabolic crisis and excitotoxicity includes 
membrane degradation and blood-brain barrier (BBB) compromise and changes in 
vascular permeability, and eventually leads to an unregulated transit of immune 
molecules in and out of the injured brain 56,57. Figure 1-2 shows an overview of pathways 
associated with the secondary injury response after TBI 58. 
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Figure 1-2 Pathways associated with secondary response to TBI (image from 58. (1) 
TBI leads to microvascular stenosis, (2) as well as swelling of astrocyte foot processes, 
which may lead to blood–brain barrier break down. (3) Astrogliosis results in (4) a 
reversal of glutamate uptake and depolarization at the neurons through excitotoxic 
mechanisms. (5) Calcium influx, due to white and grey matter injuries, leads to molecular 
cascades. (6) This results in generation of free radicals, excitotoxicity, mitochondrial 
dysfunction, caspase activity and modifications at postsynaptic receptors. (7) When 
calcium influxes and accumulates in the axons, proteases are activated, which leads to a 
degradation of the cytoskeleton (8). Secondary injury is also accompanied by a release of 
proinflammatory cytokines. (9) These cytokines activate cell-death cascades or 
postsynaptic receptor modifications. 
 
 
Genetic influences on outcome after TBI 
Besides physiological variations in humans such as age, sex and fitness, genetic 
predisposition has been suggested to influence TBI recovery, because patients matched 
on basic demographics can exhibit vastly different outcomes as a result of TBI than 
others sustaining a comparable injury.  
Multiple gene candidates have been proposed and extensively reviewed 59, for 
example genes that influence the extent of injury, such as the release of pro-and anti-
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inflammatory cytokines 60. These include variations within the tumor necrosis factor α 
(TNFα) gene, as TNFα is involved in mediating cell death, as well as promotion of 
neuronal repair at later stages 61 and genetic variations in IL-1 and IL-6 family and their 
receptors 62. 
Furthermore, genes that influence the dopaminergic system, such as variations in 
the Dopamine Receptor D2 (DRD2) and Ankyrin repeat and kinase domain containing 1 
(ANKK1) (controls synthesis of dopamine in the brain) genes have been proposed to 
influence TBI 63. Additionally, polymorphisms in genes which are part of the 
serotonergic system (including serotonin-transporter-linked polymorphic region (5-
HTTLPR), which encodes a transporter protein that removes serotonin (5HT) from the 
synaptic space and monoamine oxidase A (MAO-A), which encodes an enzyme involved 
in breakdown of serotonin, dopamine and norepinepherine), are potential candidates 59,64. 
Finally, variants in the brain derived neurotrophic factor (BDNF) gene, which encodes 
proteins involved in survival, growth and differentiation of neurons, have been suggested 
to influence TBI outcome 65.  
In addition to those listed above, many gene variants have been proposed to 
influence TBI recovery, none however has been as intensively studied as the 
Apolipoprotein E (gene: APOE; protein: apoE). Under stress, ApoE is produced by 
astrocytes, microglia and neurons in the central nervous system (CNS) 66. 
Apolipoproteins are lipid carrier proteins that transport and redistribute lipids among cells 
and play a role in growth and repair of neurons, neuronal protection, mediation of brain 
inflammatory processes and maintenance of synaptodendritic connections 67). The gene 
encodes three common alleles (ε2, ε3 and ε4), leading to six common genotypes 
 33 
including three heterozygote ε3/ε2, ε3/ε4, ε4/ε2 and three homozygote genotypes ε2/ε2, 
ε3/ε3 and ε4/ε4 68.  
APOE has long been associated with Alzheimer’s disease (AD), more precisely 
APOE ε4 was identified as a risk factor for AD 69, before a link to TBI outcome was 
made. This is of importance due to the possible link between APOE, AD and TBI 70. 
Prior to the identification of APOE ε4 as a risk factor for AD, autopsy studies had shown 
that boxers who had sustained repeated head trauma showed at autopsy similar brain 
pathology to those of AD subjects 71. Additionally, 30% of postmortem brains from 
patients sustaining a single severe TBI and surviving less than two weeks showed 
amyloid beta (Aβ) deposition, a classical hallmark of AD neuropathology 72. Since it was 
observed that APOE genotype influences Aβ accumulation in AD brain (with e4 carriers 
showing higher levels of Aβ) 73 it is logical to assume that APOE and TBI outcome are 
connected.  
In order to determine if APOE ε4 plays a role in severity of TBI outcome, meta-
analyses have aimed to evaluate the connection. Zhou and colleagues performed a meta-
analysis in 2008, including 100 studies conducted in the years between 1993 and 2007 74 
encompassing TBI severities ranging from mild to severe. The group concluded that 
APOE e4 is not involved in initial severity of brain injury, but with an increased risk of 
poor TBI outcome after 6 months post injury. A study in 2015 included 12 studies 
published since 2003, confirmed and extended the association of APOE ε4 and an 
increased risk for functional TBI outcome for over 6 month 75. Ponsford and colleagues 
detected this association even for 1 and 5 years post injury 76. 
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Although the exact underlying biological mechanisms are not completely 
understood, it appears that the ε3 isoform is neuroprotective, whilst ε4 was shown to have 
a higher binding avidity to Aβ peptides promoting aggregation 77. Furthermore ApoE4 
has been associated with a less efficient transport of lipids 78,79, an increase in 
inflammation 80–82, poorer protection against oxidative injury 83,  mitochondrial 
dysfunction 84, and diminished growth and branching of neurites resulting in poorer 
repair 85,86. 
 
1.4 Pathophysiology of PTSD  
The above-described symptoms of PTSD are present for an extending period of 
time and therefore seem to display persistent, abnormal functions of neurobiological 
systems to the stress of exposed and witnessed trauma 87. Systems that regulate stress 
responses, and are thus candidates for PTSD pathobiology, include neuroendocrine and 
chemical neurotransmitter pathways, as well as neuroanatomic brain regions that regulate 
fear. 
 
1.4.1.a Neuroendocrine responses 
Immediate neuroendocrine responses to stress involve increases in heart rate and 
blood pressure (“fight or flight” reaction). This response allows a greater perfusion of 
blood glucose to muscles and vital organs and results in increased energy to skeletal 
muscles, allowing the organism to better fight or flee adverse situations.  At the center of 
endocrine factors influencing PTSD are dysregulation of cortisol and thyroid hormones, 
regulated via the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is one of the 
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principal effectors of the stress response in the human body, responsible for the 
maintenance of homeostasis after challenge, but also for supporting baseline functioning. 
It is localized in the paraventricular nucleus (PVN) of the hypothalamus, the anterior lobe 
of the pituitary gland, and the adrenal gland. This collection of structures is commonly 
named the hypothalamic-pituitary-adrenal (HPA) axis (Figure 1-3). 
 
 
Figure 1-3 Location of the hypothalamic-pituitary-adrenal (HPA) axis in the human 
body (Image from http://www.simplypsychology.org). 
 
 
Figure 1-4 shows the basic function of the HPA axis 88. The PVN synthesizes and 
secretes corticotropin-releasing factor (CRF), also known as corticotrophin-releasing 
hormone (CRH), the principal regulator of the HPA axis; increased levels of CRH due to 
stress results in HPA axis activation 89,90. After secretion, CRH is transported to the 
anterior pituitary, where it binds to CRH1 receptors, causing the release of 
adrenocorticotrophic hormone (ACTH) into the blood stream. There, ACTH stimulates 
the adrenal cortex to synthesize and release the glucocorticoids cortisol (humans) or 
corticosterone (rodents). Amongst other functions, cortisol serves to increase glucose 
availability to be utilized as an energy resource during times of stress 91.  Feedback 
inhibition of the HPA axis is mediated in part by the binding of cortisol to glucocorticoid 
receptors (GRs) at the level of the hippocampus, hypothalamus and pituitary to dampen 
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stress-induced activation of the HPA axis 88. Modulation of the CRH response to threat 
relies on a complex feedback system involving the glucocorticoid receptors (GCCR, 
GCR2) and regulating genes (e.g., FK506- binding protein 5 (FKBP5)). Because PTSD is 
characterized by dysregulation of the stress response system, alterations in the HPA axis 
functionality, especially a hyper-responsive cortisol feedback regulation, have been 
implemented in this disorder 92,93. This dysregulation is in part due to enhanced 
sensitivity of the glucorticoid receptor (GR)-mediated feedback mechanism that 
suppresses stress-induced cortisol release. The receptor mediates many of the effects of 
GCs on target tissues via direct binding to hormone-responsive elements on the DNA or 
via interactions with other transcription factors resulting in a modulation of gene 
transcription 94.  
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Figure 1-4: HPA axis function. The paraventricular nucleus in the hypothalamus, 
releases CRH (CRF) that is transported to the anterior pituitary. There, it causes the 
release of ACTH into the blood stream. ACTH stimulates the adrenal cortex to synthesize 
and release the glucocorticoids cortisol (humans) or corticosterone (rodents). 
Glucocorticoids feed back at the level of the hippocampus, hypothalamus and pituitary to 
dampen excess activation of the HPA axis (Image source: Steven E Hyman and Kim 
Ceasar 2009 88 
 
 
1.4.1.b Neurochemical factors 
Besides endocrine factors, neurochemical factors are part of the pathophysiology 
of PTSD, as they are found in brain circuits, which influence stress and fear responses. 
This includes catecholomine, amino acids, serotonin, peptides and opioid 
neurotransmitters (Note: catecholamine and serotonin (as well as acetylcholine) 
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dysregulation is also found in patients with TBI, as a result of diffuse axonal injury 87). 
PTSD subjects have been reported to demonstrate abnormal regulation of catecholamines 
(increased dopamine and norepinephrine levels), serotonin (decreased concentrations), 
amino acids (decreased ϒ-aminobutyric acid (GABA) activity, increased glutamate), 
peptide (decreased plasma NPY concentrations and increased cerebrospinal fluid (CSF) β 
-endorphin levels 87). 
 
1.4.1.c Brain circuitry – Neuroanatomic changes 
Changes in brain structures were observed in PTSD patients that mediate adaption 
to stress and fear conditioning 95–97. These neuroanatomical changes include reduced 
volume and activity in the hippocampus, increased activity in the amygdala and reduced 
prefrontal and anterior cingulate volume, as well as decreased medial prefrontal 
activation in the cortex 87,96,97.  
 
1.4.2 Genetic influences on PTSD 
One of the key questions in trauma research is why certain individuals develop 
PTSD after a traumatic event, whilst others who experienced the same or similar trauma 
are resilient. Genetic influences on PTSD risk have received much attention, although 
only limited progress has been made in identifying the genetic variants that could explain 
the different susceptibility to trauma among humans.  
There have been numerous genetic association studies examining the role of 
various genes in PTSD that play a role in the described neurochemical and 
neuroendocrine responses (extensively reviewed in Cornelis & Nugent 2010). This for 
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example includes genes relevant to the HPA axis, such as the mentioned FKBP5, which 
mediates GR translocation 98,99. Other potential gene candidates are serotonin transporter 
genes 100,101, as PTSD can be treated by targeting the serotonin transporter (SLC6A4) 
with selective-serotonin reuptake inhibitors (SSRIs), and genes involved in the regulation 
of the dopaminergic system  (e.g. D2 DA receptor gene (DRD2) or catechol-O-
methyltransferase (COMT)). Finally, genes related to neurotransmission and 
neuromodulation have been under investigation in PTSD. An example is the brain BDNF 
gene, also of interest and relevance in TBI as discussed above. BDNF plays an important 
role in hippocampal-dependent learning and is involved in the neural plasticity 
underlying the extinction of fear and recovery from stress (Chhatwal et al., 2006; Heldt et 
al., 2007; Soliman et al., 2010). Many other genes have been suggested to contribute to 
the development of PTSD, such as neuropeptide Y (NPY, thought to have a role in 
decreasing fear states and enhancing fear extinction 102), monoamine oxidase B (MAO-B, 
which catabolizes dopamine, tyramine, tryptamine and other monoamines 103), as well as 
the inhibitory neurotransmitter GABA 104). Overall, further work is required to validate 
genetic influences on PTSD and understand their interaction 105).  
It is of importance to note that case-control candidate gene association studies in 
psychiatric disorders have resulted in many findings but produced very few consistent 
replications. This is due to the heterogeneity of the conditions, the often-small sample 
sizes used, multiple test performances and the low prior odds of association. Furthermore 
population stratification becomes an issue, due to the fact that observed significance 
could be an artifact of ethnic variations in allele frequencies.106. 
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In recent years the concept of quantitative endophenotypes has gained attention. It 
uses developing traits that directly index the underlying pathology and can be measured 
in affected and unaffected individuals, therefore facilitating investigations of genetic 
influences in TBI and PTSD107. The study of endophenotypes involves quantitative trait 
analysis in large randomly ascertained families, which facilitates the investigation of 
genetic influences in conditions as these two strategies suggests that the quantitative trait 
is correlated with disease by way of the underlying liability. 
Although it has been agreed upon that that certain pathophysiological systems are 
effected in most PTSD subjects, the myriad of trauma possibilities that causes PTSD, as 
well as the large amount of possible underlying mechanisms in conjunction with various 
genetic backgrounds, leads to the fact that not all PTSD subjects share the same exact 
pathophysiology, making treatment development difficult. 
Additionally, in military settings TBI is often the result of a traumatic event, 
therefore, the epidemiologic relationship between TBI and PTSD is not a surprise. It has 
been suggested that damage to the brain compromises neuronal circuitry for fear 
regulation 108,109. For example, functional PTSD studies revealed decreased activation in 
the hippocampus, and structural studies reported reduced volume in the frontal and 
prefrontal cortex as well as hippocampus and amygdala. It has been shown that the 
hippocampus is especially vulnerable to mTBI resulting in axonal damage. Furthermore, 
imaging studies have observed abnormalities in prefrontal and temporal brain regions in 
both disorders (reviewed by 109).  
The neurochemical abnormalities found in PTSD, such as changes in the previously 
mentioned catecholamine and serotonin, have also been observed in patients diagnosed 
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with TBI, presumably as a result of diffuse axonal injury 87. The fact that common 
systems are affected in these conditions contributes to the co-morbidity of TBI and 
PTSD, which in turn makes it difficult to make an objective diagnosis. Furthermore, other 
mental disorders such as anxiety and depression, which show comorbidities with PTSD 
and TBI as well, add to the problem of finding a diagnostic measure. 
1.5 Suggested Biomarkers and their Clinical Relevance and Limitations in 
TBI and PTSD 
 
A biomarker is defined as a “characteristic trait that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” 110. In attempting to identify 
biomarkers for these complex conditions, it is first important to adequately define the 
goal.  Biomarkers are used for multiple purposes, such as: 
Diagnostic biomarkers: Identification of patients with a disease or abnormal condition 
Prognostic biomarkers: Survival prediction 
Pharmacodynamics biomarkers: Assessment of drug safety and evaluation of target 
engagement, as well as immediate consequence on biological processes 
Predictive biomarkers: Identification of patients who are likely to benefit from a 
treatment. 
Surrogate (therapeutic) biomarkers: Prediction of outcome to a therapy response 
Theragnostic biomarkers: Can be used to identify and monitor the specific biochemical 
effect, or mode of action, of a drug, and/or to identify and monitor effects on pathogenic 
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processes downstream of the drug target. Therefore, theragnostic biomarkers can indicate 
whether a TBI patient is likely to benefit from a treatment in clinical trials.  
 
In this thesis the first priority is the identification of diagnostic biomarkers, 
however, such biomarkers could have additional value in some of the other categories. 
The heterogeneity of TBI in terms of severity, symptom presentation and post-mTBI 
complications emphasizes the need for accurate and objective biomarkers that can 
classify, diagnose and monitor disease state and its progression. Furthermore, there is a 
need for temporal biomarkers in order to observe injury progression over time, which 
could lead to the discovery of different biomarkers at various stages post-insult. This is 
also valid for PTSD, where self-reported symptoms and co-morbidities with other 
psychological disorders make an accurate diagnosis difficult. Identification, validation 
and application of biomarkers could help ensure that patients receive the best possible 
therapeutic strategies, thereby avoiding unnecessary treatments, eventually reducing total 
health costs.  
Biomarkers can come from various sources, such as brain tissues, CSF and blood. 
Advantages and disadvantages found for each one will be described below in section 1.7. 
The term “biomarker” can have a wider definition, as in the case of imaging biomarkers 
for example. In this thesis the term “biomarker” is generally used to describe a specific 
molecule or molecules that can be identified and quantified in blood.   
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1.5a TBI biomarker research 
 
In the case of TBI, there is no definitive and rapid diagnostic test, unlike some 
other organ-based diseases such as liver or kidney dysfunction. Initially, TBI biomarker 
research focused on the structural damage caused by TBI (imaging) and/or investigated 
specific molecules linked to parenchymal damage that are present in cerebrospinal fluid 
or blood (albeit represented at lower levels). Imaging biomarkers such as raised ICP or 
inadequate cerebral perfusion pressure have proven useful for TBI diagnosis when 
structural changes in the brain are being observed. However, due to the focus of this 
thesis, this section will focus on fluid biomarkers and their use in mTBI. 
After TBI, brain derived markers can be found in increased concentrations in CSF 
and plasma due to cell damage and disruption of the blood brain barrier (BBB) 111.  
However, in mild injuries, where imaging results are negative and symptoms are non-
specific, the challenge arises to objectively diagnose TBI. Many molecules have been 
suggested as potential biomarkers for TBI; below are reviewed the most clinically studied 
biomarkers along with their relevance to mTBI. Table 1-3 provides an overview of those 
candidate markers in acute/subacute mTBI. 
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Biomarker Injury Mechanism Location Results for mTBI 
S100 calcium-
binding protein β 
(S100β) 
Astroglial Injury as a 
cellular sequelae to 
primary insult/BBB 
disruption 
 
Astrocytes, 
Oligodendrocytes, 
Extracerebral cell 
types 
Increased in 
serum/CSF, results 
confounded by 
release from 
extracerebral tissues  
Glial Fibrillary 
Acidic Protein 
(GFAP) 
Astroglial 
Injury/BBB 
disruption 
Astrocytes Elevated in 
serum/CSF, 
correlates with brain 
imaging, promising 
for acute/subacute 
stage post injury 
Neuron Specific 
Enolase (NSE) 
Acute neuronal 
damage 
Neuronal 
cytoplasm 
Erythrocytes, 
Oligodendroyctes, 
Platelets 
neuroendocrine 
cells 
Increased in 
serum/CSF, low 
specificity/sensitivity, 
sensitive to lysis of 
red blood cells 
Ubiquitin C-
terminal hydrolase 
(UCH-L1) 
Neuronal loss and 
disruption of the 
BBB 
Neuron Elevated in blood/ 
CSF, promising for 
acute/subacute phases 
post injury 
AlphaII-spectrin 
breakdown protein  
 
Axonal Injury Neuron Increases acutely in 
blood, can reflect 
multiorgan damage 
  
Tau protein 
 
Axonal Injury/ 
hyperphosphorylation 
resulting in formation 
of CNS tangles 
“tauopathy 
Axon In CSF of patients 
with multiple head 
injuries, promising 
marker for 
acute/subacute phases 
post injury 
Neurofilaments 
(NF) 
 
 
NF-heavy (H) 
NF-light (L) 
Axonal Injury Axon Findings only for NF-
L in mild TBI cases 
(CSF), peak 4-10 
days 
 
Amyloid β42 
(Aβ42) 
Axonal Injury Axon terminals Elevated in plasma 
for up to 90 days 
after complicated 
mild TBI 
    
Table 1-3 Candidate markers of acute mild traumatic brain injury. 
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Astroglia Injury 
 
1. S100 calcium-binding protein β (S100β) 
 
S100β is the most extensively studied biomarker for TBI. It is a low molecular-
weight calcium binding protein, playing an important role in calcium regulation at 
intracellular levels. First thought to be specific to astrocytes, it was later shown to be 
expressed in oligodendrocytes, Schwann cells, as well as extracerebral cell types (e.g 
skeletal muscle, bone marrow cells, adipocytes and chondrocytes 112–114. 
 S100β is released after brain injury, through BBB opening, to the perivascular 
space, leading eventually to elevated levels in serum 115. It does not cross the BBB under 
normal physiological conditions, with its release depending on the disruption of the BBB 
integrity 116. As such, it is more appropriate as a marker for BBB-permeability 117. The 
application of serum S100β protein as a clinical biomarker and outcome-predicting factor 
in mild TBI also meets several obstacles given that numerous factors and pathological 
conditions can influence baseline serum S100β concentrations. Geyer and colleagues 
have shown that one of the most influential factors in determining normal baseline serum 
levels of S100β is age 118. Furthermore they demonstrated that S100β does not 
discriminate between symptomatic and asymptomatic children with minor head injury, 
showing the limitations in sensitivity. Although multiple studies have shown the value of 
S100β 119, its main limitation is its lack in sensitivity to mild and chronic brain injury 112. 
Furthermore, studies have shown lack in specificity due to observed elevation of S100β 
in plasma of bone fracture patients 120–122.  
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2. Glial Fibrillary Acidic Protein (GFAP) 
 
Glial Fibrillary Acidic Protein is a monomeric intermediate filament protein, 
which is part of the astroglial skeleton, believed to be only expressed by astroglia 114.  
Like S100β it is a marker for astrocyte reactivity expressed across numerous subsets of 
astrocytes. GFAP measurements in the blood have provided promising data for injury 
pathway indication 123 and prediction of morbidity and mortality 124–126. A study by Papa 
et al. evaluated levels of serum GFAP in mild and severe TBI and demonstrated its 
potential use as a biomarker up to 4 hours post injury 127. Furthermore, Papa and 
colleagues recently published temporal profile data from a cohort of 1831 subjects (mild 
to moderate TBI and controls) investigating levels of serum GFAP (as well as ubiquitin 
C-terminal hydrolase (UCH-L1), see below). They observed that GFAP peaked within 
24hours but was consistently raised across 7 days post-injury in mild to moderate TBI 
patients before returning to baseline; increased sensitivity and specifity was achieved 
when combined with UCH-L1 128. Finally in the most recent study by Bogoslovsky et al., 
temporal profiles (24 hours, 30 days and 90 days post injury) of mTBI patients that 
showed traumatic intracranial injury on CT scans and of moderate to severe TBI subjects, 
showed increases in plasma GFAP (as well as amyloid β (Aβ42) and tau) up to the 
longest (90 day) timepoint 129. Thus, GFAP is a potential candidate for the acute and 
subacute phase after injury. 
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Neuronal Injury 
1. Neuron Specific Enolase (NSE)  
Neuron-specific enolase is an isozyme of a glycolytic enzyme localized primarily 
to the neuronal cytoplasm 114, but is also expressed in erythrocytes and oligodendroyctes 
130. It has been associated with prediction of outcome after TBI, especially in severe TBI 
patients. However, lower sensitivities and specificities than S100β were observed for 
brain injury 131,132. The increase in levels of NSE in CSF observed in response to lysis of 
erythrocytes (hemolysis; contamination of CSF with blood during lumbar puncture) is a 
major limitation of this biomarker in peripheral blood as well as in CSF 133. 
 
2. Ubiquitin C-terminal hydrolase (UCH-L1) 
Ubiquitin C-terminal hydrolase is involved in removal and addition of ubiquitin 
from proteins. During normal and pathological conditions it plays an important role in 
removal of misfolded, oxidized and excessive proteins 134–136. Originally used as a 
histological marker for neurons it was first shown to be significantly elevated in CSF and 
serum of severe TBI patients, with detection lasting for 1 week post-injury 137,138. 
Another plasma study showed increases in UCH-L1 within one hour of injury in 
moderate to severe TBI patients, but not in mTBI 139. Moreover, Papa et al. were able to 
distinguish concussion patients (mTBI) from non-injured and non-head injured trauma 
control patients 127,140. Furthermore, a cohort study of 206 patients with TBI (r mild 
(83%), moderate (4%) or severe (13%) TBI) investigated UCH-L1 (and GFAP) plasma 
concentrations within 24 hours of injury 141. They observed that in moderate to severe 
TBI patients UCH-L1 levels were higher than in mTBI subjects. Furthermore, increased 
 48 
levels were also higher in mTBI with abnormal than normal CT. When UCH-L1 and 
GFAP were combined, increased sensitivity and specificity for diagnosing TBI was 
achieved. 
Moreover, temporal serum profile analysis showed that UCH-L1 was able to distinguish 
between mild to moderate TBI patients versus control and performed best in the early 
post-injury period, peaking at 8 hours after injury and declining over 48 hours 128. 
Finally, a recent study in children observed a step-wise increase of UCH-L1 in 
correlation of TBI severity (mild to severe) at an acute timepoint, immediately after 
hospitalization 142. UCH-L1 was also able to predict outcome 6 month post injury in 
pediatric TBI. Thus, UCH-L1 is a promising candidate for mTBI biomarker research and 
is of great interest when combined with other potential markers, such as GFAP.  
 
Axonal Injury 
1. AlphaII-spectrin breakdown protein  
AlphaII-spectrin breakdown protein is a major structural component of the cortical 
membrane cytoskeleton, being abundant in axons and presynaptic terminals 143. Usually, 
during apoptotic and necrotic cell death cysteine proteases (calpain and caspase-3), 
cleave those components of the axonal cytoskeleton, leading to the formation of signature 
molecular weight products (spectrin breakdown products (SBDPs)) 144. After TBI, 
calpains and caspases are hyperactivated, resulting in production of SBDPs and thus 
reflecting axonal damage 145. One breakdown product is the 1176 residue α-spectrin N-
terminal fragment (SNTF), which has been shown to increase measurably in the blood 
after TBI, including CT-negative mild TBI 137,146. However, whilst SBDPs are highly 
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abundant in brain, they are not specific to neurons, and it has been shown that serum 
levels can reflect multiorgan damage 147.  
 
2. Tau protein 
Recently considerable attention has been drawn to the relationship between repeated 
mild traumatic brain injury (r-mTBI) and the subsequent occurrence of the degenerative 
neurologic disorder known as chronic traumatic encephalopathy (CTE), which was 
previously described as repeated head trauma leading to the development of dementia 
pugilistica (DP) 148. Neuropathology of DP included neurofibrillary tangles in the absence 
of plaques, in contrast to the tangles and plaques seen in Alzheimer's disease (AD). 
However, not much is known about risk factors contributing to the subsequent 
development of CTE after r-mTBI. Clinical evidence comes from numerous studies, 
investigated mainly in boxers, but also in recent years in athletes and military personnel 
149. Before the term CTE was defined, Roberts and colleagues suggested that at least 17% 
of patients (boxers) with repetitive head trauma develop a neurological disorder 150.  
Although it is not clear yet if CTE is a true tauopathy (only caused by tau), 
neuropathological features of CTE include widespread deposition of hyper-
phosphorylated tau (phospho-tau/p-tau) as neurofibrillary tangles (NFTs) 15. Multiple 
clinical reports have observed this accumulation of NFTs in the brains of athletes who 
sustained several concussions (reviewed by 151). Furthermore, in preclinical mouse 
studies an increase in p-tau immunoreactivity in response to repetitive mTBI, but not to 
single mTBI has been observed 152. Presence and levels of hyperphosphorylated tau 
isoforms in CSF of TBI patients have not been examined 136. However, attention has been 
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brought to total tau, which has been examined as a biomarker of axonal injury in CSF and 
blood 136,153.  
Elevated levels of total tau were observed in the CSF of patients with severe TBI, 
peaking 1 week post injury 154. In another study increased CSF tau levels after severe TBI 
were correlated with clinical outcome 155. In blood, elevated levels of total tau have been 
found to correlate with neurological outcome in resuscitated hypoxic brain injury from 
cardiac arrest patients 156. Increased levels were also observed in plasma from patients 
with Alzheimer's disease 157, in plasma of Olympic boxers with head injury 158 and in 
concussed ice hockey players 6 days after the injury 159. Furthermore, elevation in total 
tau concentration in blood was observed in military personnel who reported multiple 
TBIs 160. Finally a recent study by Bogoslovsky et. al investigated a population of 
patients that consisted of 67% complicated mild TBI (cmTBI; patients with complicated 
mTBI show intracranial trauma-related abnormalities on a CT scan) with the remaining 
being diagnosed as moderate to severe TBI 129. Peripheral tau, analyzed at 24hours, 30 
days and 90 days post injury, was increased up to the latest time-point and associated 
with increasing severity and number of injury, as well as outcome of symptoms. 
Therefore, tau shows potential as a specific biomarker for the acute and sub-acute phase 
of TBI pathology. Furthermore, a cleaved form of tau (c-tau) has been proposed as a 
potential biomarker of CNS injury. After TBI, tau is proteolytically cleaved and can pass 
through the blood–brain barrier into the bloodstream when the nerves are injured. For 
example, increased c-tau levels measured in the CSF of severe TBI patients were a 
predictor of clinical outcome. Yet, when measured in the periphery this correlation could 
not be confirmed 161.  
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3. Neurofilaments (NF) 
Neurofilaments are heteropolymeric components of the neuron cytoskeleton, 
consisting of three chains, namely light (L), medium (M) and heavy (H) 162.  In severe 
TBI cases, high levels of phosphorylated NF-H have been found in ventricular CSF 137. 
Moreover, elevated levels of phosphorylated NF-L were observed in the CSF of boxers 
with acute mTBI, peaking 4-10 days after injury 163.  
 
4. Amyloid β42 (Aβ42) 
Aβ42 is widely known for its role in Alzheimer’s Disease 164, yet studies started to 
elucidate its connection to TBI. After injury, Aβ42 is subsequently released from the 
damaged axons into the surrounding tissue, resulting in plaque formation 165. An early 
study demonstrated diffuse Aβ42 pathology in the brains of 7 cases after fatal injury 
within 6 hours to 7 days 166. Another post mortem study observed Aβ42 deposition in the 
brains of 39 long-term survivors (up to 47 years), who had sustained a single moderate to 
severe head injury 167. Furthermore, Aβ42 was increased in the CSF in patients with 
severe TBI for up to 1 week 168,169.  A recent study by Bogoslovsky and colleagues 
showed that Aβ42 levels in plasma of complicated mild TBI patients were increased up to 
90 days post injury 129. 
 
Other potential CSF and blood biomarkers have been studied and extensively 
reviewed for TBI, such as myelin basic protein and the CSF:serum albumin ratio 136, 
however they lack the desired sensitivity and therefore all suggested molecules have 
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failed to gain FDA approval for biomarker testing. Additionally the lack of a “gold 
standard” diagnostic measure (imaging or biochemical) hinders further development of 
biomarkers, as new candidates have no standard against which specificity and sensitivity 
can be compared. So far only one company (Banyan Biomarkers) has entered into 
development agreement (a multi-year joint agreement with Royal Philips) to develop and 
commercialize a blood test to detect and evaluate acute mild TBI using Banyan UCH-
L1™ and Banyan GFAP™ (http://banyanbio.com/media-news.html). Whilst this does not 
address the issue of chronic TBI, this could enable objective diagnosis of mTBI in the 
acute and subacute stages after injury. 
 
1.5b PTSD biomarker research 
PTSD biomarker research is limited due to the varying diagnostic procedures 
utilized and the heterogeneity of traumatic events to which PTSD patients were exposed. 
Additionally, differences in the study design and type of controls included in the 
investigation further challenges biomarker discovery and these variations make it difficult 
to perform a comparison between studies and their principal conclusions. As described 
above, PTSD is currently assessed through self-reports, clinical interviews and history 
documented by trained professionals. Self-report can always lead to insufficient 
information if a patient doesn’t disclose all relevant information, especially in large scale 
screening processes, where a clinician is not always available to make a diagnosis. The 
difficulty in assessing and distinguishing co-morbidities adds to the issue of an objective 
diagnosis. As such an objective biomarker (or panel of biomarkers) would be a useful 
screening tool to detect PTSD in patients, who have difficulties describing their situation 
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and symptoms, and might also suggest treatments and facilitate evaluation of treatment 
responses 170. Ideally, a large group of PTSD patients should be compared to a group of 
healthy controls (matched for age and sex) that were exposed to comparable traumatic 
events. These conditions are best achieved in military cohorts who can often have similar 
demographics and receive somewhat similar exposures. Although progress has been 
made in the characterization of PTSD pathophysiology and various studies have shown 
that genetic background 171, endocrine factors 172 and neurotransmitter systems 173 all 
modulate PTSD outcome and susceptibility, unfortunately, to date, there are still no 
generally accepted PTSD biomarkers in clinical use 174. Consequently the potential PTSD 
biomarkers currently under investigation typically relate to these pathophysiological 
aspects of the disorder. The candidates, which have received the most attention are 
described below: 
Potential biomarkers of PTSD include the consequences of enhanced HPA 
negative feedback in PTSD, which leads to increased peripheral cortisol and CSF CRH 
levels, as mentioned in the pathophysiology of PTSD section, although studies have 
shown confounding results 175–179. It is also important to mark that cortisol levels have 
been shown to be influenced by different kinds of stress, diet, smoking, alcohol, sleep, 
exercise as well as changes in diurnal cycle 180,181. Cortisol levels have also been 
implemented as a biomarker for patients with major depressive disorder 182, lacking 
specificity for PTSD. Moreover, reduced hormone binding potential of the GR receptor, 
as well as enhanced sensitivity to glucocorticoids has been observed in peripheral blood 
mononuclear cells (PBMCs) of PTSD patients 183,184. 
In whole blood, gene expression analysis identified that expression of the GR-
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regulatory gene FKBP5 was reduced in PTSD subjects 93. However, FKBP5 has also 
been associated with mood disorders, such as major depression, and has been suggested 
as a biomarker for non-psychiatric disorders, for instance cancer 185,186. 
Brain-derived neurotrophic factor, as mentioned above, plays an important role in 
proliferation, survival, and differentiation of nerve cells 187. Multiple studies have 
evaluated BDNF as a biomarker for PTSD. For example, in plasma, reduced levels of 
BDNF were observed in PTSD subjects. Moreover, BDNF was found to correlate with 
PTSD severity over 6 months in survivors of motor vehicle accidents 188,189. Although 
studies in general confirm findings of lower BDNF levels in individuals with PTSD, 
reduced BDNF has been associated with the pathogenesis of several neuropsychiatric 
disorders (reviewed by 190 such as major depressive disorder (MDD) 191. As such BDNF 
lacks diagnostic specificity, underscoring the shared common pathophysiological 
mechanisms and comorbidity 192 
 
Genetic risk conferred by 5-HTTLPR in PTSD was discussed above, but in 
addition platelet 5-HT concentration has been associated with this condition, though as 
with many of these observations the findings are controversial. One study showed 
decreased levels of platelet 5-HT in veterans with PTSD compared to controls 193, 
whereas increased levels were observed in suicidal patients with PTSD 194. 
For Neuropeptide Y, the observation of lower levels in the CSF of veterans with 
PTSD, could not be confirmed in PTSD survivors of motor vehicle accidents 195,196. 
In conclusion, extensive efforts have been made to identify objective biomarkers 
of PTSD. This includes systems involving the HPA-axis, the neuroendocrine/metabolic 
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systems, neurotransmission, the sympathetic nervous system and others. Unfortunately to 
date, no such biomarkers have been proven reliable mainly due to the heterogeneity in 
PTSD symptom presentations and common comorbidity of PTSD. As such more work is 
needed. 
1.6 Gulf War Illness 
 
Posttraumatic stress disorder and TBI are not the only debilitating illnesses with 
high prevalence in military populations. Gulf War Illness (GWI) is a chronic 
multisymptom illness, which affects approximately one quarter of the 700,000 US 
veterans and one fifth of the 53,000 U.K. soldiers who were deployed in 1990-91 to the 
Persian Gulf 197–201. Gulf War Illness is unique to the 1990– 91 deployment and 
distinguishes itself through a multiplicity and heterogeneity of symptoms persistent over 
decades observed in GW veterans, with no such illness being reported in any other 
military campaign, indicating that GWI etiology cannot solely be attributed to combat-
related stress 202,203. 
Veterans exhibiting GWI experience health issues such as, fatigue, idiopathic 
pain, gastrointestinal problems, muscle pain, and CNS-based symptoms, with memory 
problems being one of the most reported concerns 200,204,205.  
Although it has been over 25 years since the Gulf War no effective treatment have 
been identified, and almost no veteran has recovered from this debilitating illness 
197,206,207. Furthermore, although the GWI patient population is discrete, the increased risk 
of neurodegeneration that appears to results from overexposure and/or chronic exposure 
to pesticides and insect repellents use has implications and relevance to other populations 
208. 
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1.6.1 Clinical diagnosis of GWI 
Clinical diagnosis of GWI relays on a symptom system cluster defined first by the 
Centers for Disease Control and Prevention (CDC) 198, which later was expanded by the 
Kansas criteria 200. In order to receive a positive GWI diagnosis, Gulf War veterans must 
experience three out of six of the following symptoms: 1) fatigue/sleep problems, 2) 
somatic pain, 3) neurologic/cognitive/mood symptoms, 4) gastrointestinal symptoms, 5) 
respiratory symptoms, and 6) skin abnormalities 198,200. However, due to the complexity 
of the condition and the lack of objective biomarkers, not all Gulf War veterans that 
suffer from symptoms that are consistent with GWI, are being diagnosed 209.  
 
1.6.2 Pathophysiology of GWI 
The Research Advisory Committee on GWI has named exposure to the anti-nerve 
gas agent pyridostigmine bromide (PB), the pesticide permethrin (PER) and the insect 
repellant N, N-Diethyl-metatoluamide (DEET) as key contributors to the GWI etiology 
197. Pyridostigmine Bromide is an acetylcholinesterase inhibitor (ACHEi), which was 
used by the soldiers as prophylactic agents against various nerve gases (e.g. sarin, 
mustard gas and soman). The carbamate compound PB reversibly inhibits the enzyme 
acetylcholinesterase (AChE), thus keeping nerve gas agents from degrading it. PER is a 
type 1 synthetic pyrethroid insecticide that function as a neurotoxin, affecting neuron 
membranes by prolonging sodium channel activation 210–213. DEET, which is applied to 
skin or clothing, repels insects so that they are not attracted by odors produced by humans 
214. Others exposures have also been suggested to add to GWI symptomology, such as 
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depleted uranium and various vaccinations (e.g. against anthrax) 197,202,203,215–217. 
It has been discussed that as a result of these exposures GW veterans exhibit 
alterations in HPA function, which has also been shown to affect veterans with PTSD 
(described above). Alterations include increased suppression of ACTH and cortisol in 
response to DEX 218–220. Furthermore, impaired immune response has been suggested as a 
consequence of GW agent exposure 221. GWI patients usually show altered expression in 
pro-and anti-inflammatory cytokines in peripheral immune cells although unity of 
expression patterns has not been achieved, most likely due to heterogeneity of symptoms 
and chosen cohorts. However, studies have shown that immune system alterations are 
especially pronounced in GWI patients during exercise challenge compared to controls. 
222–227  
Other pathology has been observed in GW veterans and animal models of GWI 
such as CNS involvement through reduced volume and hypometabolism in the 
hippocampi of GWI veterans compared to controls 197, as well as lipid 228,229 and 
mitochondrial dysfunction 230–232. Although much progress has been made in the past 
decade the underlying mechanisms are still poorly understand and are under intense 
investigation.  
As for TBI and PTSD, it is likely that in GW veterans, genetic vulnerabilities to 
chemicals play a role in the post-deployment development of GWI 233. However, research 
is limited and only one study has identified genetic influence on GWI presentation – this 
being variants of the enzyme butyrylcholinesterase (BChE) 234. As mentioned above, PB, 
as well as organophosphates interact with circulating enzymes in humans, including the 
two cholinesterases - butyrylcholinesterase (BChE) and AChE, Whilst inhibition of 
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AChE interferes with the breakdown of the neurotransmitter acetylcholine, BChE has 
been shown to protect from the adverse effects of chemicals by acting as a scavenger. 
BChE binds chemicals molecule-for-molecule, thereby protecting circulating levels of 
AChE 235. Besides the most common gene variant “U”, multiple minor variants within the 
BChE gene have shown to be associated with lower enzyme activity levels and/or 
binding affinity for AChE-inhibiting compounds, making subjects carrying those variants 
more sensitive to different chemicals 235. A GWI case-control study revealed that a 
subgroup of Gulf War veterans who had the less common (less enzymatically active) 
genetic variants were at significantly higher risk for GWI if they took PB pills during the 
1990-91 deployment 234. 
 
 
1.6.3 Biomarker research in GWI 
To date no biomarker or biomarker panel is used in the clinical assessment of 
GWI. The persistent and heterogeneous presentation has made it not only difficult to 
identify a possible biomarker, but has also confounded comparison between clinical 
studies, as recruitment of veterans with the same symptom cluster is not easy to achieve. 
However, a recent blood biomarker study showed higher counts of lymphocytes, 
monocytes, neutrophils and platelets in GWI, as well as identified several proteins 
associated with inflammation to be differently expressed in patients versus healthy Gulf 
War veterans 236. Although this first study requires further confirmation it holds potential.  
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1.7 The periphery as a source for biomarkers and the importance of 
translational research 
 
As mentioned above in section 1.5, molecular biomarkers for neurological 
conditions mostly come from brain tissues, CSF and blood. Depending on whether 
samples are collected from animal models or humans certain advantages and 
disadvantages can be found for each source. Table 1.4 summarizes the value of each 
biomarker origin (adapted from 237). 
 
 
Sample host 
origin 
Source of 
sample 
Obtainable 
amount 
Availability Biomarker 
signal to noise 
Human Brain tissue Low  Low High 
 CSF Medium Medium Medium to low 
 Blood High High Low 
Animal Brain tissue High  High High 
 CSF Low Low  Medium 
 Blood Medium Medium Low 
Table 1-4 Advantages and disadvantages of sample sources in animal and humans 
 
In animals, brain samples can be obtained in a controlled laboratory environment, 
at any time of choice post-exposure to the insult or trauma, whereas in humans samples 
can only come from biopsies (sometimes occurring in severe TBI cases) or from 
deceased patients, leading to the introduction of post mortem artifacts.  
 
Parenchymal cells of the brain and spinal cord are surrounded by the interstitial 
fluid (ISF), whereas spaces within and around the CNS are filled by the cerebrospinal 
fluid (CSF).  To guarantee proper brain cell function and survival the ISF provides the 
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environment within with water and solutes. Furthermore, waste products need to be 
removed. The CSF serves a number of functions, which include  buoyancy, protection, 
chemical stability, waste removal. CSF is also important in removing protein and other 
debris during and after brain ischemia238. 
Circulation of these fluids is essential for proper brain cells functioning, which is 
regulated by different barriers that prevent free exchange between brain interstitium, CNS 
and blood. The structures associated in the process can be found below in Figure 1-5 and 
include the choroid plexus, the arachnoid villi, as well as glial, pia and endothelial 
barriers. 
Most of CSF is secreted by the choroid plexus into the ventricular cavities, 
whereas the BBB generally produces interstitial fluid (ISF), which drains into CSF via 
bulk flow.  It is traditionally known that after production by the choroid plexus, the CSF 
then circulates in a bulk flow manner, unidirectional through the ventricles and the 
subarachnoid spaces, to then be passively absorbed into the venous blood at the level of 
arachnoid villi239. It has been shown that on the level of the arachnoid villi a pressure-
sensitive vacuolation cycle of one-way pores, allow for the transcellular bulk transport of 
fluid, with molecules passing through up to the size of erythrocytes.  
 However, newer experiments support the hypothesis by Klarica and Oreskovic, 
which shows that CSF circulation is not unidirectional, but rather there are cardiac cycle-
dependent systolic-diastolic to-and-fro cranio-spinal CSF movements via physiological 
oscillations of arterial and venous blood during cranio-spinal blood circulation, 
respiratory activity, and body activity and posture240. Another portions of CSF (40–48% 
of total volume may be absorbed by extracranial lymphatics 241. Additionally, studies 
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have shown ISF drainage into the lymphatic systems. 
The CSF also circulates along the Virchow–Robin spaces (VRS), which represent 
the space surrounding vessels penetrating into the parenchyma. Glial and pial barrier 
membranes that surround the VRS control the bidirectional fluid exchange between the 
VRS and the brain extracellular space.  
The BBB and its tight junctions have a low permeability for polar solutes; fluid 
secretion is regulated by Na+/K+-ATPase-depended ion channels and transporters on the 
brain side of the barrier. The astrocytes on the BBB play an important role in brain water 
homeostasis and research has shown the existence of water transporting pores (i.e. the 
aquaporins), which are localized in the end feet242. 
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Figure 1-5 Overview of the CSF “circulation”:  Different barriers limit fluid and 
cellular movement across the brain compartments, which include blood, interstitial fluid, 
the Virchow Robin space and the cerebrospinal fluid space comprising the cerebral 
ventricles, basal cisterns and cortical subarachnoid space. The choroid plexus (CP), glial 
and endothelial barriers control fluid exchange via aquaporins and other transporters. Net 
CSF production rate is surpassed by the fluid exchange rates generated the bi-directional 
flow at the glial, endothelial, and pial barrier. Inflammatory cells from the blood enter the 
brain through the VRS or CP, whereas brain water is mostly drained into the cervical 
lymphatics from the VRS and from the CSF space. Between the blood and the CSF 
compartment the CP is the only direct connection. Whilst fluid movements into and out 
of the VRS is driven by respiratory and cardiac pressure pulsations, movements at the 
barriers is depended on osmotic and hydrostatic gradients or by active transporter 
processes (picture adapted with permission from Brinker et al. 2014243. 
 
For CSF, the collectable amount in rodents is small and contamination with blood 
is an unwanted possibility if puncture technique is not done properly. In humans, CSF 
collection is routine and larger volumes can be collected, but the technique is invasive. 
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Furthermore contamination of the CSF with blood is possible, which can falsify scientific 
findings. 
In humans and animals, blood is the preferred matrix for analysis of biomarkers, 
owing to their easy and cost effective collection. Changes in the brain can be expected to 
result in altered protein or lipid levels, that will eventually be reflected in the blood 
(through the CSF) 111,244. The identification of peripheral blood biomarkers for mTBI, 
PTSD and GWI would provide many advantages.  Expensive imaging techniques fail to 
detect the majority of mTBI injuries, PTSD and GWI patients and are much more costly 
to perform than analysis of easily accessible blood samples.  
Due to the clinical presentation of mTBI, PTSD and GWI, more precisely their 
heterogeneity in regards to injury severity, physical mechanisms, pathobiology, multiple 
impact, nature of traumatic exposure etc., it is difficult to not only identify a specific and 
sensitive biomarker, but also develop relevant animal models. Basic research scientists 
and clinicians often work in separate settings, leading to a gap in informational exchange. 
However, validation of animal models and translational studies are essential to diagnose, 
prognose and further investigate treatment outcome. It is of importance that underlying 
mechanisms of the mentioned conditions are studied in appropriate animal models that 
reflect characteristics of the clinical presentations seen in patients.  Animal models 
present the possibility of investigation of peripheral biomarkers in combination with 
changes in the brain, at a range of timepoints post-exposure, and results from human 
blood analyses can then be “mapped” against the profiles from preclinical studies.  
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1.8 Hypothesis & Synopsis of following chapters 
  
Given the likely critical role of brain changes in proteins and lipids in the pathogenesis of 
mTBI, PTSD and GWI, I hypothesize that protein and lipid biomarkers exist in the 
plasma and can be detected at chronic stages. These biomarkers could be combined in a 
panel that can assist in diagnosis of these conditions post exposure. 
In this study, we used two “omic” approaches, measured via mass spectrometry (MS) to 
identify changes in plasma in humans and animal models. 
 In Chapter 2 we investigated protein changes (proteomics) among a cohort of 
active-duty military soldiers, which identified the protein Leucine-rich alpha-2-
glycoprotein 1 (LRG1) to be chronically significant different. In Chapter 3 we identified 
differences in lipid levels (lipidomics). Our findings, which indicated a strong lipid 
signal, were then translated to a mouse model of mild TBI. Additionally, LRG1 was 
measured in these animals (Chapter 4). In this model we were able to observe temporal 
profiles of lipid changes ranging from acute (24 hours) to chronic (24month) stages post 
insult to show that our model is relevant to human mTBI patients and as such is well 
fitted for translational studies. In Chapter 5 we were able to investigate the debilitating 
condition of GWI. In this chapter we used lipidomics on a veteran population and 
compared our findings to two rodent models (mouse and rat) to verify findings and the 
power our analytical tools. In Chapter 6 I discussed the overall findings in this thesis, 
which showed that there are chronic biological changes in military relevant conditions 
that could be used to track illness and help identify potential therapeutic targets. 
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Chapter 2 Proteomic discovery phase and validation of a 
protein biomarker from a military cohort study with soldiers 
exhibiting mild traumatic brain injury and/or posttraumatic 
stress disorder 
 
2.0 Summary 
 
Traumatic brain injury (TBI) is a major problem for military and civilian populations, 
with long-term sequelae including neurological and neuropsychological dysfunction. 
Furthermore, in military service members and veterans there is a high prevalence of 
comorbid TBI and posttraumatic stress disorder (PTSD) due to the inherent risk of 
psychological trauma associated with combat. An objective panel of biomarkers for TBI 
and PTSD would enable triage during acute care and appropriate medical management, 
and may indicate ongoing pathogenic processes, provide guidance in therapeutic 
development, and could be used to monitor outcome and response to treatment. The 
special need for biomarker discovery at late stages post exposure comes from the fact that 
both mTBI and PTSD are chronic conditions, the difficulties in diagnosing mTBI or 
PTSD and the issue that these conditions are not typically identified or assessed in the 
acute phase. Therefore, in this study we investigated proteomic plasma profiles of 120 
active duty soldiers categorized with mild TBI, PTSD or TBI+PTSD, as well as healthy 
controls, via liquid chromatography mass spectrometry (LCMS) in order to identify 
candidates for chronic biomarkers of these conditions. Data analysis revealed three 
 66 
significant proteins to be differently expressed between diagnostic groups before post-hoc 
analysis. Although no protein passed multiple test correction following LCMS analysis, 
we used ELISA to further investigate the protein LRG1, which had shown the most 
significant change.  The antibody-based approach revealed a significant increase of 
LRG1 by 2.8 fold in the TBI+PTSD group compared to controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
2.1 Introduction 
 
Although extensive research has uncovered major underlying biological features 
of TBI and PTSD, the question of an objective measurement for both conditions remains. 
While progress has been made in the acute setting of TBI, diagnostic tools are needed for 
later timepoints post injury. 
Plasma is widely accepted for use in clinical testing, and the fact that it is easily 
obtainable, being non-invasive and cost effective, makes it a favorable sample to study. It 
contains molecule,s which may be relevant for prediction, diagnosis or cause and effects 
of neurological disorders. Due to the increasing need to identify and quantify proteins in 
complex biological sample matrices, such as plasma, with higher sensitivity and 
specificity, the platform of liquid chromatography mass spectrometry (LCMS) has 
evolved. 
MS is a powerful analytical tool for protein research, as it can measure the 
relative or absolute abundance of a protein or proteins among biological samples.  
One major strategy of global proteomics includes an unbiased discovery oriented 
approach, which studies differential global expression of the proteome across varied 
conditions for biomarker purposes or to identify new proteins and pathways related to the 
condition of interest. Tandem mass spectrometry (the use of successive rounds of mass 
analysis and fragmentation on a single analyte, herein referred to as “MS/MS” or “MS2”), 
has been the dominant driver for the generation of proteomic data 245,246.  Protein samples 
are digested into peptides, typically with trypsin (see below).  The peptide mixture is then 
separated via liquid chromatography (LC) prior to introduction into the MS instrument, 
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which generates data pertaining to the intact mass of the peptide (precursor, or “parent” 
mass).  This is followed by a fragmentation event within the MS whereupon the peptides 
are dissociated along the amino acid backbone, thus providing a sequence-informative 
spectrum, which is later paired with the parent mass during data analysis. These fragment 
(“product”) spectra are referred to as MS/MS.  Depending on the complexity of a sample, 
a modern mass spectrometer may generate tens of thousands of parent/fragment ion 
spectra within a single hour of runtime.   
Although plasma is an easily obtainable biofluid that contains a wealth of 
potential diagnostic information about the subject, the primary obstacle for obtaining 
deep proteomic coverage is the occurrence in blood of several highly-abundant proteins, 
such as serum albumin and immunoglobulins, together constituting more than 85% of the 
total protein content. These proteins mask lower abundance proteins, which could be 
potential candidates for biomarkers. In order to avoid this masking effect, highly 
abundant proteins must first be depleted from the sample 247,248 (see methods section 
below). The remaining proteins are then digested with one or more protease, such as 
trypsin. Trypsin is the most routinely-applied protease for this purpose owing to (1) fairly 
consistent cleavage specificity (which yields peptides with at least one defined terminal 
amino acid (a useful piece of information during database searches), (2) the fact that the 
resultant tryptic peptides have a basic terminus, which facilitates fragmentation, and (3) 
the charge state of most tryptic peptides being amenable to fragmentation in most modern 
mass spectrometers relative to other proteases which cleave less frequently (and hence, 
have larger charge states). 
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In MS, relative quantification of proteins in samples can be achieved via a variety 
of approaches, summarized in Appendix, Chapter 2; Section 1 Table 1.  In this work we 
have chosen to use isobaric tagging of peptides prior to analysis, primarily as a means to 
accelerate the workflow, and also to improve the standardization of the LCMS analysis.  
The multiplexing capacity of isobaric labeling techniques, such as the tandem mass tag 
(TMT) 10-plex approach, allows for pooling of up to 10 samples, thereby reducing the 
number of LCMS analyses and instrument time required 249,250. It also lowers the 
“missing value problem” that is inherent to data-dependent acquisition (DDA) mass 
spectrometry, commonly used in proteomic discovery phase experiments.  This problem 
results from the semi-random nature of precursor peptide selection in complex samples, 
and ultimately leads to under-sampling and inconsistent data when matching peptide 
identifications from multiple LCMS data sets 251.  
Researchers conducting proteomic studies have previously used proteolytic 
digestion followed by isobaric labeling in humans and mouse models of TBI and/or 
PTSD. For example, Wishart et al. analyzed pooled iTRAQ (isobaric tagging for relative 
and absolute quantitation) labeled samples from brain tissue synapse-enriched brain 
tissue of mice to detect differential synaptic protein expression in TBI 72hrs after injury 
252. This resulted in a refined profile comprised of 93 proteins.  
Our group has previously performed an iTRAQ based proteomic analysis to investigate 
plasma proteomic profiles in a mouse model of severe and relatively mild TBI at 24 h, 1 
month, or 3 months post-injury 253. In that study, results generated by MS analysis were 
further investigated for their function using Ingenuity Pathway Analysis (IPA) software. 
We observed injury dependent changes in plasma proteins as well as temporal differences 
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post-injury in changing plasma protein levels between mild and severe TBI with acute 
elevation of certain proteins in mild TBI possibly indicating a reparatory process. 
Furthermore, the work was carried out in apolipoprotein E (APOE) 3 and APOE4 
transgenic mice, which demonstrate relatively favorable and unfavorable outcomes 
respectively following TBI.  Thus the data analysis included identification of proteins 
that were regulated differentially as a response to TBI in the different genotypes and thus 
may be relevant as prognostic biomarkers.  
A study in 11 severely injured TBI patients identified 31 serum candidate 
biomarkers, including serum amyloid A, c-reactive protein and retinol binding protein 4, 
24–36 hours post-injury via LC-MS/MS 254.  
There are a few published studies that utilize isobaric tagging proteomic 
approaches for PTSD in animal models. For example, Hennigsen et al. used a rat model 
of chronic mild stress and iTRAQ to identify 73 differently expressed proteins in the 
hippocampus 255. In a related LCMS based field – metabolomics - researchers found 
metabolites involved in processes of (neuro-) inflammation, auto-immune reactions, 
oxidative stress, energy metabolism, and biological aging serum samples of PTSD 
patients and controls 256. 
Although these studies have shown the potential of proteomic data generation, more 
investigation is required, as well as replication in other cohorts. Moreover, TBI studies 
have been performed in acute and sub-acute settings only 254. As such the identified 
proteome differently expressed in plasma, most likely represents the leakage through the 
disruption of the blood brain barrier, which, once repaired, will most likely lose the signal 
of those identified proteins. Analysis of acute samples is of importance in hospital 
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settings, however especially in case of military active duty soldiers, immediate care is 
often not present. In that case the usual acute biomarkers might no longer be present by 
the time a soldier gets admitted. This emphasizes the importance of identifying proteins 
that are differentially regulated at chronic timepoints. Furthermore, as mentioned in the 
Introductory Chapter 1, 83% of sustained TBI’s are mild, underlining the need for 
biomarker discovery for those cases. 
My objective was to examine the alteration in global expression of proteins in the 
plasma of mild TBI and PTSD subjects in comparison with healthy controls. The TMT 
approach was utilized to analyze albumin-depleted plasma samples to reveal candidate 
biomarkers. TMT labeled groups obtained from digests of the prepared plasma samples 
from healthy controls, as well as subjects with a history of mild TBI, chronic PTSD and 
mild TBI+PTSD, were analyzed by LCMS. It was expected that studying plasma proteins 
in these chronic samples using discovery-based proteomics could identify potential new 
protein biomarkers that persist in the periphery well after the initial insult(s). 
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2.2. Methods  
 
Research participant selection  
 Pre-deployment data from 120 active-duty U.S. soldiers, aged 18 to 49 years old, 
were collected within 30 days prior to a 12 -18 month deployment to the Middle East for 
Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF). Participation was 
voluntary and the study was carried out in collaboration with Dr. (Major) Michael 
Dretsch and his team at the United States Army Aeromedical Research Laboratory,  
 (USAARL) in Alabama. There were no inclusion/exclusion criteria because all soldiers 
were deemed medically fit for deployment (i.e., physical and psychiatric screening) 
through the deployment medical screening. 
 
Procedures 
 The study was approved by the Institutional Review Board (IRB) at Headquarters 
U.S. Army Medical Research and Materiel Command, Fort Detrick, MD. HQ 
USAMRMC IRB and the protocol and procedures were carried out in accordance with 
the latest version of the Declaration of Helsinki. Soldiers were given the opportunity to 
voluntarily participate after receiving a study brief by the Principal Investigator (Dr. 
Dretsch) at a designated facility on the military installation. Data were collected from two 
brigade combat teams deploying to Iraq and Afghanistan (active-duty US Army soldiers 
from the 2nd Brigade, at Fort Riley, KS. and the Ohio National Guard stationed at Camp 
Shelby, Mississippi). An IRB approved informed consent was provided to each potential 
participant in accordance with the International Conference on Harmonization (ICH) 
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guidelines and a signed consent was obtained from all participants in the presence of an 
ombudsperson. The volunteers were then escorted to a separate classroom for 
computerized testing and to the phlebotomy stations where several tubes of blood were 
drawn for genotyping and pre-processing for omic analyses. Standard operating 
procedures (SOPs) were employed for recruitment and sample processing for all 
individuals (controls, TBI, PTSD and TBI+PTSD subjects) so that they were identical.  
Briefly, samples were processed and frozen immediately after collection. For whole 
blood, a 1 ml aliquot was transferred from the vacutainer tube a 2.0ml Eppendorf tube. In 
order to minimize pre-analytical artifacts Ethylenediaminetetraacetic acid (EDTA) tubes 
were used for plasma collection. Plasma was then centrifuged for 10 minutes at 3,200 x g 
RCF at 4ºC before being added to protease inhibitors (antipain and pepstatin) in order to 
prevent protein degradation. Plasma was then aliquoted into Eppendorf tubes and samples 
were immediately stored in a dry ice freezer prior to transport to a -80°C medical 
specimen freezer at the end of each day. 
Throughout the study technicians were blinded to the diagnostic status of the samples. 
Members of the Roskamp Institute staff were deployed to both sites during the 
recruitment periods in order to conduct and oversee all blood collection and processing 
according to our SOPs. Approval was attained from brigade commanders. Participants 
received a check for $50 (USD) for the blood draw. 
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Psychological tests and questionnaires (the following described tests can be found 
in the appendix, Chapter 2; Section 2): 
Screening included basic demographics including: history of TBI (including 
military-associated injury and all other traumas), alcohol use, medical history, prior 
deployments, current medications, PTSD symptoms, and depression.  
 
PTSD Checklist—Military Version (PCL-M)257: The PCL-M  is a 17-item self-report 
measure of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) symptoms of PTSD. The used cut-off score of ≥35 has been shown to have 
sensitivity and specificity for screening troops for PTSD is recommended by the National 
Center for PTSD258. 
 
The Life Events Checklist (LEC) 259: The LEC is a 17-item self-report measure, screening 
for potentially traumatic events in a respondent’s lifetime. Sixteen of the items assess 
exposure, which is known to potentially result in PTSD or distress; the remaining item 
assesses any other extraordinarily stressful event not captured in the first 16 items. 
 
Brief Traumatic Brain Injury Screen (BTBIS) 260: The BTBIS is a three-item assessment 
used by the Army to identify soldiers who may have sustained an mTBI. Subjects 
identify the mechanism (e.g., fragment, vehicular, blast, etc.), symptoms that occurred 
immediately after the injury, and current symptoms believed to be associated with an 
injury. A positive mTBI score required both the endorsement of an injury-related event 
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and, at minimum, an altered state of consciousness (e.g., being dazed, confused, or 
“seeing stars”; post-traumatic amnesia; loss of consciousness <20 min). 
 
Zung Depression Scale (ZDS) 261: The ZDS is a 20-item self-report depression rating 
scale. The ZDS produces scores ranging from 20 through 80; 20–44 for normal range, 
45–59 for mildly depressed, 60–69 for moderately depressed, and 70 and above for 
severely depressed. 
 
Zung Anxiety Scale (ZAS) 262:  This ZAS is a 20-item self-report anxiety rating scale. The 
ZAS has scores ranging from 20 through 80; 20–44 for normal range, 45–59 for mild-to- 
moderate anxiety, 60–74 for marked to severe anxiety, and 75–80 for extreme anxiety.  
 
Alcohol Use Dependency Identification Test (AUDIT) 263: This 10-item instrument is 
used to assess alcohol use. A score of 8 or more in men, and 7 or more in women, 
indicates possible hazardous or harmful alcohol use. A score of 20 or more suggests 
potential alcohol dependence. 
 
Epworth Sleepiness Scale (ESS) 264: This instrument asks the subject to rate his or her 
probability of falling asleep on a scale of increasing probability from 0 to 3 in eight 
different situations.  
 
Pittsburgh Sleep Quality Index (PSQI) (Buysse et al. 1989): This 19-item instrument is 
used to measure sleep quality during the previous month and discriminates between good 
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and poor sleep. The PSQI assess several domains including subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep 
medications, and daytime dysfunction.  
 
Neurocognitive measures 
Central Nervous System-Vital Signs (CNS-VS)265: The CNS-VS is a computerized 
neurocognitive assessment battery. The present study used five CNS-VS subtests (verbal 
memory, symbol digit coding, Stroop test, continuous performance test, and shifting 
attention test). The CNS-VS domain scores calculated were verbal memory, complex 
attention, reaction time, processing speed, cognitive flexibility, and executive 
functioning.  
 
Plasma protein fractionation 
For proteomic analysis, after lipid depletion through a non-denaturing solvent 
system, the dynamic range of protein abundance in plasma was first reduced through 
protein fractionation and albumin depletion followed by alkylation. Protein concentration 
for each sample was assessed before tryptic digestion, peptide labeling and offline high-
pH reversed phase chromatography in order to decrease sample complexity at the peptide 
level. This was followed by LC MS/MS analysis. For proteomic experiments low-
retention tips/tubes were used and all reagents were LCMS grade. 
 
Non-denaturing delipidation: 
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Equal amounts of sample from each subject (150µl) were centrifugally 
delipidated according to van Eyk, and the partially clarified plasma was transferred to a 
new tube.  Each sample was then diluted with 400µl of chilled phosphate-buffered saline 
(PBS). 500µl of a non-denaturing solvent system [2:3 n-butanol : DIPE (diisopropyl 
ether) 266] was added for further delipidation of plasma. After centrifugation, the upper 
(lipid-containing) phase was removed and the lower (protein-containing) phase was used 
for protein fractionation.  
 
Albumin depletion and protein fractionation: 
Albumin depletion was carried out by addition of concentrated ethanol to a final 
concentration 42% v/v with shaking to avoid sample variability due to localized 
concentrations of EtOH that exceed 42% v/v.  The samples were then incubated at 4ºC 
for one hour, followed by centrifugation to collect an albumin-depleted fraction.  The 
resultant pellet was resuspended in 25mM Triethylammonium Bicarbonate (TEAB), pH 
= 8.0 and 0.5% sodium deoxycholate (SDC). Protein concentrations for each sample were 
assessed using the bicinchoninic acid (BCA) assay (standards were 0, 5, 10, 20, and 30 
µg of BSA per 50 µl of buffer) and prepared in triplicates. The color change of the BCA 
reagent was measured via absorbance at 562nm. BCA concentration data and sample 
integrity were verified using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and staining.  10µg of the delipidated, albumin-depleted samples were 
separated on a 4-12.5% Nu-PAGE gel (Invitrogen) in MES (2-(N-morpholino) 
ethanesulfonic acid) buffer. Following electrophoresis, gels were fixed in 30% 
isopropanol, 2% H3PO4, followed by Sypro staining and imaging.  
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Tryptic digestion, internal standards, and Tandem Mass Tagging (TMT) 
Following verification, equal amounts of sample from each subject (100µg) were 
de-salted using acetone precipitation and the pellets were re-suspended in 10µl of 10X 
reduction, alkylation, resuspension buffer (RB), containing 25mM TEAB, 5% SDC and 
1mM tris(2-carboxyethyl)phosphine (TCEP) and 2mM chloroacetamide (CAM) for 
simultaneous sample reduction and alkylation. Samples were incubated for thirty minutes 
at 37ºC in darkness.  Finally, each sample was digested by addition of 90µl 25mM TEAB 
supplemented with 0.5µg of porcine sequencing grade trypsin, and the small subunit (ss) 
of Rubisco (0.125ug/sample) as an internal standard [a plant protein with an amino acid 
sequence not present in the human proteome, ssRubisco will not interfere with 
identification of endogenous plasma proteins. Samples were digested overnight at 37ºC. 
In order to enable multiplex relative quantitation by mass spectrometry of ten different 
samples the Thermo Scientific TMT TM Mass Tag Labeling Kit (10plex) was used. The 
TMT reagents contain an amine-reactive group, which covalently binds to peptide N-
termini or to lysine residues, a MS/MS reporter and mass normalizer (balancer) 
group. Each isobaric reagent contains an identical set of light and heavy isotopes that are 
uniquely divided between the balancer and reporter regions (Figure 2-1).  
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Figure 2-1 Chemical structures of the amine-reactive Tandem Mass Tag™ Reagents 
A. Functional regions of the reagent structure including MS/MS fragmentation sites by 
higher energy collision dissociation (HCD) and electron transfer dissociation (ETD). B. 
Structures of the TMT10 plex reagent distinguishable through the 13C and 15N heavy 
isotope positions (shown in red asterisks). Picture permitted to use from Thermo Fisher. 
 
Therefore, all reagents have an identical mass, while each reporter region produces a 
unique m/z reporter ion. Since each sample is derivatized with a different isotopic variant 
of an isobaric mass tag from a set, samples can be pooled and analyzed simultaneously in 
MS after being labeled (Figure 2-2). 
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Figure 2-2 Example of TMT-based proteomic workflow, adapted from Thermo Fisher 
TMT-10plex system. 
 
In the MS1 scan peptides labeled with isotopic variants of the tag appear as a 
single composite peak at the same m/z value with identical liquid chromatography (LC) 
retention time (Figure 2-3, top). The following MS/MS fragmentation generates from 
each modified precursor ion reporter ion peaks and peptide fragment ion peaks (Figure 2-
3, bottom). Quantification is then achieved via correlations of the relative intensity of 
reporter ions to that of the peptide selected for MS/MS fragmentation. For peptide 
identification, fragment ion peaks are used which are observed at higher m/z. They are 
specific for peptide amino acid sequence that can be assigned to the proteins that they 
represent. Finally, TMT reagents label every tryptic peptide; therefore more than one 
peptide representing the same protein can be identified, which increases identification 
and quantification confidence. 
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Figure 2-3 MS workflow of an isobaric labeling experiment. Following MS1, peptides 
with the same sequence from different samples appear as a single unresolved additive 
precursor ion. After MS/MS, the ten reporter ions (here only shown six) appear as distinct 
masses between m/z 126−131, and the remainder of the sequence-informative b- and y-
ions remains as additive isobaric signals. Intensity of the reporter ion indicates the 
relative amount of peptide in the mixture that was labeled with the corresponding reagent. 
Used with permission from Rauniyar et. al. 267 
 
 
Participant samples (Controls, TBI, PTSD and TBI+PTSD) were labeled using 
TMT reagents 126−129 (N and C tags included), while the reference samples (pooled, 
depleted plasma from multiple healthy controls) were consistently labeled using TMT-
130C and TMT-131. The experimenter was blinded to the diagnostic group. There were a 
total of 120 participant samples to analyze, and additionally two reference samples 
required per 10-plex, which led to a total of fifteen separate 10-plexes. Each TMT sample 
was resuspended in 20mM TEAB in acetonitrile (ACN) and then added to 10µg of dried 
peptide samples. Samples were incubated with their respective label for 1.5h in the dark 
Labeled & pooled 
samples 
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and then pooled (10 samples with 10 different labels) into one sample and 0.1% formic 
acid (FA) was added to stop the reactions. Labeled samples within each TMT 10-plex set 
were combined into one vial and processed according to the workflow outlined in Figure 
2-2. Each 10-plex contained randomized samples, but was balanced in regards to number 
of controls, TBI, PTSD and TBI+PTSD subjects. 
 
Offline high-pH reversed phase chromatography 
In order to decrease sample complexity at the peptide level, a modified protocol 
adapted from Gilar 268  was used to perform two-dimensional high pH reverse phase spin 
column chromatography (HPRP) prior to LCMS analysis for each pooled 10-plex. Dried 
samples were re-suspended in 20mM Ammonium Formate (pH = 10) and applied to a 
C18 reversed phase Spin Column (Thermo). Acetonitrile (ACN) in binding buffer was 
added to the column with stepwise increments of 10% ACN, yielding 5 fractions (0, 10, 
20, 30, and 40% acetonitrile in 20mM Ammonium Formate) for each sample. All 
samples were dried down and re-suspended in 10µl 0.1% FA in preparation for additional 
de-salting using C18 reversed phase ZipTips (Millipore) according to manufacturer’s 
instructions.  
LCMS/MS 
To remove residual ACN following HPRP, the peptide fractions were again taken 
to dryness in a vacuum centrifuge.  After being dried down again, samples were re-
suspended in 0.1% FA and applied to a 0.075 x 150mm C18 (1.3µm particle size) 
Pepmap column (Dionex). Separation was carried out for over a 100-minute linear 
gradient from 2 to 30 % acetonitrile at 300nl/min. Mass spectrometry was 
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performed using a Q-Exactive Orbitrap (Thermo).  The MS was run in data-dependent 
acquisition (DDA) mode, using a top-10 duty cycle, wherein one full scan spectrum was 
acquired, followed by ten MS/MS spectra.  The scan ranges were 380 – 1250 m/z for full 
scans, and a minimum m/z of 100 for MS/MS scans (the maximum m/z of each MS2 scan 
is derived from the precursor mass of the peptide being fragmented).  Full scan MS 
resolution was set to 140,000 (FWHM, at m/z = 200) resolution and 35,000 resolution for 
Higher-energy C-trap dissociation (HCD) MS2 spectra.  The isolation width was set to 1.2 
m/z and MS2 reactions were performed at chromatographic peak apex.  These settings 
were chosen as a compromise between quantitative accuracy (relies on statistically-
reliable numbers of full scan spectra for peak integration) and sensitivity (number of 
peptides identified).  
 
Proteomic Data Processing and Statistical Analysis 
Samples were analyzed by LCMS/MS (Q-Exactive). PMi Preview software was 
used to survey the data files and if necessary add other modifications to the search 
criteria. Also, Preview results were used to choose the precursor and fragment ion mass 
tolerances (4 ppm, 0.02 Da, respectively).  The Uniprot Human database (Downloaded 
march 2014) and common contaminant protein database provided by Byonic used in 
searches. The following settings were used to search the data using SEQUEST and 
BYONIC as the search algorithms; dynamic modifications; Oxidation / +15.995 Da (M), 
Deamidated / +0.984 Da (N, Q), Methyl / +14.016 Da (H, N, R) static modifications of 
TMT 10 plex / +229.163 Da (N-Terminus, K), Carbamidomethyl +57.021 (C).  Only 
unique peptides were considered for quantification purposes. The peptide validator 
 84 
feature of Proteome Discoverer 2.1 was used to set a false discovery rate (FDR) of 0.01.  
Quantitative analysis of the TMT experiments was performed simultaneously to protein 
identification using Proteome Discoverer software. Reporter ion quantification of HCD 
MS2 spectra was enabled, and TMT-10 plex was set as the quantification method. The 
quantification values were extracted from the reporter ion intensities. The "Total Peptide 
Abundance" method was used to adjust for loading bias. Reference samples 130C and 
131 were utilized to allow for cross set comparison. However, upon manual checks it was 
decided that channel 130C was not consistent across different plexes and was excluded 
from analysis. TMT channel 131 was used as a denominator to control abundance 
variation for each plex. Peptides identified in at least 8 of plexes were used in the 
quantitative analysis. Proteins (including the ones identified by a single peptide) were 
only included in subsequent analyses if they met the following requirement: the peptides 
that were assigned to them could not be assigned to other possible proteins. Proteins 
passing this cutoff value were exported to JMP (SAS) 8.0.2 for data cleaning and 
statistical analysis. After log2 transformation of the raw ion counts, each channel was 
divided with channel 131. The protein level abundance ratios were calculated according 
to formula 2.1 where p is a given unique peptide.  
 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 = !!!!!!!!….!!"!!!!!!!!….!!"     Formula 2.1 
 
 
Finally, we used mixed model ANOVA where Subject ID was a random variable 
nested in Plex no. and Category, and where Plex no. was random and Category were 
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fixed effects, to identify proteins that were regulated across comparison groups 
(Category). Statistical analysis was performed using JMP 8.0.2 (SAS). The multiple 
testing correction as per Benjamini & Hochberg (B-H) 269 was applied to have a FDR of 5 
percent. P values < 0.05 were considered statistically significant. 
 
ELISA 
The concentrations of human leucine-rich alpha-2 glycoprotein 1 (LRG1) and 
hemoglobin subunit beta (HBB) in plasma were determined using a competitive 
inhibition enzyme-linked immunoassay (LRG1 ELISA (MyBioSource.com) and HBB 
sandwich ELISA (LifeSpan BioSciences, Inc, WA) respectively), following 
manufacturer’s instructions. Briefly, for LRG1, samples were added to 96-well plates that 
were coated with a Horseradish Peroxidase (HRP) conjugated LRG1. A competitive 
inhibition reaction was launched between LRG1 in samples and HRP-conjugated LRG1 
with the pre-coated antibody specific for LRG1. The more the amount of LRG1 in the 
samples, the less antibody bound by HRP-conjugated LRG1. Samples were washed and a 
substrate was introduced that was converted by the enzyme attached to the detection 
antibody and color development was inversely related to the amount of LRG1 in the 
sample. The color development was stopped and absorbance of each well was quantified 
at a 450nm wavelength.  
For HBB, samples were added to a 96-well plate that was coated with a target 
specific capture antibody. A biotin-conjugated detection antibody was added followed by 
a wash step and an HRP conjugate, which bound to the biotin. Unbound HRP conjugate 
was washed away and a 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate added which 
reacted with the HRP enzyme resulting in color development. The color development 
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was stopped and absorbance of each well was quantified at a 450nm wavelength.  
A standard curve was created (www.elisa analysis.com/) and LRG1, as well as HBB 
concentrations were calculated. Significance was determined by one-way ANOVA. P 
values < 0.05 were considered statistically significant. 
Logistic regression modeling was employed to construct receiver operator curves 
(ROC) to examine the predictive performance of LRG1 in relation to the diagnoses of 
TBI, PTSD and TBI+PTSD. ROC curve comparisons were based on area under the curve 
(AUC), SE, and the associated 95% confidence interval (CI).  Subsequently sensitivity of 
the various diagnostics using the predicted probability of each subject by logistic 
regression modeling with specificity of at least eighty percent was calculated. All 
analyses were conducted using the SPSS version 24.0 for Macintosh. 
 
2.3 Results 
The baseline demographics for the cohort of active-duty soldiers investigated in 
this study are given in Table 2-1. After screening 458 soldiers, a total of 120 samples 
were included in the study, containing controls (n=52), subjects with a history of TBI 
(n=21), PTSD (n=34) and TBI+PTSD (n=13). Figure 2-4 shows the recruitment 
disposition chart. No difference was observed for mean age between the described 
groups. Education (in years) was slightly higher within the TBI+PTSD group compared 
to control, TBI and PTSD subjects (p=0.035). No significant difference was observed for 
ethnicity among groups. There were no significant differences between the controls and 
TBI, PTSD, and TBI+PTSD subjects’ age and education. All participants were male. 
With regard to prior deployments, we ensured during our experimental design that not 
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only the TBI, PTSD, and TBI+PTSD cohorts comprised soldiers with previous 
deployments, but the control group also was composed of soldiers who had been 
previously deployed to the Iraq/Afghanistan conflicts (n=35 control subjects, n=14 in the 
TBI group, n=23 in the PTSD group, and n=13 in the TBI+PTSD group). Subjects were 
included if they sustained a TBI during military training, which is common among active 
duty soldiers or from previous deployments. Control subjects had no history of TBI 
and/or PTSD, depression, alcohol abuse or sleep deprivation. Chi-square analysis 
revealed that prior deployment status was not significantly different across the diagnostic 
categories (p=0.213). 
 
 
 
 
  Control  TBI PTSD TBI+PTSD Chi 
  n=52 n=21 n=34 n=13 square 
Age (M, SD) 26.7 ± 6.9 25.9 ± 6.3 26.4 ± 7.4 29.9 ± 5.6  p = 0.416 
Education 
(M, SD) 12.9 ± 1.3 13.0 ± 1.4 12.9 ± 1.4 14.2 ± 1.7 
 
p = 0.051 
Male  52  21  34  13   
Ethnicity 
   
 p = 0.903 
White (%) 39  (75.1) 15 (71.5) 25 (75.8) 10 (83.3)  
African 
American (%) 2 (3.8) 2 (9.5) 4 (12.1) 0 (0) 
 
Hispanic (%) 5 (9.6) 2 (9.5) 3 (9.1) 2 (16.7)  
Others (%) 6 (11.5) 2 (9.5) 1 (3.0) 0 (0)  
 
Table 2-1 Baseline demographics for clinical cohort. Recruited subjects were all male 
active duty soldiers. No differences in age, education and overall ethnicity were observed 
among the diagnostic groups. 
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Figure 2-4 Disposition chart: A total of 469 subjects were recruited into the study. 4 
Samples were misplaced, 4 mislabeled and 22 samples had missing data. 52 subjects 
were excluded from the study, as they are being used for another pre and post deployment 
study paradigm. From the 387 remaining subjects 267 subjects were excluded, as 58 
subjects showed a history of other psychological conditions (e.g. anxiety, depression) or 
undocumented PTSD history, 111 had undocumented, not military related concussions, 
claimed to have brain damage within the last year but did not receive a TBI diagnosis 
(n=7). 91 subjects were excluded, as they are being used in other studies. The remaining 
120 subjects were included in omic analyses. 
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Neuropsychological measurements 
Category averages for the neuropsychological measurements are presented in 
Table 2-2. For positive PTSD diagnosis, participants had to score ≥35 on the PCL-M. 
PCL-M scores were significantly higher for the PTSD (45.1 ± 1.4) and TBI+PTSD (42.8 
± 1.6) groups compared to controls (19.8 ± 0.5) and TBI only (21.6 ± 1.5) (p<0.001 for 
PTSD and TBI+PTSD compared to TBI and controls). Data was normally and not 
biphasic distributed. Participants positive for PTSD also had significantly higher scores in 
anxiety (p<0.001), depression (p<0.001), sleepiness (p<0.001) as well as exhibited lower 
sleep quality (p<0.001). There were no differences in groups regarding alcohol 
consumption (p=0.19) and the Neurocognitive Composite Index (p=0.98).  
Subjects within the TBI and TBI+PTSD group had sustained TBIs, which were 
categorized as mild TBIs resulting from one or more of the following: fragment, bullet, 
vehicle, fall, Improvised Explosive Device (IED), rocket-propelled grenade (RPG), land 
mine or grenade. Symptoms at the time of injury included: being dazed, confusion, not 
remembering the injury, loss of consciousness up to a maximum of thirty minutes, as well 
as continuous symptoms of concussion post injury (headaches, dizziness, irritability etc.) 
and at the current time of participant recruitment and sample collection. Of ongoing 
symptoms 42% of subjects who had sustained a TBI reported sleep problems and 
headaches, 38% experienced memory problems, 29% heard ringing in their ears, 24% 
showed irritability. Less common symptoms included dizziness (19%) and balance 
problems (14%). Control subjects scored negative on all traumatic stress questionnaires 
and had sustained no TBI. 
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  Control  TBI PTSD TBI+PTSD Chi-square 
PCL-M  19.8 ± 0.5 21.6 ± 1.5 45.1 ± 1.4 42.8 ± 1.6 p < 0.001 
ZDS  31.7 ± 0.8 34.7 ± 2.4 46.5 ±1.5 41.1 ±1.5 p < 0.001 
ZAS  29.4 ± 0.7 32.5 ± 2.1 37.1 ± 1.6 33.8 ± 2.2 p < 0.002 
ESS  7.5 ± 0.6 9.1 ± 1.2 11.0 ± 0.8 8.4 ±1.0 p < 0.0093 
PSQI   5.2 ± 0.3 6.9  ± 0.5 8.2 ± 1.1 7.4 ± 0.9 p < 0.001 
AUDIT  6.0 ± 0.6 6.2 ± 1.2 8.4 ± 1.1 7.2 ±1.3 p = 0.19 
CNS-VS  72.7 ± 4.8 72.6 ± 5.2 72.9 ± 3.9 69.4 ± 8.7 p = 0.98 
Total previous 
deployments 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 1.9 ± 0.2 p = 0.213 
 
Table 2-2 Neuropsychological measurements in mean ± SEM. Subjects scoring 
positive for PTSD had significantly higher scores at the PCL-M (score≥35; p<0.001), as 
well as higher scores for ZDS (p<0.001), ZAS (p<0.002) and ESS (p<0.0093). TBI 
subjects scored below 35 at the PCL-M and scored positive for TBI on the BTBIS. 
Control subjects had PCL-M scores below 35 and no sustained TBI. No differences were 
observed for AUDIT and CNS-VS screening between groups. 
 
 
 
Proteomic analysis 
We performed quantitative proteomics, by using TMT isotopic labeling of trypsin 
digests and separation via LC, which was followed by MS2 to quantify any global protein 
changes, which correlated with TBI and/or development of PTSD. A comparative 
analysis between controls and the three groups (1) TBI diagnosis 2) PTSD diagnosis 3) 
TBI/PTSD diagnosis, was performed using the workflow described in Figure 2-1. We 
identified a total of 703 peptides in at least eight 10-plex groupings. 136 proteins were 
included in the statistical analysis and 4 reverse sequence proteins and one contaminant 
and one human albumin were excluded. Before multiple test correction was applied three 
proteins reached significance (see below), however after post-hoc analysis no protein 
passed the threshold (Table 2-3).  
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Description Accession Prob > F 
FDR Adjusted 
p Value 
Leucine-rich alpha-2-glycoprotein P02750 0.014 0.45 
Hemoglobin subunit beta  P68871 0.024 0.97 
Vitamin K-dependent Protein S P07225 0.036 0.97 
 
Table 2-3 Statistically significant proteins identified by ANOVA before post-hoc 
analysis and with corrected FDR p-value. 
 
In Figure 2-5 a-c scatterplots of these 3 proteins are shown, as identified by 
LCMS. MS data is represented as log2 (data) of subject/channel 131. Although 
significance was not achieved after post-hoc analysis, we decided to perform ELISA on 
Leucine-rich alpha-2-glycoprotein (LRG1), as the scatterplot indicated a higher trend for 
the TBI+PTSD group (data represented in log2(mean concentration)).  
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Figure 2-5 Scatterplots of proteins, identified via LCMS, which reached significance 
after ANOVA, before post-hoc a) LRG1 b) Vitamin K dependent Protein S c) 
Hemoglobin subunit β. Data are represented in log2 of (subject/channel 131) for MS 
analysis. 
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The ELISA revealed significantly elevated levels of LRG1 in TBI, PTSD and 
TBI+PTSD subjects compared to controls (Prob>Chi square: TBI:  p < 0.001; PTSD p = 
0.001; TBI+PTSD p<0.001; Figure 2-6). Mean (and SEM) concentration for LRG1 in 
plasma was observed as follows: Control: 33.7 ± 1.5 µg/ml; TBI: 57.1 ± 3.3 µg/ml; 
PTSD: 43.3 ± 2.1 µg/ml; TBI+PTSD: 95.1 ± 5.1 µg/ml. 
 
 
 
Figure 2-6 ELISA LRG1 in subjects with TBI, PTSD and TBI+PTSD. LRG1 levels 
were significantly elevated in TBI, PTSD and TBI+PTSD patients (data represented in 
log2 (mean concentration). 
Examination of sensitivity and specificity using ROC analysis revealed the AUC 
for the different diagnostics/control as follows: For TBI/Control the AUC was 0.886 
(95% CI [0.802–0.971], p< .001). For PTSD/Control the AUC was 0.715 (95% CI 
[0.605–0.825], p< 0.05). When investigating TBI+PTSD/Control subjects, the AUC was 
increased to 1.000 (95% CI [0.86–0.95], p< .001). The various ROC curves are displayed 
in Figure 2-7. Note: As ranges of LRG1 concentration of control and TBI+PTSD subjects 
did not overlap, a ROC curve could not be created at this point. Optimal sensitivities with 
Co
ntr
ol TB
I
PT
SD
 
TB
I+P
TS
D
4.0
6.0
8.0
lo
g2
 (d
at
a)
LRG1 Elisa
Control
TBI
PTSD 
TBI+PTSD
 94 
specificity of at least 80% predicted probabilities are shown in Table 2-4. The highest 
sensitivity and specificity was achieved with LRG1 for TBI+PTSD/Control. ROC tables, 
containing all values for sensitivity and 1-specificity can be found in the appendix section 
2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model (LRG1 
concentration) 
 
 
Sensitivity  Specificity  # R2 
 
TBI/Control 
  
76% 
  
80% 
  
0.52 
PTSD/Control  50%  80%  0.19 
TBI+PTSD/Control  100%  100%  1.00 
Table 2-4 Optimal sensitivities with specificities at least 80% for the various 
diagnostic models*.  
*Calculations based on predicted probabilities form binary logistic Regression.  
# Represents Nagelkerke R2  
 
 
Figure 2-7 ROC curves for TBI/Control (red) and 
PTSD/Control (blue). TBI+PTSD/Control is not displayed. 
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We further used the same regression analysis to develop models for PTSD/TBI, 
TBI+PTSD/TBI and PTSD/TBI+PTSD prediction. ROC analysis revealed the AUC for 
as follows: For PTSD/TBI the AUC was 0.767 (95% CI [0.633–0.900], p < 0.05). No 
model could be deployed for TBI+PTSD/TBI and TBI+PTSD/PTSD, as LRG1 
concentration did not pass significance test during linear regression. The ROC curve for 
the PTSD/TBI model is displayed in Figure 2-8. Table 2-5 shows specificity of 80% 
predicted probabilities for PTSD/TBI. ROC tables can be found in the appendix section 
2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-8 ROC curve for PTSD/TBI. 
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*Model Sensitivity Specificity # R2 
PTSD/TBI 50% 80% 0.241 
TBI+PTSD/TBI NA NA NA 
TBI+PTSD/PTSD NA NA NA 
    
Table 2-5 Optimal sensitivities with specificities at least 80% for the various 
diagnostic models*.  
*Calculations based on predicted probabilities form binary logistic Regression.  
# Represents Nagelkerke R2  
 
As significance was achieved for LRG1 we also employed an ELISA for the 
second most significant protein on the list before multiple test correction (HBB). Using 
this antibody-based approach for HBB, no significant difference was observed between 
control, TBI, PTSD and TBI+PTSD subjects (Figure 2-9). Mean (± SEM) concentration 
for HBB in plasma was observed as follows: Control: 13.8 ± 0.5 ng/ml; TBI: 13.1 ± 0.6 
ng/ml; PTSD: 14.0 ± 0.5 ng/ml; TBI+PTSD: 12.9 ± 0.6 ng/ml. 
 
 
 
Figure 2-9 ELISA HBB in subjects with TBI, PTSD and TBI+PTSD. Plasma levels of 
HBB showed no differences across TBI, PTSD and TBI+PTSD patients or controls (data 
represented in log2(mean concentration). 
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As HBB, being the second most significant protein on the list before FDR 
correction, did not reach significance for any diagnostic group, no ELISA was performed 
for Protein S. 
 
2.4 Discussion 
 
In this study we tried to evaluate if mTBI and PTSD, and biomarkers unique to 
their chronic presentation, are detectable in the plasma and influence protein changes, 
which can be used for diagnosis or to identify potential therapeutic approaches. The field 
of proteomics has developed rapidly in the past decade, leading to the discovery of 
biomarkers not previously available 270. The global proteomics approach used in this 
analysis allowed us to objectively investigate changes in control versus disease state, in 
order to identify distinctive protein biomarkers uniquely up- or down-regulated. 
In this cross-sectional study, we investigated plasma profiles in active-duty 
soldiers that had a history of mild TBI, PTSD, or both, and controls (with respect to TBI 
and/or PTSD). 
We chose plasma over serum, because plasma can be processed immediately. 
Serum has to clot before it can be processed and stored. The time from collection to 
processing and freezing leads to an increase in sample complexity due to the activity of 
degrading enzymes. This can result in a wrongly representation of the observed 
biological parameters. Furthermore, we chose a centrifugation speed of 3,200 x g RCF. 
Our protocols are optimized to ensure that there is no coagulation and that shearing of 
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cells does not occur due to high centrifugation speed, to which mammalian cells are 
particularly sensitive, and which could contribute to generating cellular debris 271. 
Another important factor, which can potentially influence the results of our study, 
is the time of sample collection. Many parameters, such as peptide hormones and 
cytokines have diurnal rhythms. Therefore, compounds like cortisol should be measure 
with caution. Other analytes, such as Aβ peptides, have shown to be more stable over 24h 
with little intra-individual variation272. 
 Three proteins (LRG1, Protein S, and Hemoglobin) were identified to be 
significantly different in the plasma of subjects across these diagnostic categories, 
however the false discovery rate (FDR) calculated for each protein was higher than the 
initial threshold established. Although the FDR was high for each of these proteins across 
the different diagnostic categories, we decided to further investigate the protein with the 
lowest p-value and FDR (LRG1) by performing antibody-based analysis with ELISA. 
The reasoning behind this analysis was the fact that the most stringent statistical analysis 
was used for data generation and that scatterplots of the data suggested an increase of 
LRG1 within the TBI+PTSD group. Moreover we did not want to inadvertently overlook 
a true positive marker due to relatively high p value caused by lack of statistical power. 
Furthermore, the TMT approach is limited by reporter ion ratio compression, which 
partially obscures the observation of significant differences within heterogeneous 
samples 273. After ELISA, we observed a significant increase for TBI, PTSD and 
TBI+PTSD subjects for LRG1 compared to controls. In our study the TBI+PTSD group 
showed the largest difference to control subjects with an increase of 2.8 fold (1.7 fold for 
TBI and 1.3 fold for PTSD).  The physiological concentrations for LRG1 in plasma of 
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healthy subjects ranges from 21-50 µg/ml 274. We measured a mean of 33.7 µg/ml in our 
control subjects, which lies within the normal range of LRG1.  If we would use the upper 
end of the physiological range of LRG1 (50 µg/ml), instead of our measured mean of 
control subjects (33.7 µg/ml) the fold increase would diminish but still be significant with 
approximately 1.9 fold for TBI+PTSD, whereas the data from the pure TBI and PTSD 
cohorts would lose their significance. While LRG1 levels in the TBI cohort gave an 
acceptable 76% sensitivity at 80% specificity, in the PTSD cohort the sensitivity and 
specificity performance for LRG1 was poor.  Thus LRG1 plasma concentration was best 
for predicting TBI+PTSD. 
The human glycoprotein LRG1 consists of 312 amino acids with a molecular 
weight of 34-36 kD 275. Although LRG1 function still remains unknown it has been 
implicated in various roles such as in granulocytic differentiation 276 and cell adhesion 
277,278, as well as in cell migration 279. It furthermore has been shown to be involved 
upstream of the TGF-βR II pathway 280,281, suggesting a role in signaling and was 
proposed to be important for cell survival and apoptosis 274,282.  LRG1 is usually 
characterized as an “acute phase” protein, which is produced by the liver in response to 
infection or injury 274. Although LRG1 has not been implicated in chronic TBI and PTSD 
physiology itself, the protein has been studied in conjunction with stress. A recent study 
investigated changes in gene expression levels in response to psychogenic stress in mice 
283. Findings showed stress induced up regulation of the Lrg1 gene within the 
hippocampus. Besides its involvement in the stress response, LRG1 has been the focus in 
other disease areas. For example increased expression levels of LRG1 were detected in 
serum of ovarium cancer patients 284,285. LRG1 has been further suggested as a potential 
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biomarker for detection of epithelial ovarian cancer (EOC) as it has been shown that 
LRG1 is significantly increased in EOC cases compared to healthy controls 286. 
Moreover, studies have shown increased LRG1 levels in the medium and low abundance 
serum proteins of individuals suffering from lung and pancreatic cancers 287,288. As such, 
elevation of LRG1 as a biomarker for chronic TBI+PTSD might have potential but is not 
unique to the condition. Furthermore, although plasma is an ideal platform for biomarker 
discovery, due to its easier accessibility, and relatively cheap analytical protocols, one 
challenge is the diversity in protein abundance, with a total of 90% of the whole plasma 
proteome being distributed across a dozen proteins (e.g., albumins and 
immunoglobulins). This makes the discovery of low-abundant TBI and PTSD biomarkers 
difficult, and as described, different techniques are required to deplete those abundant 
proteins before MS analysis. Yet differences in sample preparation can influence 
biomarker discovery, which could explain why the proteins we observed via MS did not 
reach significance after multiple test correction. Furthermore, one of the major challenges 
with this approach is the broad scattering of the quantitative data caused both by 
individual variations in protein abundances and in analytical variation 251, as such large 
cohorts are needed to confirm these data. Additionally, our cohort consists of male 
subjects only. In the future, female subjects should be included in the analysis.  
Finally, LRG1 concentration should be investigated in mouse models of the 
described conditions. In Chapter 4 we will observe LRG1 in a mouse model of mTBI. 
Furthermore, animal models of PTSD, as well as TBI+PTSD are being developed at the 
Institute. In the future we will expand our analyses to validate LRG1 as a potential 
marker. 
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Finally, our cross-sectional study is a case vs. control study. Subjects were 
categorized into different diagnostic groups and compared on the bases of the described 
attributes (Method section). This type of observationally study allows for the 
identification of factors that contribute to the condition and have the advantage of being 
less costly with fast sample collection. Case-control studies are also used for 
epidemiological studies. They also can have the advantage of having greater statistical 
power, because cohort studies often have to wait for 'sufficient' number of disease events 
to accrue. Yet one has to keep in mind that case-control studies are observational and 
obtaining reliable information about a patient can be difficult, especially considering the 
self-report biases. Furthermore, they do not include symptom-clustering, severity of the 
condition or outcome observations over time. Therefore, cohort studies should be 
conducted in the future to gain more information about the observed changes in TBI and 
PTSD. 
Complementary to the study of the proteome is the study of lipids (lipidomics) via 
MS. Lipid pathway dysfunction has been suggested to be part of the pathological 
underlying mechanism of TBI and PTSD (see next chapter for description), yet 
biomarker research of these conditions has mainly focused on the identification of protein 
and cytokine profiling. Thus, we suggest that the additional investigation of lipids in 
biological samples could add to the identification and value of TBI and PTSD biomarker 
research.  
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Chapter 3 Plasma Lipidomic Profiling in a Military Population 
of Mild Traumatic Brain Injury and Posttraumatic Stress 
Disorder with Apolipoprotein E ε4–Dependent Effect 
 
3.0 Summary 
 
  This chapter continues the characterization of the military cohort of active duty-
soldiers, which was described in Chapter 2. Soldiers were demographically matched and 
blood samples analyzed as before (N = 120) with mTBI, PTSD and mTBI + PTSD and 
those who were considered cognitively and psychologically normal. In this chapter we 
used liquid chromatography/mass spectrometry (LC/MS) analysis to investigate changes 
in phospholipids (PLs). Additionally, soldiers were genotyped for apolipoprotein E 
(APOE) ε4, as ApoE is a regulator of plasma lipids and APOE genotype has been 
associated with TBI outcome. We observed significantly lower levels of several major PL 
classes in TBI, PTSD and TBI+PTSD compared to controls. PTSD severity analysis 
revealed that significant PL decreases were primarily restricted to the moderate-to-severe 
PTSD group.  An examination of the degree of unsaturation showed that 
monounsaturated fatty acid (MUFA) containing phosphatidylcholine (PC) and 
phosphatidylinositol (PI) species were lower in the TBI and TBI+PTSD groups. However 
these PLs were unaltered among PTSD subjects compared to controls. Similarly, ether 
PC (ePC) levels were lower in PTSD and TBI+PTSD subjects relative to controls. Ratios 
of arachidonic acid (AA) to docosahexaenoic acid (DHA) containing species were 
significantly decreased within PC and PE classes. APOE ε4 (+) subjects exhibited higher 
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PL levels than their APOE ε4 (-) counterparts within the same diagnostic groups.  These 
findings suggest that PL profiles, together with APOE genotyping, could potentially aid 
differential diagnosis of mTBI and PTSD.  
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3.1 Introduction 
 
Lipids are defined as organic compounds that are poorly soluble in water but 
miscible in organic solvents. They are a class of biomolecules that play a crucial and 
highly diverse role, not only structural as a major constituent of cell membranes, but also 
in various metabolic pathways. They are involved in regulation of membrane proteins, 
membrane trafficking, cellular architecture and creating specific sub-compartments in 
membranes that contribute to cellular function 289. Thus, it is logical to assume that lipids 
play an important role in various disease and injury pathways. Although the exact 
mechanisms of how lipid complexity affects cell homeostasis remains unclear, the 
emerging field of lipidomics has gained much attention in recent years by the scientific 
community. Furthermore, due to their involvement in various biological processes, lipids 
have become an interesting treatment target and clinical studies have started to 
investigate the effects of dietary lipid supplementation (docosahexaenoic acid (DHA)) in 
injury and disease.  
Sphingomyelin and glycerophospholipids, together defined as phospholipids 
(PLs), are the most abundant lipid constituents in plasma, and also represent 20-25% of 
the dry weight of the adult brain and 50–60% of the total membrane mass, with proteins 
accounting for most of the rest 290. The structure of PLs contains a glycerol backbone 
(except for sphingomyelin (SM), which has a sphingosine backbone) with hydroxyl 
groups esterified at positions 1 and/or 2 with long-chain fatty acids (FA). The first 
position of the glycerol backbone (sn1) contains in general a saturated fatty acid (e.g., 
palmitic or stearic acid), whereas the second position of the glycerol backbone (sn2) 
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contains unsaturated fatty acids, such as arachidonic acid (AA) and docosahexaenoic acid 
(DHA) 290. Among other things, the degree of saturation of these lipids affects membrane 
fluidity. For instance, an increase in saturated lipids elevates viscosity while an increase 
in unsaturated lipids leads to elevated membrane fluidity 290. Phospholipids are divided 
into subclasses based on their unique polar head group, which is linked to the remaining 
position of the glycerol backbone (Figure 3-1). Thus for the phospholipids 
phosphatidylcholine (PC) and SM (on sphingosine backbone), the last position contains a 
choline moiety. For phosphatidylethanolamine (PE) an ethanolamine can be found at this 
spot and for phosphatidylinositol (PI) an inositol group.  Therefore, PLs are amphipathic 
molecules, having a polar head group and non-polar FA chains. 
Lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE) are 
phospholipids derived from PC and PE respectively via phospholipases 291. In blood, LPC 
and LPE are complexed to albumin and lipoproteins, comprising 5-20% of total PL. 
Unsaturated LPC and LPE are mainly released by the liver and their role is to supply 
extrahepatic tissues with both choline/ethanolamine and polyunsaturated fatty acids 
(PUFA) 292–294. 
Phospholipids exhibit various biological functions in mammalian cells: a) 
Providing structural integrity through formation of lipid bilayers, b) Energy reservoir 
functions (e.g. triglycerides), c) Serving as precursors for second messengers such as 
arachidonic acid (AA), docosahexaenoic acid (DHA), ceramide, 1,2-diacylglycerol 
(DAG), phosphatidic acid, and lyso-phosphatidic acid 295. 
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Figure 3-1 Structure of glycerophosphate-based lipids. The complete lipid structure 
shown is 1,2-distearoyl-sn- glycerol-3-phosphocholine or phosphatidylcholine (PC). 
Substitution of choline (in the box) with any of the head groups listed on the side results 
in other phospholipid structures as indicated. Image from 296 Biochemistry of Lipids, 
Lipoproteins and Membranes. 
 
Ether phospholipids (ePL) have one or more of the carbon atoms on glycerol 
bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. If the 
ether lipid has an acetyl group instead of an acyl chain at the sn-2 position it is called 
platelet-activating factor (PAF).  The majority of ether glycerolphospholipid species are 
plasmalogens 297. Plasmalogens are glycerol-containing phospholipids with an 
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unsaturated O-(1-alkenyl) (vinyl ether) group at the sn-1 position on the glycerol chain. 
Plasmalogens are the most abundant form of alkenyl-glycerophospholipids, and their 
synthesis requires functional peroxisomes. Thus, measurement of ePLs can be seen as an 
indirect measure of peroxisome function. 
Altered lipid metabolism is suggested to be a key event which contributes to CNS injury 
298 and abnormal PL profiles have been reported in the CSF of patients with TBI. 
Pasvogel et al. showed that in subjects with severe TBI, levels of PC and PE were 
increased in the CSF of subjects who died days following injury compared to those who 
survived 299. Moreover, studies on veterans with chronic PTSD showed increases in 
cholesterol, low-density lipoprotein, triglycerides, and a reduction of high-density 
lipoproteins in blood 300–303. 
These studies point to a possible association between lipids and TBI and/or 
PTSD. Since certain lipids, such as long-chain polyunsaturated fatty acids (PUFA) are 
acquired from the periphery and transported to the brain, we hypothesize that a history of 
mTBI and/or PTSD in a military population will affect blood PL levels months after the 
trauma; and that lipidomic technology will be ideally suited to identify such biomarkers.  
Using a cross-sectional design, in this exploratory study, we performed PL profiling of 
plasma from active-duty soldiers with TBI and/or PTSD and healthy controls using a 
sophisticated lipidomic platform, which can qualitatively and quantitatively analyze 
several hundred PL species with high efficiency 304.  
Another key regulator of plasma lipid levels is the apoE protein. More 
specifically, apoE is involved in the homeostatic control and distribution of plasma and 
tissue lipid content (Reviewed by 305). ApoE mediates this by binding lipoproteins or 
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lipid complexes in plasma to specific cell-surface receptors such as the low-density 
lipoprotein (LDL) and very low-density lipoprotein (VLDL) receptors. The apoE 
isoforms (apoE2, apoE3, and apoE4) differ in their binding affinity and ability to interact 
with these receptors.  
The APOE polymorphisms have been associated with TBI clinical outcome, which could 
be due to the apoE isoform specific effects with regards to lipid regulation. Multiple 
studies have shown that presence of the APOE ε4 allele has a negative effect on outcome 
following head injury and although widely accepted, these findings have not been 
consistently replicated (extensively reviewed by 306) However, a recent meta-analysis of 
12 studies observed a significant association of APOE ε4 with an increased risk of 
unfavorable long-term (<6 months) functional outcome after TBI 75. As such it is of 
importance to further study APOE in conjunction with TBI in order to understand its 
particular role in injury. 
Given the importance of the ApoE protein in lipid transport, metabolism, and the 
mentioned relationship to TBI, we stratified our study population to investigate any 
potential influence of APOE ε4 genotypes on PL profiles associated with our diagnostic 
categories.  In this study, we explored PL profiles as a first step in the identification of 
mTBI and/or PTSD clinical classifications. With validation in larger cohorts, these 
studies could lead to the development of a biomarker panel that could be used for a 
differential diagnosis of mTBI and PTSD as well as comorbid cases.  
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3.2 Methods 
 
Recruitment of subjects, sample collection and screening measures for the active-
duty military participants is described in Chapter 2 - Method section 2.3. 
 
APOE genotyping 
The laboratory staff was blinded to any sample specific diagnostic classification during 
APOE genotyping. The Gentra Puregene Blood Kit (Gentra Systems) was used to purify 
DNA from frozen whole blood according to the manufacturer’s instructions. For 
amplification and digestion of the APOE gene from extracted DNA, standard PCR 
procedure was used as described by Emi et al. 307. The oligonucleotide primers used in 
this study were:  
F4 (5'-ACAGAATTCGCCCCGGCCTGGTACAC-3')  
F6 (5'-TAAGCTTGGCACGGCTGTCCAAGGA-3')  
Each amplification reaction contained 10 pg of DNA, 1 pmol/ µl of each primer, 
0.05 units/µl of AccuPrime™ GC-Rich DNA Polymerase and AccuPrimeTM GC-Rich 
Buffer (10mM MgSO4, 1mM of each dATP, dGTP, dCTP, dTTP) with water added to a 
final volume of 30 µl. Each reaction mixture was heated at 95°C for 5 min for 
denaturation, and subjected to 40 cycles of amplification by primer annealing (62°C for 1 
min), extension (72°C for 2 min), and denaturation (95°C for 1 min). Polymerase chain 
reaction products were cleaved with restriction endonuclease CfoI (Promega, Madison, 
WI, USA), at 37°C overnight. Digested fragments were separated on 3% agarose gel and 
APOE genotypes were identified from the characteristic electrophoresis patterns. 
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Lipidomic Analysis 
All samples were analyzed using a randomized block design (n=20) where the 
experimenter was blind to the diagnostic group to which each subject was assigned. 
Lipids were extracted from plasma samples (n = 120) using the Folch method (Folch et 
al. 1957). Briefly, synthetic internal standards (di-14:0 FA containing PC and PE, 14:0 
FA containing (LPE) and (LPC), d18:1/17:0 SM, and di-16:0 for PI) were added to 
plasma prior to lipid extraction. 50µl plasma was combined with 20 vol. of chloroform: 
methanol (2:1), followed by centrifugation at 20,000 x g for 10min. The supernatant was 
transferred to a clean vial and then combined with 0.2 vol. of 0.88% Potassium Chloride 
Solution (KCl) followed by centrifugation. The Folch lower phase containing 
phospholipids was dried immediately. Lipid extracts were re-suspended in isopropanol 
and separation was achieved using hydrophilic interaction chromatography (HILIC) on a 
1mm x 100mm column packed with 3µm Pinnacle II silica particles (Restek Corporation, 
Bellefonte, PA, USA). An isocratic run was performed with 70% solvent A (100% 
acetonitrile [ACN]) in 30% solvent B (78% methanol, 1% formic acid, 0.6% ammonium 
hydroxide) for 15 min at a flow rate of 55 µl/min with the column temperature at 40°C. 
Mass spectrometry (MS) was performed with a Thermo LTQ-XL linear ion trap mass 
spectrometer equipped with a Surveyor HPLC pumping system and Micro AS 
autosampler (Thermo-Fisher, Waltham, MA, USA). Full scan negative ion mass spectra 
were acquired from m/z 200 to 2,000 with in-source collision induced dissociation 
(SCID), with relative energies at 15%. All spectra were obtained with a 200 msec 
maximum ion time and by summing of 5 microscans.  
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Figure 3-2 shows a representative total ion chromatogram from an LC/MS run of the 
internal standards for PC, LPC, PE, LPE, PI and SM molecular species and Figure 3-3 
shows an ion MS spectrum of PC molecular species. In order to locate peaks for each PL 
class on the chromatogram the m/z values corresponding to the fragment ions from each 
head-group were used. Furthermore, m/z 184 (the PC fragment ion produced by SCID) in 
the negative ion mode was additionally used to identify the PC, SM and LPC peaks, 
whereas PE and LPE were located on the chromatogram using m/z 140 for PE fragment 
ion. Phosphatidylinositols were identified using the m/z 241 PI fragment ion. 
 
 
 
 
 
 
Figure 3-2 Representative total ion chromatogram: The chromatogram shows ion-plots 
for PC, LPC, SM, PE, LPE and PI internal standards mapping to the time where each of 
these PL classes elute within a 25 minute runtime. Ion plot for m/z 722.5 is [M+CHO2]- 
ion for PC (28:0), a di-14:0 fatty acid containing internal standard. Ion plot for m/z 512.5 
is [M+CHO2]- ion for LPC, a 14:0 fatty acid containing internal standard. Ion plot for 
m/z 761.5 is [M+CHO2]- ion for SM (17:0). Ion plots for PE, LPE and PI uses [M-H]- for 
detection with m/z 424.25 LPE (14:0), m/z 634.5 PE (28:0) and m/z 809.5 PI (a di-16:0 
fatty acid containing internal standard; 32:0). 
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Figure 3-3 Mass Spectrometry spectra of LC/MS analysis: An image of negative ion 
MS spectra summed over the chromatogram covering the elution period of PC molecular 
species. All m/z values displayed here correspond to [M+CHO2]- ions for each PC. The 
m/z 722.5 corresponds to the formate adduct of PC(28:0) internal standard. MS spectra 
image shows PC species PC(34:2) having a m/z 802.6 and PC (40:6) having m/z 878.6.  
Consistent with its higher carbon number, PC(40:6) elutes earlier than PC(34:2).  
 
 
Mass spectra were summed over the chromatographic peak for each PL class and spectra, 
(each as a list of m/z versus intensity signal) and were exported from the acquisition 
program to Microsoft Excel (Microsoft, Redmond, WA, USA). Files were then uploaded 
to LipidomeDB online (University of Kansas, Lawrence, KS, USA; 
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http://129.237.137.125:8080/Lipidomics/) to identify and quantify (with reference to the 
added internal standards without correction for response differences) each PL molecular 
species. The mass of target lipids and abundances of their isotopic variants were 
calculated from the chemical formula by adding the masses of the formate adduct ions 
[M+CHO2]-. Located in the input data by m/z are the peaks corresponding to specified 
adduct ions of the internal standards and target lipids are, and the value of each 
corresponding signal is collected. Within a specified mass tolerance window (specified 
compound mass ± the mass tolerance) any located mass is considered a candidate mass 
for the specified target lipid or internal standard. This is followed by the search algorithm 
“Sum of Signals”. This alorithm sums signals within the specified mass tolerance target 
window. Each sample was run in triplicates to control for technical variability. An 
independent reference sample was added to each run to control for run-to-run variability. 
 All molecular species identified within each PL class were summed to generate 
total PC, LPC, PE, LPE, SM and PI concentration values.  Each phospholipid class of 
PC, LPC, PE, LPE, and PI was then separately grouped according to their degree of 
unsaturation of each molecular species (SFA – saturated fatty acids, MUFA – 
monounsaturated fatty acids, and PUFA – polyunsaturated fatty acids). Sphingomyelin 
was excluded from this analysis due to its lack of PUFA-containing SM species. 
 We analyzed the ratios of arachidonic acid (AA)-containing lipid species to 
docosahexaenoic acid (DHA)–containing species of PC, LPC, PE, LPE and PI. For PC, 
we used AA-containing PC (36:4, 16:0/20:4), PC (38:4, 18:0/20:4) and PC (38:5, 
18:1/20:4) to DHA-containing PC (38:6, 16:0/22:6) and PC (40:7, 18:1/22:6).  For LPC, 
a ratio of AA-containing LPC (20:4) to DHA-containing LPC (22:6) was examined. For 
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PE, a ratio of AA-containing species, PE (38:4, 18:0/20:4) and ether PE (ePE 38:4, o-
18:0/20:4) to DHA-containing species, PE (40:6, 18:0/22:6), and ePE (ePE; 40:6, o-
18:0/22:6), was calculated. For LPE, a ratio of AA-containing LPE (20:4) to DHA-
containing LPE (22:6) was used. . For (AA)-containing PI species we calculated PI (36:4, 
16:0/20:4) and PI (38:4, 18:0/20:4), and for DHA-containing PI species we used PI (40:6, 
18:0/22:6)/ We previously determined the identification of these species as containing 
AA and DHA based on MS/MS analyses 304. Ether PC (ePC) and ePE were grouped 
separately, as these lipids contain ether linkage at the sn1 position. 
 
 
Statistical analyses  
 Data were checked for normal distribution histogram plots and skewness/kurtosis 
measures. Statistical analyses were performed as previously described 228. Principal 
Component Analysis (PCA) was used to minimize multicollinearity and achieve 
dimension reduction, as used routinely for the evaluation of lipidomic data.  First, the 
Kaiser-Mayer-Olkin (KMO) and Bartlett’s test for Sphericity was used to ensure 
sampling adequacy for PCA.  Sampling adequacy as determined by a KMO value of > 
0.6 and Bartlett p value < 0.05 were further investigated. Variables with eigenvalues of 
≥1 were retained, PCA was used for extracting components, and varimax with Kaiser 
normalization was used for rotation to simplify and clarify the data structure.  In order to 
perform mixed linear modeling (MLM) regression analysis on each component (the 
outcome measure), the Anderson-Rubin method was used for exporting uncorrelated 
scores while adjusting for random (human) factor and assess independent fixed 
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(diagnostic and replication). Following data analysis using MLM, Fisher's least 
significant difference (LSD) correction and the Benjamini–Hochberg procedure (B-H) 
were used for multiple-test correction and control of false discovery rate (FDR). All data 
were analyzed using SPSS version 22.0.0 (IBM Corporation, Armonk, NY). B-H 
(α=0.05) was calculated using JMP 11 (SAS, Cary, NC).  Data were normally distributed; 
therefore parametric tests were used to analyze data and presented in mean and standard 
derivation (SD). If data was not normally distributed, log-transformation was performed 
that allowed for the use of parametric testing afterwards instead of non-parametric 
approaches. Standard deviation was used instead of standard error of mean (SEM), as SD 
measures the amount of variability for a subject set of data from the mean. Meanwhile, 
SEM measures how far the sample mean of the data is likely to be from the true 
population mean, making SD the appropriate statistic to plot. 
Logistic regression and ROC analysis were performed as previously described in Chapter 
2 (Method section). 
 
3.3 Results 
 
The baseline demographic distribution of the study population can be found in 
chapter 2-Results section. Figure 3-4 gives the overview of lipidomic workflow of this 
study. Lipidomic analysis was performed on a total of 120 subjects, including controls (n 
= 52), and subjects with traumatic brain injury (TBI; n = 21), post-traumatic stress 
disorder (PTSD; n = 34) or both (n = 13). The apolipoprotein E ε4 carrier effect was 
investigated on all subjects. For secondary analysis, we separated TBI and PTSD 
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subjects. For PTSD analysis, PTSD Checklist-Military Version (PCL-M) scores were 
used. The data was normally and not biphasic distributed. Table 3-1 shows APOE 
genotype frequencies within the cohort, as well as grouped APOE ε4 (-) and APOE ε4 
(+) subjects. No difference was observed for genotype frequencies (p=0.70), or for the 
APOE ε4 (-) and ε4 (+) distribution between controls, TBI, PTSD and TBI+PTSD 
subjects (p=0.84), via Chi Square and Pearson coefficient.  
 
 
 
Figure 3-4 Overview and workflow of group analysis. A total of 120 subjects were 
recruited, including controls (n = 52), and subjects with traumatic brain injury (TBI; n = 
21), post-traumatic stress disorder (PTSD; n = 34) or both TBI and PTSD (n = 13). In 
addition apolipoprotein E (APOE) ε4 carrier effect was investigated. For secondary 
analysis, we separated TBI and PTSD subjects. For PTSD analysis, PTSD Checklist-
Military Version (PCL-M) scores were used. 
 
 
 
 
 
Total Subjects 
N = 120 
Controls n =52 
TBI n = 21 
PTSD n = 34 
TBI+PTSD n = 13 
Complete analysis PTSD analysis 
Controls n = 52, PCL-M 0-34 
Mild PTSD n = 20, PCL-M 35-43 
Moderate to severe PTSD n = 14, PCL-M >44 
TBI cases excluded 
ApoE4 effect 
ApoE4(-) n = 85 
Controls n=37, TBI n=16, PTSD = 24 TBI+PTSD n=8 
ApoE4(+) n = 35 
Controls n=15, TBI n=5, PTSD = 10, TBI+PTSD n=5 
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Control 
(n=52) 
 TBI      
(n=21) 
 PTSD 
(n=34) 
TBI+PTSD 
(n=13) 
APOE (n, %) 
    ε2/ ε2 1 (1.9%) 0 (0%) 1 (2.9%) 0 (0%) 
ε2/ ε3 3 (5.8%) 1 (4.8%) 3 (8.9%) 0 (0%) 
ε2/ ε4 4 (7.7%) 0 (0%) 0 (0%) 0 (0%) 
ε3/ ε3 33 (63.5%) 15 (71.4%) 20 (58.8%) 8 (61.5%) 
ε3/ ε4 11 (21.1%) 4 (19.0%) 9 (26.5%) 4 (30.8%) 
ε4/ ε4 0 (0%) 1 (4.8%) 1 (2.9%) 1 (7.7%) 
  
    APOE ε4 (-) 37 (71.2%) 16 (76.2%) 24 (70.6%) 8 (61.5%) 
APOE ε4(+) 15 (28.8%) 5 (23.8%) 10 (29.4%) 5 (38.5%) 
 
Table 3-1 APOE frequencies. For each diagnostic group APOE frequencies were 
calculated and APOE ε4 carrier (ε2/ ε4, ε3/ ε4, ε4/ ε4) and non-carrier (ε2/ ε2, ε2/ ε3, ε3/ 
ε3) were combined for statistical analysis. 
 
 
Changes in total phospholipid content in plasma of TBI, PTSD and TBI+PTSD 
subjects 
 
Comparison of plasma levels of total PC, LPC, SM, PE, LPE, and PI in subjects 
with TBI, PTSD, and TBI+PTSD showed significant decreases in all PL classes, 
compared with controls. To determine differences in total content of various PL classes 
for each diagnostic category (TBI, PTSD, TBI+PTSD), compared with controls, the 
levels of each molecular species within PC, LPC, SM, PE, LPE, and PI were summed to 
calculate the total for each class. 
Figure 3-5 shows total levels of PC, LPC, SM, PE, LPE, and PI in the plasma 
subjects with TBI, PTSD, and TBI+PTSD as a percentage of control levels – SD. Overall 
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total PC, LPC, PE, LPE, SM, and PI were significantly decreased in TBI, PTSD, and 
TBI+PTSD subjects, compared with the control group. 
Total PC was significantly decreased by an average of 19% in TBI subjects (p = 
0.009), 12% in PTSD subjects (p = 0.01), and 24% in subjects with both TBI+PTSD (p < 
0.001), compared with in controls. LPC was decreased by 24% in the TBI group (p = 
0.002), 17% in the PTSD group (p = 0.002), and 32% in the TBI+PTSD group (p < 
0.001). Total PE levels were decreased by 26% in TBI (p = 0.03), 17% in PTSD (p = 
0.01), and 34% in TBI+PTSD (p < 0.001). Total LPE was decreased by 24% in the TBI 
group (p < 0.001), 17% in the PTSD group (p = 0.001), and 26% in the TBI+PTSD group 
(p = 0.001). Post hoc analysis showed that, relative to controls, total PI was significantly 
lower in the TBI group by 30% (p = 0.008), in the PTSD group by 19% (p = 0.01), and in 
the TBI+PTSD group by 40% (p < 0.001), compared with control subjects. For SM, TBI 
subjects showed a decrease of 17% (p = 0.001), PTSD subjects of 18% (p = 0.01), and 
TBI+PTSD subjects of 33% (p < 0.001). 
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Figure 3-5 Significant changes in total plasma phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), lysophosphatidylcholines 
(LPC), sphingomyelin (SM), and lysophosphatidylethanolamide (LPE) in human 
subjects with traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), 
or TBI and PTSD, represented by mean ± standard derivation (SD) as a percentage 
of control values. Individual molecular species of PC, PE, PI, LPC, SM, and LPE 
quantified by liquid chromatography/mass spectrometry were summed after LipidomeDB 
analyses to generate total lipid levels. For all species TBI, PTSD and TBI+PTSD groups 
were significantly decreased, compared with controls, based on mixed linear modeling 
regression (*denotes to p < 0.01). 
 
 
Degree of unsaturation of PC, LPC, PE, LPE, and PI between diagnostic 
categories, compared with controls 
 
We examined whether there was an effect of injury and/or PTSD on the degree of 
unsaturation within different PL classes (Figure 3-6). Compared with controls, we found 
that the degree of unsaturation of PC, LPC, PE, LPE, and PI varied significantly across 
different diagnostic groups. For SFA- containing PC species TBI subjects showed a 
decrease of 14% (p = 0.03), PTSD subjects of 9% (p = 0.01) and TBI+PTSD subjects of 
17% (p = 0.04), compared with controls. For PUFA-containing PC species, post hoc 
analysis revealed a significant decrease of 17% of PUFA-containing PC species in TBI 
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subjects (p = 0.03), 10% in PTSD subjects (p = 0.05), and 23% in TBI+PTSD subjects (p 
= 0.001). However, MUFA-containing PC species only differed in two groups. MUFA-
containing PC showed differences for TBI versus controls (p = 0.03) and TBI+PTSD 
versus controls (p = 0.001), differences did not reach significance for PTSD versus 
controls (p = 0.06; Fig. 3-6A).  
For SFA-containing LPC species levels were decreased by 22% in TBI subjects (p 
= 0.003), 18% in PTSD subjects (p = 0.001), and by 34% in TBI+PTSD subjects (p < 
0.001). For MUFA-containing LPC species, we found as well a decrease of 23% in TBI 
subjects (p = 0.02), 15% in PTSD subjects (p = 0.02) and 32% in TBI+PTSD subjects (p 
< 0.001). PUFA - containing LPC species were decreased by 27% in TBI subjects ( p = 
0.001), 16% in PTSD subjects (p = 0.005), and 28% in TBI+PTSD subjects (p < 0.001; 
Fig. 3-6B).  
For SFA-containing PE, TBI subjects showed a decrease of 24% (p = 0.02), 
PTSD subjects of 19% (p = 0.02), and TBI+PTSD subjects of 26% (p = 0.03), compared 
with controls. For MUFA-containing PE species, post hoc revealed a significant decrease 
of 20% of MUFA-containing PE species in TBI subjects (p = 0.006), 13% in PTSD 
subjects (p = 0.05), and 23% in TBI+PTSD subjects (p < 0.001). For PUFA-containing 
PE species, we observed a significant decrease of 25% of PUFA-containing PE species in 
TBI subjects (p = 0.005), 17% in PTSD subjects (p = 0.02), and 35% in TBI+PTSD 
subjects (p < 0.001; Fig. 3-6C).  
For SFA-containing LPE, TBI subjects showed a decrease of 18% (p = 0.05), 
PTSD subjects of 17% (p = 0.01), and TBI+PTSD of subjects 24% (p = 0.06), compared 
with controls. For MUFA-containing LPE, post hoc analysis revealed a significant 
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decrease of 23% of MUFA-containing LPE species in TBI subjects (p < 0.001), 12% in 
PTSD subjects (p = 0.004), and 22% in TBI+PTSD subjects (p = 0.002). For PUFA-
containing LPE, TBI subjects showed a decrease of 27% (p < 0.001), PTSD subjects of 
18% ( p = 0.001), and TBI+PTSD subjects of 29% (p < 0.001), compared with controls 
(Fig. 3-6D). 
For PUFA-containing PI species, TBI subjects showed a decrease of 28% (p = 
0.02), PTSD subjects of 20% (p = 0.01) and TBI+PTSD subjects of 39% (p < 0.001). 
However, MUFA-containing PI species were only significantly different for TBI and 
TBI+PTSD, whereby post hoc comparison revealed these differences to be a decrease of 
35% in TBI subjects (p = 0.02) and 42% in TBI+PTSD subjects (p < 0.001). For PTSD 
no significance was observed for MUFA-containing PI (Fig. 3-6E). 
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Figure 3-6 Degree of unsaturation of phospholipids (PL) classes in plasma of 
traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and 
TBI+PTSD, compared with controls. Mean ± standard derivation (SD) as a 
percentage of controls. (B-D) show that within the TBI, PTSD, and TBI+PTSD groups, 
saturated fatty acid (SFA)–containing, monounsaturated fatty acid (MUFA)–containing, 
and polyunsaturated fatty acid (PUFA)–containing lysophosphatidylcholines (LPC), 
phosphatidylethanolamine (PE), and lysophosphatidylethanolamide (LPE) were 
significantly decreased relative to controls. (A) and (E) show a decrease in SFA- and 
PUFA containing LPC and phosphatidylinositol (PI) for TBI, PTSD, and TBI+PTSD. 
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However, MUFA-containing LPC and PI species show only significance for TBI and 
TBI+PTSD. *p < 0.05; mixed linear modeling regression with post hoc analyses 
 
As APOE genotype is known to influence plasma lipid profiles, and the ε4 allele 
confers risk for poor outcome after TBI, we examined the impact of an APOE ε4+ or ε4- 
genotype on the relationship between degree of unsaturation status of specific PL classes 
and the diagnostic categories TBI, PTSD, and TBI+PTSD. As such, we grouped subjects 
according to their APOE ε4status (APOE ε4 [-] = genotypes ε2/ ε2, ε2/ ε3, or ε3/ ε3) vs. 
APOE ε4 [+] = subjects with genotypes ε2/ ε4, ε3/ ε4, or ε4/ ε4; Figure 3-7).   
For LPC, examination of APOE ε4genotype carrier status on SFA-, MUFA-, and PUFA-
containing LPC species revealed significant differences only in MUFA-containing LPC 
species (p < 0.05). APOE ε4 (-) subjects showed significantly lower levels by 32% in 
TBI subjects (p < 0.001), 20% in PTSD subjects (p < 0.001), and 35% in TBI+PTSD 
subjects (p < 0.001), compared with controls, whereas levels of MUFA-containing LPC 
species in APOE ε4 (+) subjects showed no significant difference for the TBI and PTSD 
groups, compared with controls (p > 0.05). Only APOE ε4 (+) TBI+PTSD subjects had 
significantly lower levels of MUFA-containing LPC species, compared with controls (p = 
0.02). No APOE ε4 effect was found for SFA-containing and PUFA-containing LPC 
species Figure 3-7A shows LPC’s SFA, MUFA, and PUFA levels as a percentage of 
control levels for each diagnostic category in APOE ε4 carriers, that is, APOE ε4 (+) 
versus non-APOE ε4 carriers (APOE ε4 [-]).  
For PE, APOE ε4 genotype carrier status revealed a strong effect on saturation 
levels of the plasma of TBI, PTSD and TBI+PTSD subjects (Figure 3-7B). After post hoc 
analysis, SFA-containing PE species in APOE ε4 (-) subjects showed significantly lower 
levels by 33% in TBI subjects (p < 0.001), 25% in PTSD subjects (p < 0.001), and 22% 
 124 
in TBI+PTSD subjects (p = 0.01), compared with controls, whereas levels of SFA-
containing LPC species in APOE ε4 (+) subjects showed no significant difference for the 
any diagnostic group, compared with controls (p > 0.05).  For MUFA-containing PE 
species, APOE ε4 (-) subjects showed significantly lower levels by 25% in TBI subjects 
(p < 0.001), 17% in PTSD subjects (p < 0.001) and 19% in TBI+PTSD subjects (p = 
0.01), compared with controls, whereas levels of MUFA-containing PE species in APOE 
ε4 (+) subjects showed no significant differences by diagnosis. TBI+PTSD groups 
remained significantly decreased, compared with controls (p = 0.01). For PUFA-
containing PE species, APOE ε4 (-) subjects showed significantly lower levels by 32% in 
TBI subjects (p < 0.001), 20% in PTSD subjects (p < 0.001), and 33% in TBI+PTSD 
subjects (p < 0.001), compared with controls, whereas levels of MUFA-containing PE 
species in APOE ε4 (+) subjects showed no significant difference for TBI or PTSD 
diagnostic categories; levels of MUFA-containing PE were significantly decreased in the 
TBI+PTSD group compared with controls to (p = 0.01).  
For LPE, no changes were observed for SFA-containing species (Figure 3-7C). 
For MUFA-containing LPE species, APOE ε4 (-) subjects showed significantly lower 
levels by 24% in TBI subjects (p < 0.001), 13% in PTSD subjects (p = 0.006), and 30% 
in TBI+PTSD subjects (p < 0.001), compared with controls, whereas levels of MUFA-
containing LPE species in APOE ε4 (+) subjects showed no significant difference for 
PTSD and TBI+PTSD subjects, compared with controls (p > 0.05). However, the APOE 
ε4 (+) TBI subject group showed a significant decrease of 19% (p = 0.03). For PUFA-
containing LPE species, APOE ε4 (-) subjects showed significantly lower levels by 25% 
in TBI subjects (p < 0.001), 19% in PTSD subjects (p = 0.002), and 35% in TBI+PTSD 
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subjects (p < 0.001), compared with controls, whereas levels of PUFA-containing LPE 
species in APOE ε4 (+) subjects showed no significant difference for TBI+PTSD, 
compared with controls (p > 0.05). However, like the APOE ε4 (-) subjects, the APOE ε4 
(+) TBI and PTSD subjects, showed a significant decrease of 31% (p = 0.03) and 17% (p 
= 0.04) respectively.  
For PC and PI, examination of APOE ε4 genotype carrier status on SFA, MUFA-, 
and PUFA-containing PC and PI species revealed no significant differences in TBI, 
PTSD, and TBI+PTSD subjects compared to controls (p > 0.05; data not shown). 
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Figure 3-7Apolipoprotein E (APOE) ε4 effect on phospholipids (PL) levels in 
subjects with traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), 
and TBI+PTSD, compared with controls. Mean ± standard derivation (SD) 
expressed as a percentage of controls. (A-C) show that within the TBI, PTSD, and 
TBI+PTSD groups, SFA-, MUFA-, and PUFA-containing lysophosphatidylcholines 
(LPC), lysophosphatidylethanolamide (LPE), and phosphatidylethanolamine (PE) are 
affected by APOE ε4 genotype. *p < 0.05; mixed linear modeling regression with post 
hoc analyses. 
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Examination of ePC and ePE in plasma between TBI, PTSD, and TBI+PTSD 
subjects, compared with controls 
 
In order to obtain an indirect measure of peroxisome function, we examined ePC 
and ePE lipids. For ePC (Figure 3-8), subjects exhibiting PTSD showed a decrease of 
12%, compared with controls (p = 0.007), whereas subjects with TBI+PTSD had a 
decrease of 22% (p < 0.001). No difference was observed for TBI (p = 0.08). For total 
ePE levels, the TBI group showed a decrease of 25% (p = 0.01), PTSD of 16% (p = 
0.04), and TBI+PTSD of 35% (p < 0.001). 
 
 
Figure 3-8 Differences in total ether phosphatidylcholine (ePC) and ether 
phosphatidylethanolamine (ePE) in plasma of subjects exhibiting traumatic brain 
injury (TBI), post-traumatic stress disorder (PTSD), or TBI+PTSD. Mean ± 
standard derivation (SD) as a percentage of controls. Levels of ePC were significantly 
decreased in the PTSD and TBI+PTSD groups, relative to controls. Levels of ePE were 
significantly lower in all diagnostic categories (*p < 0.05; mixed linear modeling 
regression with post hoc analysis). 
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In Figure 3-9, we also examined the effect of APOE ε4 genotype carrier status on 
ether PLs. For ePC, APOE ε4 (-) subjects showed significant lower levels by 20% in TBI 
subjects (p < 0.001), 14% in PTSD subjects (p = 0.001), and 25% in TBI+PTSD subjects 
(p < 0.001), compared with controls, whereas ePC levels in APOE ε4 (+) subjects of all 
diagnostic categories showed no significant difference, compared with controls (p > 
0.05). The same tendency was observed for ePE, where APOE ε4 (-) subjects showed 
significant decreases of 34% in TBI subjects (p < 0.001), 20% in PTSD subjects (p = 
0.001), and 33% in TBI+PTSD subjects (p = 0.001), while in APOE ε4 (+) subjects the 
ePC levels were only significantly reduced for TBI+PTSD (p < 0.001). 
 
 
 
Figure 3-9 Apolipoprotein E (APOE) ε4 effect on ether lipid levels in subjects with 
traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and 
TBI+PTSD, compared with controls. Mean ± standard derivation (SD) expressed as 
a percentage of controls. Within the TBI, PTSD, and TBI+PTSD groups, APOE ε4 non-
carriers showed significant decreases in all categories for ether phosphatidylcholine 
(ePC) and ether phosphatidylethanolamine (ePE) species. APOE ε4 carriers only showed 
significance differences in TBI+PTSD for ePC *p < 0.05; mixed linear modeling 
regression with post hoc analyses. 
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Ratios of AA- to DHA-containing LPC, PC, LPE, PE, and PI species between the 
TBI, PTSD, and TBI+PTSD groups, compared with controls 
 
We continued our analysis by determining the ratios of AA to DHA-containing 
PLs and observed changes in ratios of PC and PE in plasma for TBI, PTSD, and 
TBI+PTSD, compared with controls (Figure 3-10), as well as the influence of APOE ε4 
(Figure 3-11). 
For PC, the AA to DHA ratio was significantly decreased in subjects with 
TBI+PTSD (p < 0.05). Further post hoc analysis of APOE ε4carrier status in TBI+PTSD 
subjects revealed the influence of APOE genotype on this finding, as the APOE ε4 (+) 
group showed no significant difference in the AA to DHA compared to controls (p > 
0.05) whereas the APOE ε4 (-) subjects exhibited an AA to DHA ratio that was 
significantly lower than APOE genotype stratified controls by 17% (p = 0.002). 
For LPC, there was no significant difference in the AA to DHA ratio in any of the three 
diagnostic categories, compared with controls (p > 0.05). However, further analysis 
revealed significant differences in the ratio in the diagnostic categories with regard to 
their APOE ε4carrier status. APOE ε4 (-) subjects exhibited a significantly lower AA to 
DHA ratio by 14% in TBI+PTSD subjects (p = 0.002), whereas there was no significance 
in APOE ε4 (-) TBI alone or PTSD alone subjects, compared with APOE genotype 
stratified controls. However, for APOE ε4 (+) subjects, there was a significant increase of 
12% in TBI subjects (p = 0.04), 10% in PTSD subjects (p = 0.04), and 1% in TBI+PTSD 
subjects (p = 0.006), compared with controls. TBI+PTSD reached significance due to the 
15% change between APOE ε4 (-) and APOE ε4 (+) subjects, compared with controls. 
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For PE, the AA to DHA ratio levels were lower in subjects with TBI (p = 0.04) and with 
TBI+PTSD (p < 0.001). Further post hoc analysis of APOE ε4 carrier status revealed no 
significant difference in the AA to DHA ratio for any diagnostic categories regardless of 
APOE ε4 carrier status. 
For LPE, there was no significant difference in the AA to DHA ratio in any of the 
three diagnostic categories, compared with controls (p > 0.05), and post hoc analysis of 
APOE ε4 carrier status found no significant difference in AA to DHA ratio for any 
diagnostic categories.  
For PI, there was also no significant difference in the AA to DHA ratio in any of 
the three diagnostic categories, compared with controls (p > 0.05). However, APOE ε4 (-
) subjects exhibited significantly lower AA to DHA ratio by 8% in TBI subjects (p = 
0.02), 7% in PTSD subjects (p = 0.03) and 16% TBI+PTSD subjects (p = 0.01), whereas 
there was no significance in APOE ε4 (+) TBI, PTSD, or TBI+PTSD subjects, compared 
with controls (p > 0.05). 
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Figure 3-10 Differences in the ratios of arachidonic acid (AA)–containing to 
docosahexaenoic acid (DHA)–containing phospholipids (PL) in plasma of subjects 
exhibiting traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), or 
TBI+PTSD, relative to control subjects. Mean ± standard derivation (SD) as a 
percentage of controls. Within phosphatidylcholine (PC), ratios of AA to DHA were 
decreased in TBI+PTSD subjects. In addition, within phosphatidylethanolamine (PE), 
ratios were decreased in TBI and TBI+PTSD subjects (*p < 0.05; mixed linear modeling 
regression with post hoc analysis). 
 
 
 
Figure 3-11 Effect of Apolipoprotein E (APOE) ε4 on ratios of arachidonic acid 
(AA)–containing to docosahexaenoic acid (DHA)–containing phospholipids (PL) in 
plasma of subjects exhibiting traumatic brain injury (TBI), post-traumatic stress 
disorder (PTSD), and TBI+PTSD. Mean ± standard derivation (SD) as a percentage 
of controls. Figure shows an APOE ε4 dependent effect on lipid levels. *p < 0.05; mixed 
linear modeling regression with post hoc analyses. 
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The Appendix 1 contains tables with concentrations of significant individual molecular 
species, which we identified in all 6 phospholipid classes (Appendix Chapter 3; Section 
1: Tables 1-6). We performed a preliminary logistic regression analysis with significant 
species for each class to identify a model (containing multiple species) that allowed for 
examination of sensitivity and specificity using ROC analysis for TBI/Control, 
PTSD/Control and TBI+PTSD/Control. The model identified certain species for each 
diagnostic criterion (Table 3-2.). ROC analysis revealed the AUC for the different 
diagnostics as follows: For TBI the AUC was 0.892 (95% CI [0.819–0.965], p< 0.05). 
For PTSD the AUC was 0.697 (95% CI [0.587–0.807], p< 0.05). When investigating 
TBI+PTSD subjects, the AUC was increased to 0.862 (95% CI [0.754–0.970], p< 0.05). 
The ROC curves for each model are displayed in Figure 3-12.  
Optimal sensitivities with specificity of at least 80% predicted probabilities are shown in 
Table 3-2 as well.  The highest sensitivity and specificity was achieved with the model 
for TBI. ROC tables can be found in the Appendix, Chapter 3, Section 2. 
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 *Model Sensitivity Specifity # R2 
TBI/Control LPC(20:3) 81% 80% 0.539 
 DSM(16:0)    
 SM(22:0)    
 SM(24:1)    
PTSD/Control ePC(40:6) 51% 80% 0.156 
 LPC(16:0)    
TBI+PTSD/Control PC(36:5) 81% 80% 0.404 
 ePE(34:0)    
Table 3-2 Optimal sensitivities with specificities of at least 80% for the various 
diagnostic models*.  
*Calculations based on predicted probabilities form binary logistic Regression.  
# Represents Nagelkerke R2  
 
 
 
Figure 3-12 ROC curves for TBI (red), PTSD (blue) and TBI+PTSD (purple). The 
largest area under the curve was achieved for the model of TBI. 
 
 
 134 
We further used the same regression analysis to develop models for PTSD/TBI, 
TBI+PTSD/TBI and TBI+PTSD/PTSD prediction. ROC analysis revealed the AUC for 
as follows: For PTSD/TBI the AUC was 0.771 (95% CI [0.646–0.897], p < 0.05). For 
TBI+PTSD/PTSD the AUC was 0.867 (95% CI [0.755–1.000], p< 0.05). No model could 
be deployed for TBI+PTSD/TBI as no individual lipid species passed significance test 
during linear regression. The ROC curves for each model are displayed in Figure 3-13.  
Optimal sensitivities with specificity of at least 80% predicted probabilities are shown in 
Table 3.3 as well.  The highest sensitivity and specificity was achieved with the model 
for TBI+PTSD/PTSD. ROC tables can be found in the Appendix, Chapter 3, Section 2. 
 
 
 
 
 *Model Sensitivity Specifity # R2 
PTSD/TBI LPC(o-18:0) 63% 80% 0.268 
 LPC(20:3)    
 LPE(18:1)    
TBI+PTSD/TBI - NA NA NA 
TBI+PTSD/PTSD PI(36:1) 91% 80% 0.458 
 PI(38:4)    
 PE(42:6)    
     
Table 3-3 Optimal sensitivities with specificities of at least 80% for the various 
diagnostic models*.  
*Calculations based on predicted probabilities form binary logistic Regression.  
# Represents Nagelkerke R2 
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Figure 3-13 ROC curves for TBI+PTSD/PTSD (red) and PTSD/TBI (blue). The 
largest area under the curve was achieved for the model of TBI+PTSD/PTSD. 
 
Plasma profiling of total PC, LPC, SM, PE, LPE, and PI in plasma of mild, and 
moderate to severe, PTSD subjects 
 
The above analysis used a dichotomous grouping to differentiate controls from 
the diagnostic groups (exhibiting TBI, yes or no; PTSD, yes or no; or having both, yes or 
no), using measurements described in the Methods section. However, for PTSD, the 
PCL-M test allows for a severity screen by using the continuous variable scores in the 
test. As such, we were able to analyze PTSD subjects separately according to their PCL-
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M scores in regards to PTSD severity. Subjects with 0 to 34 points were grouped as 
controls, 35 to 43 as mild PTSD and >44 as moderate-to-severe PTSD. Overall, total 
LPC, SM, LPE, and PI were decreased (p < 0.05) in the plasma of subjects with 
moderate-to-severe PTSD. There were no significant differences in total PC (p = 0.052) 
or total PE (p = 0.063) levels in the plasma of PTSD subjects (mild or moderate-to-
severe), compared with controls, based on post hoc analyses (p > 0.05). Figure 3-14 
shows total levels (mean ± SD) of PC, LPC, PE, LPE, SM, and PI for subjects with mild 
PTSD (PCL-M, 35-43) and moderate to severe PTSD (PCL-M > 44) as a percentage of 
the control group (PCL-M, 0-34). Compared with the control group, total LPC was 
decreased by 22% for the moderate-to-severe PTSD group. For total SM, the moderate-
to-severe PTSD group was significantly decreased by 17%, 22% for LPE and for 30% PI. 
No significant differences were found in LPC, SM, LPE, and PI levels between mild 
PTSD and the control group. 
 
 
Figure 3-14 Significant changes in total plasma phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), lysophosphatidylcholines 
(LPC), sphingomyelin (SM), and lysophosphatidylethanolamide (LPE) in human 
subjects with post-traumatic stress disorder (PTSD), represented as the mean, and 
standard derivation (SD), as a percentage of controls. Individual molecular species of 
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PC, PE, PI, LPC, SM, and LPE quantified by liquid chromatography/mass spectrometry 
were summed after LipidomeDB analyses to generate total lipid levels. Lipid species 
were investigated in groups of PTSD severity, based on mixed linear modeling regression 
(*p < 0.01). 
 
 
3.4 Discussion 
 
 Neurobiological changes associated with mTBI and PTSD can impact service 
members’ well-being, long after the primary insult, causing lasting neurological 
dysfunction and long-term health consequences 309. Despite the well-studied chronic 
impact of both TBI and PTSD, diagnostic biomarkers are not available at chronic post-
injury time points. Given the complexity of the underlying pathology, unbiased omic 
approaches, such as lipidomics are needed to dissect the heterogeneous clinical 
presentations of these illnesses. Brain PL disturbances have previously been detected in 
the CSF of TBI subjects 310, suggesting that alterations in the brain can be detected in 
peripheral biofluids. In fact, studies have shown that certain PLs, particularly those that 
contain PUFA may be transported from blood to brain, where they are used for various 
functions (e.g. membrane repair, lipid mediators, etc.) 311. Phospholipid disturbances 
were observed in the brain of a TBI mouse model, and showed that major PL classes (in 
particular PUFA-containing PLs, DHA, and ePLs) were significantly altered three 
months post-injury 304.  Therefore, we examined PL changes in soldiers with mTBI and 
PTSD, particularly in relation to the degree of unsaturation to determine if blood PL 
levels are altered at a chronic timepoint.  
 The ApoE protein plays an important role in regulating transport and homeostasis 
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of various lipids, including triglycerides, PL, and fatty acids, in both the periphery and 
the brain and is known to facilitate transport of these lipids from the blood into the brain. 
Production of the ApoE protein is controlled by the APOE gene, and three common 
isoforms of APOE are found in humans, encoded by the alleles ε2, ε3 and ε4 312.  
Whilst the distribution of ApoE among lipoproteins is influenced by the apoE allele 
(apoE4 has a preference for large, triglyceride-rich VLDL particles; apoE3 and apoE2 
associate with the small, phospholipid- rich HDL), the effect it has on circulating plasma 
PL is not well understood305. Yet, characterization of various PL classes (PC, PE, PI and 
SM) in plasma from young (2month) and old (12month) human APOE ε2, ε3, and ε4 
knock-in (KI) mice showed decreased total PE and increased SM levels in young APOE 
ε2 compared to APOE ε4 animals. Furthermore total SM levels were increased in APOE 
ε2 compared to ε3 in 12month old mice313. A clinical study, which investigated the 
consumption of 1.1.g/day of DHA for six week showed that the rise in DHA level was 
60% lower in plasma triglycerides APOE4 carriers as compared to the non-carriers314.  
Overall, effects on APOE on circulating plasma PL needs further investigation and we 
therefore stratified our analysis by apoe ε4 carrier status.  
Furthermore, clinical studies suggest poor long-term cognitive and functional outcomes 
in TBI patients with the APOE ε4 compared to those without the ε4 allele 74,315. In 
another human study that included participants with combat trauma sustained during the 
Vietnam War, Lyons et al investigated apoE ε4 (-) and ε4 (+) genotype interaction with 
level of combat exposure to predict the number of PTSD symptoms given exposure to 
combat trauma 316. Their findings suggest that the APOE ε4 allele is a risk factor for the 
negative consequences of combat exposure.  At the blood-brain barrier (BBB), fatty acids 
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are taken up by brain astrocytes and then utilized as an energy source and for lipid 
synthesis 317. Since APOE represents an important mediator between injury and lipid 
abnormalities, we investigated a possible effect of the APOE ε4 carrier status on PL 
profiles, which are discussed below.  
Our results revealed a significant decrease in PL levels (total PC, LPC, SM, PE, LPE, and 
PI) in active-duty soldiers screened for mTBI, PTSD, and mTBI with comorbid PTSD 
compared to healthy controls. Although PL plasma profiling in humans has not been done 
for chronic stages of the injury, clinical studies by Pasvogel et al. showed that subjects 
with severe TBI have increased levels of PC and PE in the CSF in those who died days 
following injury compared to those who survived 299.  Furthermore, studies show elevated 
levels of serum cholesterol, LDL, triglycerides (TG), and decreased high-density 
lipoprotein (HDL)300–302 in subjects with chronic PTSD. However, further investigation 
of lipid transport is necessary in order to determine how peripheral lipid changes are 
associated with mTBI and PTSD pathogenesis.  
The brain can synthesize SFAs and MUFAs, whereas PUFAs are largely acquired 
through the periphery due to the low capacity of the brain to synthesize these de novo 318. 
Therefore, we examined the degree of unsaturation of PL species to determine if PUFA 
containing PLs were differentially affected in response to injury. The results indicated 
that for LPC, PE, and LPE species, there was no effect on the degree of unsaturation. 
LPC, PE, and LPE containing SFA, MUFA, and PUFA species were all decreased in 
TBI, PTSD, and/or TBI+PTSD compared to controls. In addition, PC and PI, SFA and 
PUFA containing species were decreased in all three groups compared to controls. 
However, MUFA containing PC (ePC [34:1], PC [34:1], ePC [36:1] and PC [36:1]) and 
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PI (PI [34:1] and PI [36:1]) species were lower in the TBI and TBI+PTSD groups only, 
whereas levels of PTSD were not affected.  
As ApoE is involved in PUFA transport we examined PLs and their subcategories 
by APOE ε4 carrier status within our study population. An examination of APOE 
genotype on the degree of unsaturation revealed that subjects carrying the APOE ε4 allele 
showed differences of PL profile levels for TBI, PTSD, and TBI+PTSD compared to 
APOE ε4 non-carriers. For PE, we found a significant interaction between APOE ε4 and 
diagnosis on SFA and MUFA containing PE species. APOE ε4 non-carriers showed 
decreases in SFA and MUFA containing PE species for TBI, PTSD, and TBI+PTSD 
groups compared to controls. Among APOE ε4 carriers, there were no significant 
differences between the TBI and the PTSD group for SFA and MUFA containing PE 
species.  However, the differences in SFA and MUFA species were also significant 
among the APOE ε4 carriers for the comparisons between the TBI+PTSD group and the 
controls. There was a significant interaction between the presence of APOE ε4 allele and 
diagnosis of TBI+PTSD on MUFA-containing LPC and LPE species. For MUFA-
containing LPC and LPE species, APOE ε4 non-carriers showed a significant decrease in 
lipid levels for TBI, PTSD, and TBI+PTSD as compared to controls, whereas APOE ε4 
carriers only showed decreases for TBI+PTSD subjects compared to controls. 
We also observed a significant effect of APOE ε4 together with diagnosis on PUFA-
containing LPE species. APOE ε4 non-carrier showed significant decrease in LPE levels 
in TBI, PTSD, and TBI+PTSD subjects, whereas levels of LPE were elevated in APOE 
ε4 carriers with PTSD and in the TBI+PTSD group. These observations might be of 
particular interest, as PUFAs are primarily acquired through the periphery into the brain.  
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We hypothesize that carrying the APOE ε4 allele leads to a reduced transport of PUFAs 
to the brain via the apolipoproteins, which might explain why plasma PUFA levels in 
mTBI subjects were not statistically different from control subjects; not meeting the 
brains higher energy needs. However, we did not observe a significant APOE ε4 effect on 
PUFAs of the other PL classes we investigated.  
Phospholipids and their metabolites activate downstream inflammatory cascades, 
which contribute to the immune and inflammatory balance within the CNS and the 
periphery. Of particular note, DHA and AA are the most abundant ω-3 and ω-6 PUFAs in 
the brain. However, also in plasma, brain, and CSF, DHA is a precursor of the anti-
inflammatory mediators, resolvins, and neuroprotectins, whereas AA is a precursor of 
pro-inflammatory lipid mediators, such as prostaglandins and leukotrienes 319,320. Studies 
by Vandal et al., showed a lower BBB transport of DHA in mice homozygous for APOE 
ε4 relative to APOE ε4 non-carriers 321. We therefore examined ratios of AA to DHA 
containing PLs and found a significant decrease in ratios in TBI+PTSD subjects for PC 
and LPC, and PE for TBI and TBI+PTSD subjects. AA containing species are 
preferentially being metabolized over DHA, which might be further propagating 
inflammation already associated with TBI and PTSD. This might indicate increased DHA 
over AA, leading to the generation of anti-inflammatory neuroprotectins in order to 
resolve ongoing inflammation. We also examined the effect of APOE ε4 carrier status on 
the PL lipid species and observed a significant effect on the ratios of AA to DHA 
containing PC, PI, and LPC classes. Among APOE ε4 non-carriers, for PC, PI, and LPC, 
there was a significant decrease for the ratios of AA to DHA with respect to different 
diagnostic categories (PC; TBI+PTSD, PI; TBI, PTSD and TBI+PTSD, LPC; 
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TBI+PTSD) compared to controls.  However, within APOE ε4 carriers, lipid level did not 
differ from control subjects. Moreover, we observed a significant increase of the ratio in 
LPC species in mTBI and PTSD subjects in APOE ε4 carrier subjects. As the brain needs 
certain lipids, such as PUFA and DHA, there might be an increased need for lipids after 
injury for repair and other related functions 322–324. Given the role of APOE in transport of 
PUFA and the observed deficiencies in transport of these lipids as a result of the APOE 
ε4 allele (as described above), it is possible that the APOE ε4 carrier status could further 
exacerbate the effects of injury/disease.  
In recent years, the question of how ApoE regulates DHA metabolism and 
transport has arisen, as low plasma DHA concentration has been associated with 
cognitive decline in otherwise healthy elderly individuals and patients with Alzheimer’s 
Disease 325–328. Moreover, studies have suggested that dementia patients who do not have 
the APOE ε4 allele benefit from DHA supplementation in contrast to APOE ε4 carriers 
329–331. We observed an increased ratio of AA to DHA in APOE ε4 carriers, which might 
suggest impaired transport of these species to the brain resulting in an accumulation of 
DHA in the plasma. However, further investigation of lipid transport in relation to the 
APOE genotype and mTBI/PTSD is required to support this hypothesis. 
 In order to investigate which subtypes of PLs could be useful in the future for 
diagnostic purposes, we evaluated ether PLs and platelet-activating factors (PAFs). These 
PLs promote inflammation and increased BBB permeability after brain injury and are 
produced by hydrolysis of alkyl ether ePCs 332,333. We observed differences in total ePC 
in plasma of subjects with TBI, PTSD, and TBI+PTSD. In general, ePCs are abundant in 
PC and PE species. Levels of ePC were significantly decreased in PTSD and TBI+PTSD 
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groups relative to controls. In the current study, we also found a significant APOE ε4 
interaction effect with ePC and ePE species. In APOE ε4 non-carriers, ePC lipid levels 
were significantly decreased in TBI, PTSD, and TBI+PTSD subjects, whereas APOE ε4 
carriers in all groups showed similar levels to control subjects. Among APOE ε4 non-
carriers, ePEs were significantly decreased in TBI, PTSD, and TBI+PTSD subjects, 
whereas APOE ε4 carriers showed only a significant decrease for TBI+PTSD. As such, 
measurement of ePE levels combined with APOE genotyping might be useful to evaluate 
as a differential diagnostic tool in future studies. 
We also performed a preliminary ROC analysis via a model established through 
linear regression containing significant individual lipid species for each diagnostic group. 
The model revealed to have highest sensitivity and specificity for TBI/Control, whereas 
PTSD/Control performed poorly.  The model for TBI+PTSD/Control achieved similar 
sensitivity at the given 80% specificity mark as TBI/Control. For TBI+PTSD/TBI no 
model could be established, whereas PTSD/TBI performed poorly. The model for 
TBI+PTSD/PTSD however achieved good sensitivity at 80% specifity. It is important to 
note that this analysis has to be extended and further investigation is needed to develop a 
final model for prediction of diagnostic groups. 
In our final analysis, we examined differences in total PL levels in subjects by 
PTSD severity. This allowed us to observe if our previously investigated lipid species 
correlated with the established PCL-M questionnaire. Subjects were subdivided based on 
PCL-M scores to investigate if lipid levels correlate with PTSD severity. In subjects with 
moderate-to-severe PTSD (PCL-M ≥ 44), we found a significant decrease of LPC, LPE, 
SM and PI levels. In contrast, we did not find significant differences between controls 
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and subjects with mild PTSD (PCL-M: 35-43), suggesting that dysfunction in lipid 
homeostasis only occurs as a result of more severe PTSD. 
Finally, in order to minimize the effect of other factors that could influence lipid 
levels only subject were included, who did not use lipid level altering medication. 
Furthermore, as metabolism can influence plasma lipid levels, a military cohort was 
sampled in order to provide subjects with comparable fitness level and standardized 
training as well as uniform diet.  
 
3.5 Limitations 
 
One limitation of this study is that for the subjects diagnosed with mTBI, an 
accurate estimation of the duration of time between the injury and the blood collection is 
unavailable, though this is a common issue in cross-sectional study designs. 
Another limitation of the current study was sample size. Although sufficient size was 
achieved to power the conducted analyses, sample sizes are small for the APOE ε4 carrier 
analysis (n=5 for APOE ε4 carriers in the mTBI and mTBI+PTSD group). This was 
mainly due to the disproportionately low number of ε4 allele carriers within our sample, 
which is reflected in the general population. Larger samples sizes are of course desirable; 
however studies such as these are very difficult to coordinate and, given their importance 
to the research community, we, along with others in the field 334–336, consider their 
presentation of critical importance for validation and replication in the community. 
Future studies should emphasize collecting data on larger numbers of military service 
members in order to explore potential interactions and genetic mediators of combat-
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related PTSD and mTBI. Moreover, this will allow for analysis of specific PTSD 
subgroups based on symptom clusters. Furthermore, diagnostic categories were 
established using screening instruments, not provider diagnoses. The military health care 
system is developing and implementing tools with mechanisms in order to track patients 
through all stages of their care. Advancements, such as these, will be invaluable for 
addressing many caveats beyond the scope of this current work. Nonetheless, this study, 
which enabled work with an active duty population, addresses a chronic perspective of 
TBI/PTSD biomarker research, which has not been done before in this format. 
 
3.6 Conclusion 
  
The current study performed lipidomic characterization of different plasma PL 
classes in active-duty soldiers with a history of mTBI, PTSD, and comorbid mTBI and 
PTSD, in order to evaluate if secondary injury damage and traumatic stress have an 
impact on PL levels. We successfully showed a characterization of PLs in plasma, 
associated with these diagnostic categories. In addition, we revealed that the APOE 
genotype, specifically ε4 carrier status, may be associated with plasma PL levels. Despite 
the extensive research of APOE and lipid metabolism in TBI, more studies are needed to 
identify the underlying mechanisms in order to develop a biomarker panel that has the 
sensitivity and specificity to diagnose mTBI and PTSD. We expect that additional 
profiling of proteins, other lipid species, and genetic interactions can lead to a successful 
identification of diagnostic and prognostic biomarkers. However, findings need to be 
replicated in larger cohorts to determine the potential utility of PLs as biomarkers. 
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Chapter 4 Mild TBI results in a long-term decrease in 
circulating phospholipids in a mouse model of injury 
 
4.0 Summary 
 
In this chapter I continued the omics analysis in an animal model of mTBI that 
has been established and characterized at the Roskamp Institute. Neurophysiological and 
neurological dysfunction is usually experienced for a short period of time in patients with 
mild traumatic brain injury (mTBI). However, around 15% of patients continue to exhibit 
symptoms months after TBI. Phospholipid (PL) changes have been observed in plasma 
from mTBI patients at chronic stages, suggesting a role in TBI pathology. We examined 
long-term plasma phospholipid profiles in a mouse model of mTBI to validate its value in 
reproducing PL changes observed in mTBI patients.  Plasma samples were collected at an 
acute time point (24 hrs post-injury) and at several chronic stages (3, 6, 12 and 24 months 
post-injury) from injured mice and sham controls. Phospholipids were identified and 
quantified using liquid chromatography/mass spectrometry (LC/MS) analysis. In 
accordance with our human data, we observed significantly lower levels of several major 
PL classes in mTBI mice compared to controls at chronic time points. Saturated, 
monounsaturated and polyunsaturated fatty acids (PUFAs) were differently regulated 
over time. As PUFA levels were decreased at 3 months we measured levels of 
malondialdehyde to assess lipid peroxidation, which we found to be elevated at this 
timepoint. Ether containing PE species were elevated at 24 hrs post-injury and decreased 
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relative to controls at chronic stages. Arachidonic acid (AA) and docosahexaenoic acid 
(DHA) containing species were significantly decreased within all PL classes at the 
chronic stages. Our findings are similar to the changes we observed in PL levels in 
human mTBI subjects (Chapter 3). Furthermore, I measured LRG1 levels in this mTBI 
model to investigate if the increases I observed in humans (Chapter 2) could be observed, 
and found significant elevations at specific timepoints in mTBI versus control mice. 
Despite the significant disabilities evident at chronic stages after TBI, little attention has 
been paid to the identification of biomarkers at chronic stages post-injury. Our study 
shows biochemical abnormalities that persist long after the initial injury and provides 
support for our human study. The validation of this model will further help with the 
investigation of preclinical studies. 
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4.1 Introduction 
 
We previously discussed how mild TBI typically results in the lack of structural 
abnormalities using conventional brain imaging techniques, with most patients recovering 
after injury. Yet, a significant number of individuals (10-15%) experience persistent post-
injury symptoms 337,338. Very few studies to date have demonstrated the chronic effects of 
mTBI on neuropathological outcome in humans and in animal models 339,340.  
It is challenging to study mTBI in humans, due to the heterogeneity, as well as the 
lack of initial appearance of severity, which therefore can lead to a lack of medical 
attention in the acute aftermath. The type of TBI, patient demographics, time post injury 
at the time of sample collection and genetic predisposition can all influence sensitivity 
and specificity of possible candidate biomarkers. Therefore the use of animal models 
presents an opportunity to control for the mentioned confounding factors and will lead to 
better understanding of physiological and molecular changes from the acute phase of 
minutes to hours, up to sub-chronic and chronic stages (days to months).  The use of 
laboratory models of relevance to human TBI enables biomarker profiling over extended 
periods post-injury, which would be very difficult to assess in human patient populations. 
In this chapter, we used the previously described liquid chromatography/mass 
spectrometry (LC/MS) analyses to investigate long-term plasma PL profiles and also to 
assess changes in LRG1 concentration in a closed head injury (CHI) mouse model of 
mTBI in order to determine whether this model captures the lipid and protein changes 
observed in human mTBI subjects.  
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The mouse model described here has been previously characterized 341,342 ( 
Mouzon pers. comm.).  Mouzon and his colleagues at the Roskamp Institute specifically 
developed a CHI model of mild TBI to address this understudied area of TBI research.  
Other models such as the fluid percussion injury (FPI) or controlled cortical impact (CCI) 
require a craniectomy and are relatively severe by comparison. It has been previously 
demonstrated that these invasive methods can confer profound behavioral and 
proinflammatory damages 343. The described CHI model has been characterized over an 
extensive period of time and the group has shown that mice exposed to a single mTBI 
had subtle and transient behavioral and immunohistochemical abnormalities with long 
lasting pathology. Firstly, behavioral testing during the first 2 weeks post injury showed 
transient deficits in motor function and spatial memory in mTBI mice. Furthermore, at 
24hrs, reactive astrocytosis and sparse APP-immunoreactive axonal pathology in the 
corpus callosum were observed 341. Secondly, investigation of this group was extended to 
several chronic timepoints (6 and 12 month timepoints published; 3 month and 24 month 
unpublished). The group showed that cognitive performance returned to normal by 6 
months after a single mTBI 342. These observations are consistent with findings in human 
patients in which those suffering from mild head injury often return to their pre-
concussive cognitive status within a week 344,345.  Yet, injured animals showed 
neuroinflammation and white matter loss (thinning of the corpos callosum (CC)), which 
peaked at 6 months and remained static at the 12 months timepoint compared to controls 
342.  The neuropathology we see in these mice is consistent with some aspects of human 
TBI as confirmed by our clinical collaborator Dr. William Stewart in Glasgow, Scotland, 
who is a clinical neuropathologist specializing in TBI. Therefore, we used our 
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phospholipid analysis platform to investigate plasma samples collected from these 
animals at 24hrs, 3, 6, 12 and 24 months post injury. We hypothesized that changes in the 
PL of mice could reflect our previous findings in human subjects. 
 
4.2 Materials and Methods 
 
Animals 
Male, C57BL/6J mice (10 weeks, 24–30g, Jackson Laboratories, Bar Harbor, 
ME) were singly housed under standard laboratory conditions (23°C±1°C, 50%±5% 
humidity, and 12 h light/dark cycle) with free access to food and water throughout the 
study. We used a standard diet (ENVIGO, IN) that contains a standard mixture of fatty 
acids (both omega-6/omega-3, SFA (0.8%), MUFA (1.1%) and PUFA (2.9%)). Mice 
were allowed to adapt to the vivarium for 1 week prior to experimental procedures. All 
procedures involving mice were performed under Institutional Animal Care and Use 
Committee approval and in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals.  
 
Injury protocol 
Mice were injured via a CHI mTBI model as previously described 341,342. Briefly, 
mice were anesthetized with 1.5 L/min of oxygen and 3% isoflurane and their heads 
shaved; each mouse was transferred into a stereotaxic frame (Stereotaxic, Stoelting, 
Wood Dale, IL) mounted with an electromagnetic (EM) controlled impact device (Impact 
OneTM Stereotaxic Impactor, Richmond, IL). The injury was triggered above the sagittal 
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suture midway using the myNeuroLab controller at a strike velocity of 5 m/sec, strike 
depth of 1.0mm, and dwell time of 200 ms, a paradigm specifically developed to avoid 
fractures and bleeds to allow correlation with human mTBI.  Based on the manufacturer’s 
instructions, the force applied to the mouse head at the time of impact is 72N under these 
conditions.  At the end of the procedure, each animal was allowed to recover and was 
then returned to its home cage. Control animals underwent the same procedures and 
anesthesia of the same duration, but did not receive a hit, in order to control for the 
effects of anesthesia.  
 
Injury groups and schedule 
For the lipidomic analyses, a total of 40 mice were randomly assigned to one of 
two groups - single injury (mTBI) or single sham controls (control: anesthesia alone 
matched for the anesthesia duration of injured mice). Samples were collected at five 
different timepoints - 24 hours and 3, 6, 12 and 24 months post injury (n=8 per timepoint, 
comprising 4 mTBI and 4 control mice).  
 
Sample preparation 
To obtain blood specimens suitable for measurement of plasma phospholipid 
analysis, animals were lightly anesthetized with isoflurane prior to euthanasia, and 
approximately 500µl of blood was withdrawn into EDTA capillary tubes by cardiac 
puncture to avoid coagulation. Protease and phosphatase inhibitors were added as 
additional preservatives. Blood was then centrifuged at 5,000 x g for 3min to avoid 
shearing of cells 253,346. Plasma was collected and stored at -80°C until lipidomic analysis. 
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Figure 4-1 shows the outline of our experimental schedule. On the day of euthanasia, all 
mice in that cohort were euthanized randomly (control or injured) between 9am and 2pm 
to avoid any bias due to collection time. All mice were non-fasting at the time of 
euthanasia; it has been shown that fasting has no effect on changes in PL levels 347; given 
the standardization of diet and treatment/handling of all animals we expect PL levels to 
be stable across groups apart from any influence of mTBI. 
 
 
 
Figure 4-1 Outline of experimental schedule 
 
 
Thiobarbituric Acid Reactive Substances (TBARS) ELISA 
For the 24hrs and 3 months timepoint, lipid peroxidation was assessed via a 
TBARS ELISA (Cayman Chemical, MI).  As lipid peroxides are unstable a number of 
compounds are formed, including malondialdehyde (MDA). Therefore, the level of 
peroxidation is measured by the occurrence of MDA. The ELISA was performed 
following manufacturer’s instructions. A MDA-thiobarbituric Acid (TBA) adduct was 
formed by the reaction of MDA and TBA under high temperature (90-100°C) and acidic 
conditions, and measured colorimetrically at 530-540 nm. 
Lipidomic analysis 
Acclimation 
-7 days 0 day 
Injury for mTBI 
Euthanized & plasma collection 
n = 4 mTBI 
n = 4 Control 
Per timepoint 
24hrs 3month 6month 12month 24month 
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Leucine-rich alpha-2 glycoprotein 1 ELISA 
LRG1 concentrations were determined using a competitive inhibition enzyme-
linked immunoassay (ELISA, www.mybiosource.com) applying the same principle as the 
human LRG1 ELISA (Chapter 2).  
For both TBARS and LRG1, significance was determined by one-way ANOVA. P values 
< 0.05 were considered statistically significant. 
 
Lipidomic Analysis 
All samples were analyzed with the experimenter blinded to the group and time 
point to which each animal was assigned. Lipids were extracted from plasma (n = 4 
mTBI and n=4 control for each of the 5 timepoints post injury; in total N=40) using the 
Folch method (Folch et al. 1957; Emmerich et al. 2015). Lipidomic mass spectrometry 
analysis was performed as previously described in Chapter 3. 
 
Statistical lipid analyses  
 For phospholipids, statistical analyses were performed as we have previously 
described in Chapter 3 228,348.  
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4.3 Results 
 
We used HILIC LC/MS to identify and quantify various phospholipid classes and 
their molecular species.  
 
Long-term plasma profiling of total phospholipid classes in mTBI and control 
animals 
Our aim was to establish a temporal plasma PL profile in mTBI injured mice for 
comparison against matched control mice (sham). We examined PL profiles at an acute 
timepoint (24h) and at multiple chronic post-injury time-points (3-, 6-, 12- and 24 months 
post injury).  
In Figure 4-2 A-F, we first show the possible effects of aging on total PL levels in 
control mice (solid lines) and mTBI mice (dashed lines) ranging from 24hrs to 24 
months. For control mice, we observed significantly lower PC, PE, PI and SM levels at 
the 24 month timepoint relative to 24hrs (p < 0.05), but no significant differences 
between 24hrs and any of the other timepoints evaluated in this study. No effect of aging 
was observed for LPC and LPE in control mice. The mild TBI group showed as well 
significantly lower levels at the 24 month timepoint for PC, PI and SM. For LPC in mTBI 
mice, no changes were observed for all timepoints. However, in mTBI mice total LPE, 
reached significantly lower levels at 24 months compared to 24hrs. For total PE, the 12 and 
24 month levels were decreased compared to 24hrs. 
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Figure 4-2 A-F.  Effect of aging on total plasma PC, PE, PI, LPC, SM and LPE in control 
and mTBI animals, represented as the mean ± SD as a percentage of their value at the 
24hrs timepoint. Individual molecular species of PC, PE, PI, LPC, SM and LPE quantified by 
LC/MS were summed after lipidomeDB analyses to generate total lipid levels. Levels of each 
total lipid class were analyzed in relation to their respective 24hrs timepoint (100%). For 
control mice, total PC, PE, PI and SM were significantly decreased at 24 months post injury.  
No significant change was observed for any other timepoints or for total LPC and LPE (* 
denotes p<0.05 in control, solid line). mTBI mice behaved in a similar fashion to their control 
counterparts for total PC, LPC, PI and SM. However, for total LPE, mTBI mice reached 
significantly lower levels at 24 months compared to 24hrs. For total PE, the 12, and 24 month 
values were decreased compared to 24hrs (⊥denotes to p<0.05 in mTBI, dashed line). 
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Next, we analyzed plasma PL changes for mTBI vs. control animals at each 
timepoint. Total concentrations of each PL class are shown in Figure 4-3. Overall, plasma 
levels of several major PL classes were decreased in mTBI compared to control mice at 
several chronic post-injury timepoints. More specifically, relative to control mice, total 
PC, LPC, PE, LPE and PI were consistently lower in mTBI mice at the post injury 
timepoints of 3 to 24 months, with differences being statistically significant for 3, 12 and 
24 months post-injury. However, SM levels were only significantly lower at 24 months 
post-injury. Absolute plasma concentrations for all major PL classes in control and mTBI 
mice can be found in supplemental table 1 (Appendix, Chapter 4, Section 1). Figure 4-4 
shows a summary figure of total lipid changes over time following head injury. Overall, 
while there is a small but non-significant increase at 24hrs post injury, PL decreases are 
prominent at 3 months post injury, which is then followed by a recovery phase at 6 
months. Long-term PL changes are evident at 12 months post injury with PL further 
decreasing at 24 months post injury, where an additional aging effect is evident.  
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Figure 4-3 Significant changes in total plasma phospholipids in mTBI mice, 
represented as mean percentage of control ± SD at 24hrs, 3month, 6month, 12month 
and 24month post injury. Individual molecular species of PC, PE, PI, LPC, SM and LPE 
quantified by LC/MS were summed after lipidomeDB analyses to generate total lipid levels. 
The table shows the timepoints at which significance was achieved. Based on MLM 
regression and post hoc analysis, total PC was significantly decreased at 3 month, 12 month 
and 24 month post injury (p<0.01) compared to control mice. Total LPC (p<0.01) and LPE 
(p<0.001) were significant at the 3 month and 24 month timepoint. Total PE (p<0.01) and PI 
(p<0.05) were decreased at 3 month, 12 month and 24 month. Total SM was different 
between injury and control at 24 month  (p<0.01). The table gives p values for the 
timepoints, where changes between mTBI vs. control mTBI vs. control were significantly 
different. 
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Figure 4-4 Summary figure providing an overview of our PL findings. Our overall data 
suggest decreases in PL at 3 months post injury, followed by a recovery phase (up to 6 
months) and long-term lipid changes, which are then accompanied by aging effects. 
Black/grey lines indicate total changes of each PL class over time. The red line shows 
average changes at 24hrs, 3, 6, 12, and 24 months post injury in mTBI mice relative to 
controls. 
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Analysis of the degree of unsaturation of PL classes 
The brain can synthesize SFA and MUFA, whereas PUFA are largely acquired 
through the periphery due to the low capacity of the brain to synthesize these de novo. 
We therefore examined whether there was an effect of injury on the degree of 
unsaturation within different PL classes (Figure 4-5 A-E) at the chronic post-injury 
timepoints.  Overall, SFA, MUFA and PUFA were decreased at several timepoints for 
PC, LPC and LPE in mTBI mice compared to their control counterparts. Exceptions were 
MUFA containing PE and PI species, which did not reach significance for any given 
timepoint (p<0.05, Figure 5C and E). However, 24h post injury, SFA containing PE 
species were significantly increased (p<0.05), whereas the degree of unsaturation of other 
PL classes was unaffected at this acute timepoint. Moreover, for all PL classes, PUFA-
containing lipids were significantly decreased 24 months post injury. 
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Figure 4-5 Degree of unsaturation of PL classes in plasma of mTBI mice compared to 
control. Mean percentage of control ± SD. A) Significant changes of SFA (p<0.01), MUFA 
(p<0.001) and PUFA (p<0.05) containing PC species were observed over time. B) Within 
mTBI mice, SFA (p<0.01), MUFA (p<0.001) and PUFA (p<0.001) containing LPC species 
were significantly decreased at 3mo and 24mo post injury. C) Within mTBI mice, SFA 
containing PE species (p<0.01) were significantly increased 24h after injury and decreased 
by 3 mo, whereas MUFA-containing PE species showed no change after mTBI. PUFA-
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containing PE species (p<0.01) were significantly decreased at 3mo, 12mo and 24mo. D) 
SFA (p<0.01), MUFA (p<0.01) and PUFA (p<0.01) containing LPE species showed 
significant changes in mTBI mice compared to control animals.  E) Within mTBI mice, 
MUFA-containing PI species showed no significant difference (p>0.05). PUFA-containing PI 
species (p<0.05) were significantly decreased at 3mo, 12mo and 24mo, *p<0.05; MLM 
regression with post hoc analysis. The table gives p values for the timepoints 
 
Examination of ether lipids in plasma of mTBI injured mice compared to control 
animals 
Since ether PC and ether PE are dependent upon peroxisomes for their synthesis, 
we grouped these lipids separately. Figure 4-6 shows that ePE levels were significantly 
different in injured mice compared to controls (p<0.05). Ether PE species were increased 
24h post injury and then decreased afterwards, significantly at 3, 12 and 24 months. Ether 
containing PLs in other classes were not altered after post-hoc correction. 
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Figure 4-6 Differences in total ePC, eLPE, ePE and eLPE in plasma of mTBI mice. 
Mean values expressed as a percentage of control ± SD. Levels of ePC, eLPC and eLPE 
were not significantly different in mTBI mice compared to control. Ether PE species were 
increased 24h post injury before showing a decrease at 3mo and 12mo (p<0.05), p*<0.05; 
MLM regression with post hoc analysis. The table gives p values for the timepoints, where 
changes between mTBI vs. control mTBI vs. control were significantly different. 
 
Profiling of AA- and DHA-containing phospholipid species in mTBI mice 
We examined AA- and DHA-containing species due to their potential role in 
inflammatory responses, which are shown to accompany the chronic pathology of mTBI.  
Figure 4-7 shows the individual DHA containing PL species in the plasma of mTBI mice 
compared to controls, whereas Figure 4-8 represents individual AA containing PLs. In 
general, DHA containing PL species (such as PC(38:6), PC(40:6), LPC(22:6), PE(40:6), 
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LPE(22:6) and PI (40:6); p < 0.05) were decreased at several chronic post-injury timepoints.  
However, ePE(40:6) was elevated at 24hr post-injury but significantly decreased at 3- and 
12- months post-injury (p < 0.05). 
Similar to the results for DHA, in general, AA containing PL species were decreased 
at several chronic post-injury timepoints (such as PC(36:4), PC(38:4), PC(38:5), LPC(20:4), 
PE(36:4), PE(38:4), PE(38:5), LPE(20:4), PI(36:4) and PI(38:4); p < 0.05; Figure 4-8). As 
with DHA, an ePE species (ePE(38:4)) was increased at 24hr post injury and decreased at 
3- and 12- months (p<0.05). 
 
 
Figure 4-7 DHA containing phospholipid species in the plasma of mTBI mice 
compared to controls. Means expressed as a percentage of control ± SD. DHA containing 
PC species were significantly different in the mTBI group compared to controls (p<0.05). 
Within the mTBI group, DHA-containing PC(38:6) and PC(40:7) showed significant 
decreases at 12mo and 24mo post injury. PC(40:6) was only lower at 12mo. LPC(22:6) was 
significantly decreased at 3mo and 6mo post injury (p<0.05). DHA-containing PE species 
(p<0.001) revealed an increase at 24h for ePE(40:6) and, together with PE(40:6), showed a 
decrease at 3mo and 12mo post injury. For LPE(22:6) a decrease was observed at 12-, and 
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24month (p<0.01) for injured animals. PI(40:6) (p<0.05) showed significantly lower levels 
at 12mo. *p<0.05; MLM regression with post hoc analysis. The table gives p values for the 
timepoints where changes between mTBI vs. control were significantly different. 
 
 
 
Figure 4-8 AA containing phospholipid species in plasma of mTBI mice compared to 
control. Mean expressed as a percentage of control ± SD. Within mTBI mice, AA 
containing PC species were significantly different in mTBI mice compared to controls 
(p<0.05). AA-containing PC(36:4) was decreased at 3mo and 12mo post injury, whereas 
PC(38:4) showed significant changes only at 12mo. PC(38:5) was reduced at 3mo,12mo and 
24mo. For LPC(22:4) we observed a significant decrease in mTBI animals (p<0.01) 3mo and 
6mo post injury. AA-containing PE species ePE(38:4) revealed an increase at 24h and a 
decrease at 3mo and 12mo. PE(36:4) and PE(38:5) were both lower at 3mo and 12mo post 
injury. PE(38:4) was significantly decreased at 3mo, 12mo and 24mo. LPE(20:4) (p<0.001) 
showed lower levels at 12mo and 24mo. AA-containing PI species revealed lower levels of 
PI(36:4) in injured mice at 24h and 24mo, (p<0.05),  whereas PI(38:4) was significantly 
reduced at 3mo, 12mo and 24mo post injury, *p<0.05; MLM regression with post hoc 
analysis. The table gives p values for the timepoints, where changes between mTBI vs. 
control mTBI vs. control were significantly different. 
 
 
Profiling of individual molecular species of PC, LPC, SM, PE, LPE and PI in the 
plasma of mTBI mice.  
Appendix Tables 2-7 (Appendix, Chapter 4; Section 2) show the concentrations of 
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individual phospholipid molecular species in plasma, grouped by class, that were 
identified by PCA to be significantly associated with injury at different time points. 
 
For PC, multivariate PCA of the plasma data shows that component 1 explained 
81% of variance in the dataset and was the strongest predictor of mTBI (p < 0.001) of 
individual PC species at time points 24hrs, 6 months (PC(32:0) only) and 24 months 
post-injury. Components 2 and 3 were associated with the 3 and 12 month timepoints.  
PC(42:6) was only modulated at the acute timepoint, whereas PC(34:1), PC(38:6), 
PC(40:5) and PC(40:7) started to be significantly lower at the most chronic timepoints of 
12 and 24 months post injury.  Appendix Table 2 shows individual PC species that were 
significant for different time points post injury. 
 For LPC, component 1 of the PCA showed significance for mTBI, which 
explained 70% of the total variance in the dataset (p < 0.05) and was associated with 
24hr, 3, 6, and 24 months post injury. For the acute timepoint only LPC(16:1) was 
significantly modulated in mTBI mice and LPC (o-16:1) showed a 46% decrease by 24 
months post injury. Appendix Table 3 shows all individual LPC species that were 
identified as significant by PCA in component 1 for different timepoints post injury.  
For PE, multivariate PCA of the plasma data showed that component 1 explained 
68% of the variance in the dataset and was a strong predictor for injury (p < 0.001) at 
timepoints 24hrs, 3-, 12-, and 24 months. For the acute timepoint several species (e.g. 
ePE(38:5), ePE(38:6) and PE(38:0)) showed an increase of between 66-72%. The same 
species were observed to be decreased at chronic stages. Appendix Table 4 shows 
individual PE species that were significant for different timepoints post-injury. 
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For LPE, component 1 of the PCA, explained that 52% of the total variance in the 
dataset (p< 0.05) was significantly associated with mTBI for all chronic timepoints. No 
individual LPE species was different from control at 24hrs post-injury. Appendix Table 5 
shows individual LPE species that were specific to PCA component 1.  
For PI, component 1 explained 66% (p < 0.05) of the total variance and was a 
predictor for mTBI for all timepoints. Appendix Table 6 shows individual PI species in 
plasma with significant changes for the different timepoints post-injury.   
For SM, component 1 explained 59% of the total variance (p < 0.05) and was 
significantly associated with mTBI at 6-and 24 months post-injury. No significance was 
observed at the acute timepoint. Moreover, SM species SM(d18:1; 22:1) and SM(24:0) 
were only modulated at 24 months post injury.  Appendix Table 7 shows individual 
significant SM species that were specifically significant with PCA component 1.  
 
Lipid peroxidation at 24hrs and 3months post injury 
The PL analysis revealed that there were no differences between control and 
mTBI mice at 24hrs post injury, whereas we observed a significant decrease for many 
PUFA-containing PL species at 3 months. Thus we investigated lipid peroxidation at both 
timepoints by measuring MDA production (Figure 4-9 A-B). No difference was observed 
for mTBI and control mice at 24hrs post injury (p > 0.05). At 3 months, we observed a 
significant increase for MDA in mTBI mice compared to controls with a fold change of 
1.77 (p = 0.003). 
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Figure 4-9 MDA concentrations in plasma of mTBI mice compared to control at 24hrs 
and 3 months post injury. (A) No differences were observed in peroxidation levels between 
control and mTBI mice at 24hrs post injury (p>0.05; control: 2.04 ± 0.58µM; mTBI: 2.40 ± 
0.67µM in mean ± SEM. (B) MDA concentration was significantly increased in mTBI mice 
(n=4) compared to control (n=4) at the 3 months timepoint (p=0.003; control: 2.32 ± 
0.44µM; mTBI: 4.10 ± 0.49µM). 
  
 
Change of LRG1 levels over time 
The LRG1 ELISA showed no differences 24hrs after injury between mTBI mice 
and controls (Figure 4-10). At the 3 month timepoint marginally higher levels of LRG1 
were observed in mTBI animals (Prob>Chi square p<0.01), whereas at 6 months changes 
between the two groups become more significant with injured animals showing increased 
levels of LRG1 (Prob>Chi square p<0.009). Although LRG1 levels did not decrease in 
mTBI mice at the 12 and 24 months timepoint, the concentration of this protein rose in 
control animals with age, and thus significance was lost at these the later time-points. 
Mean (and SD) concentration for LRG1 at each timepoint in plasma was observed as 
follows: 24hrs: mTBI 214.9 ± 45.1 µg/ml; Control 152.9 ± 30.3 µg/ml, 3 months: mTBI 
310.9 ± 34.3 µg/ml; Control 189.2 ± 37.9 µg/ml, 6 months: mTBI 279.7 ± 29.3 µg/ml; 
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Control 172.8 ± 17.6 µg/ml, 12 months: mTBI 341.8 ± 55.7 µg/ml; Control 326.5 ± 32.3 
µg/ml, 24 months: mTBI 272.8 ± 26.1 µg/ml; Control 298.8 ± 60.5 µg/ml. 
 
 
Figure 4-10 LRG1 concentrations in the plasma of mTBI mice compared to control at 
24hrs, 3-, 6-, 12-, and 24 months post injury. No differences were observed in LRG1 levels 
between control and mTBI mice at 24hrs post injury (p>0.05). LRG1 concentration was 
significantly increased in mTBI mice (n=4) compared to control (n=4) at the 3 months 
(p=0.01) and 6months (p=0.009) timepoints. At 12 and 24 months no significant differences 
were observed, as levels in mTBI mice stay elevated, whilst LRG1 in control animals 
increased. 
 
4.4 Discussion 
 
The secondary damage that follows TBI includes inflammation, blood brain 
barrier dysfunction and axonal injury, which can persist over a long time period 340339. 
Previous studies, including ours, have shown that PL levels are altered in subjects with a 
history of mTBI, and in a controlled cortical impact mouse model of relatively severe 
CCI induced TBI 348,349.  These findings suggest that PL may be important in the 
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pathophysiology of TBI and could in the future serve as biomarkers.  They would also be 
useful for improving our diagnostic and prognostic capabilities for brain injury. Such 
biomarkers could be also used theragnostically, as surrogate markers for assessing the 
therapeutic response to potential TBI treatments. Given our previous findings suggesting 
PL biomarkers of TBI at chronic time points post-injury in a human population, we 
sought to determine if such changes were evident in our laboratory model of mTBI, 
which would support its relevance to the human population and lead to further 
translational studies. 
We first examined PL profiles in control mice to determine if aging itself had an 
impact on plasma PL profiles.  While LPC and LPE levels did not differ over time, PC, 
PE, PI and SM all showed a significant decrease at the 24month time point. At 24 months 
post injury (26.5 months of age) mice are nearing the end of their lifespan 350. It is known 
that PL are the major components of membranes and play a role in maintaining the 
membrane integrity as well as in functional activity. Lipid metabolism and its turnover, 
especially oxidation of fatty acids, have been implicated in apoptosis, and aging causes 
an increase in molecular damage to the cell membranes and changes in the normal 
asymmetrical architecture of membranes 351–354. Ovsepian et al. have shown that PC, PE 
and SM were decreased in the brains of 25-month-old rats, whereas LPC and PI 
increased. Moreover, a study by Kim et al. compared PC, LPC and SM levels in the sera 
of young (4 month) and old (21 month) mice and showed that lipid levels were decreased 
with age for PC and SM, as well as some of the LPC species 355. Our findings confirm 
these results. Although the age-dependent decrease in LPC does not reach significance at 
24 months in our study, a non-significant trend is visible. A decrease of PL at 24 months 
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post injury could be due to an increase in oxidation. Yet, further studies are needed in 
order to understand the biological pathway underlying these changes. When evaluating 
the aging effect in mTBI mice we observed the same decreases as in control mice. 
However, additionally, we observed a significant decrease in LPC at 24 months when 
compared to the 24hrs levels, as well as an earlier initiation (12 months) of the significant 
age-dependent decrease in PE. Because we used age-matched controls our subsequent 
analysis of mTBI versus control for each time point was not affected by the aging 
component. Yet, as seen by comparing control and mTBI mice with their 24 hrs 
counterparts, 24 months post injury, the TBI group showed lower PL levels, beyond that 
of “normal aging”. Moreover, the fact that lower levels were also observed at 12 months 
could suggest an accelerated aging effect in the TBI animals. Although more 
investigation on this subject is necessary, a link between TBI and accelerated ageing has 
been suggested (reviewed by 356). For example, people who had recovered from a minor 
TBI who were exposed experimentally to a stressful situation (induced mild hypoxia) had 
significantly impaired vigilance and memory abilities compared to healthy subjects 357. 
In the case of mTBI, overall, total PL levels for all classes evaluated in this study 
did not show major differences at the acute 24 hrs post injury time point. We then 
focused our study on the impact of mTBI on plasma profiles over time post-injury. At 3-
months post-injury, we observed a decrease in injured animals compared to their control 
counterparts in PC, LPC, PE, LPE and PI, but not for SM. Total PC, PE and PI also 
showed significantly lower levels at 12 months and all classes were decreased at 24 
months post injury in the mTBI group compared to controls. The 6-month time point did 
not reach significance due to increased variance in control animals seen at this time point. 
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Higher variance was also observed for SM levels at time points prior to 24 months post 
injury.  
Kay et al. were able to detect PL disturbances from the brain in the CSF in 
humans, showing that brain alterations can be detected in peripheral biofluids 310. 
Moreover, Abdullah et al. investigated PL profiles in different brain regions, as well as 
plasma at 3 months post injury in a CCI model showing that even at chronic stages post 
injury, PL changes persist 349. We also conducted a clinical study involving active duty 
military with a history of mTBI and we detected changes in plasma lipids at this chronic 
stage (Chapter 3). It is important to note that clinical evidence from our military study 
confirms the findings of this study. Total PL levels were decreased in soldiers with mTBI 
compared to controls for all PL classes 348. 
Overall, lipid levels showed no difference in mTBI mice compared to control at 
24hrs post injury but changed over the next 3 months as indicated by the decrease in 
mTBI versus controls at the 3 months timepoint. We then observed a possible recovery 
phase around the 6 months timepoint, where PL levels returned to those of control 
animals. Finally, lipid levels dropped again at the chronic 12- and 24 months timepoints 
post injury. 
 It is known that saturated and monounsaturated fatty acids can be synthesized de 
novo within the brain, however polyunsaturated fatty acids are mainly supplied from the 
periphery 318. In this study, we observed that saturation status, specifically levels of 
unsaturation, was different in injured compared to control mice.  
Overall SFAs, MUFAs and PUFAs were decreased for PC, LPC and LPE at different 
time points.  In our clinical study we also showed differences in PL degree of 
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unsaturation and its decrease at the chronic stage. It is interesting to observe that SFAs, 
MUFAs and PUFAs are differently regulated within different PL classes. It is also 
interesting to mention that in mice, MUFAs of PE and PI did not reach significance at 
any time point. However, in order to better understand the molecular mechanisms of PL 
involvement following TBI and their unsaturation status, it will be necessary to 
investigate enzymes that are involved in their BBB transport, desaturation of SFAs and/or 
elongation of MUFAs to PUFAs. This study was not intended to investigate specific 
aspects of TBI pathogenesis as it related to lipid metabolism, but rather to develop 
potential biomarker profiles. Nonetheless, we were interested in whether or not lipid 
peroxidation was a factor in our findings and we found total lipid peroxidation to be 
elevated in mTBI compared to control at 3 months post injury chronic timepoint when 
PUFA levels were significantly reduced. As PUFAs, owing to the presence of multiple 
double bonds, are susceptible to oxidative degradation these findings of higher levels of 
lipid peroxidation are consistent with the observed decreases in PUFA levels at this 
timepoint.  However an assay with the sensitivity to detect oxidized PL by MS needs to 
be employed to draw further mechanistic conclusions. 
We analyzed ether-containing PLs and characterized their response to injury. 
Changes in ether PLs (LPC o-16:0 and LPC o-18:0), which are precursors to 
inflammation promoting platelet-activating factors (PAFs) were found to be significant. 
Although eLPC were not significantly modulated by mTBI, LPC (o-16:0) was 
significantly lower at 24 months post injury. Furthermore, for other ether lipids, such as 
ePC and eLPE, no significant differences were observed. A majority of ether PE species 
are plasmalogens 297. We observed increased ePE 24 hrs post injury before it decreased at 
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3 months and again at 24 months. This correlates with our clinical studies, where we only 
observed lower levels of ePE in TBI subjects, all of whom were recruited at chronic time 
points after injury. As ePEs are enriched for DHA and AA, serving as reservoirs for their 
bioactive lipid metabolites297, a decrease in these lipids could mean increased synthesis of 
eicosanoids and docosanoids that modulate inflammation following TBI. However, 
specific monitoring of bioactive lipid metabolites will be necessary to draw further 
conclusions in this regard. 
It is known that bioactive metabolites of DHA and AA, the most abundant ω-3 
and ω-6 PUFAs in the brain, contribute to the immune and inflammatory balance within 
the CNS and the periphery. DHA is a precursor of the anti-inflammatory mediators, 
resolvins, and neuroprotectins, whereas AA is a precursor of pro-inflammatory lipid 
mediators, such as prostaglandins and leukotrienes 319,320. Therefore we further 
investigated DHA and AA containing lipid species. We only observed a significant 
reduction in the AA:DHA ratio in TBI mice for the lipid class PE, at 24 hrs post injury 
(data not shown). This correlates with our clinical data, where we observed reduction of 
AA to DHA containing molecular species only in PE for mTBI subjects compared to 
controls. Although ratios didn’t change for other lipid classes in mice, we observed 
changes in specific DHA-containing and AA-containing PL species in mTBI versus 
control mice. For the acute 24 hrs time point, we observed a significant increase in AA 
containing ePE(38:4) as well as in DHA-containing ePE (40:6). Although no other AA or 
DHA containing species reached significance at 24 hrs, PC(40:6), PE(40:6), as well as  
PE(38:4) showed a trend of higher levels. This correlates with a clinical study by Yang et 
al., who showed that AA was enhanced in serum metabolites in TBI subjects shortly after 
 175 
injury 358. Apart from elevation at the 24 hrs timepoint, individual DHA and AA 
containing species were significantly decreased at several chronic stages in mTBI mice 
compared to control animals. As the brain particularly needs DHA, there may be an 
increased need for DHA containing lipids after injury for repair and other related 
functions 322–324.  Therefore the acutely lowered AA:DHA ratio could reflect the early 
DHA increase in response to injury, and subsequent decrease owing to their increased 
utilization. Tracking the changes in plasma AA and DHA in PL could potentially serve as 
a surrogate marker once it is confirmed that AA and DHA changes in plasma reflect brain 
changes. Furthermore, truncated products, such as prostaglandins and resolvins of AA 
and DHA, respectively, should also be evaluated. Moreover, we hope to replicate this 
study in mTBI mice of other strains and genetic backgrounds, which will help further 
verify our work. Our focus in recent years has been on mild TBI; therefore this study 
does not include severe head injury paradigms, though for future study this would 
definitely be an interesting area of investigation and comparison. 
Furthermore, the observed injured animals showed neuroinflammation and white 
matter loss, which peaked at 6 months and remained static at the 12 months timepoint 
compared to controls 342.  Although it is not possible at this point to relate plasma PL 
chances with the observed persistent neuroinflammation, the ongoing dyregulation of PL 
could be related to the pathology of this injury model. However, in order to better 
understand this connection, PL should be measured in the same brain regions (e.g 
hippocampus), in which neuroinflammation was detected. As this mild TBI model does 
not show gross structural changes more severe injury or repetitive mild TBI models could 
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be used to investigate if resulting structural changes, as well as a stronger 
neuronflammatory response relate to PL in brain as well as plasma. 
Finally, our measurements of LRG1 concentration in our mouse model revealed 
interesting findings. No differences were observed at the acute 24hrs timepoint. However, 
significant elevations of LRG1 in mTBI mice were seen at the 3 month with significance 
increasing at 6 months. At later timepoints (12 and 24 months) the LRG1 concentration 
in the plasma of control animals was raised as well, resulting in a loss of significance 
between the two comparison groups. This is of interest, as it appears that aging has an 
effect on LRG1 levels. In our proteomic study in human samples (Chapter 2), we 
observed a significant increase in LRG1 concentration compared to controls in the TBI 
and TBI+PTSD group as well, matching the mice 3 month and 6 month timepoint. 
As previously described, LRG1 was proposed as a modulator of angiogenesis, acting via 
TGFβ1 endothelial cell signaling 359. Angiogenesis has been proposed to play a role in 
mediating functional recovery after TBI, as tested neurorestorative agents have been 
shown to improve functional outcome after TBI and increase angiogenesis (reviewed by 
360. Furthermore, acute increases in CD34+ endothelial progenitor cells (EPC), an inducer 
of angiogenesis, have been observed after TBI in peripheral blood and brain tissue of rats 
361. Another study investigated angiogenesis via vascular endothelial growth factor 
(VEGF) and VEGF receptor 2 expression and showed increases up to 48hrs post injury 
362. Although these major regulators of angiogenesis are believed to resolve within days 
after injury, other mechanisms could be ongoing. As LRG1 is suggested to act via the 
ALK1-Smad1/5/8 pathway, increased levels at more chronic timepoints could indicate a 
pro-angiogenic transcriptional response. However, further studies are needed to 
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understand the mechanism behind LRG1 in TBI not at acute but chronic timepoints. 
Finally, TGFβ1 signaling is induced with age 363,364. Perhaps this could explain why 
LRG1 is increased in controls as well at later timepoints. However, further investigation 
is needed to understand the potential role of LRG1 in TBI. Finally, known potential acute 
biomarkers, such as S100β, GFAP, Tau and UCH-L1 could be determined in this cohort 
the 24hrs, as well as sub-acute 3month timepoint and be used as a “positive control”. 
 
4.5 Conclusion 
 
We were able to confirm that our human findings of altered plasma PL profiles 
after TBI are also seen in our mouse model, validating it as a platform for future 
translational studies. This will include investigating the underlying molecular pathways 
that are associated with perturbed plasma PL profiles and LRG1increases in TBI. 
Moreover, this mTBI model has previously shown pathological and behavioral features, 
over time points with which these changes correlate, which are comparable to those 
observed in human subjects. Additional investigation of lipid metabolizing enzymes, lipid 
transport and oxidation studies will build our understanding of the biological mechanisms 
behind the PL observations. Furthermore, in our clinical study we observed a strong 
influence of APOE genotype on plasma lipid levels. The study of mTBI in mice 
genetically modified at the APOE locus could bring further understanding of the effects 
of mTBI, to not only enable the development of biomarkers but also the discovery of 
molecular targets for personalized medicine. 
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Chapter 5 Phospholipid profiling of plasma from GW veterans 
and rodent models to identify potential biomarkers of Gulf 
War Illness 
 
5.0 Summary 
 
In this chapter we investigated another debilitating military condition, namely 
Gulf War Illness (GWI). GWI is characterized through chronic heterogenic symptoms, 
including pain, fatigue and cognitive problems.  As a consequence this illness remains 
difficult to diagnose. Rodent models have been shown to exhibit symptomatic feature of 
GWI through exposure to GW-agents (pyridostigmine bromide, permethrin and DEET) 
and/or stress paradigms and preclinical analysis has shown activation of microglia and 
astroglia as a pathological hallmark. Although much has been learned in recent years 
from those models as well as independent clinical studies, translational studies between 
animals and humans have been lacking. Thus, in this study we aimed to identify 
biomarkers, which are translational between plasma of rodent models of GWI and human 
patients. We observed increases of multiple phospholipid (PL) species across all studied 
cohorts. Furthermore, our data suggest dysfunction within ether- and DHA- and AA-
containing PL species, supporting the proposed role for immune and inflammatory 
balance with veterans with GWI. Overall, we show that peripheral lipid disturbances can 
be found not only in humans but as well in the studied animal models. This emphasizes 
the value of further study in these models, as well as the use of lipidomics as a potential 
platform for further biomarker discovery for objective diagnosis. 
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5.1 Introduction 
 
Gulf War Illness (GWI) is a chronic multisymptom illness, which affects 
approximately one fourth of the 700,000 US veterans, who were deployed to the 1990-91 
Persian Gulf War (GW) 197,198,200,201,233. Veterans with GWI experience chronic health 
symptoms such as fatigue, muscle and joint pain, and gastrointestinal problems 221. 
Among the central nervous system (CNS) based symptoms, memory problems are among 
the most commonly reported complaints 198,200,205,221,365. The multiplicity and 
heterogeneity of symptoms observed in GW veterans is unique to the 1990–91 
deployment, with no identical illness being reported in any other military campaign, 
indicating that GWI etiology cannot solely be attributed to combat-related stress 
198,205,210,366–368. Twenty-five years later, GW veterans are still coping with this chronic 
illness, which remains difficult to diagnose due to a lack of objective diagnostic tests.  
Currently, clinical diagnosis is most commonly made by   self-report of health symptoms 
using the Fukuda CDC criteria or the Kansas GWI criteria 198,200,233. Consequently, many 
GW veterans report symptoms consistent with GWI but have not received a formal 
diagnosis of their condition. Blood based biomarkers of GWI are needed to assist 
clinicians with providing an objective diagnosis of GWI and for developing targeted 
treatment strategies.  
After performing a comprehensive review of clinical and animal research 
conducted to identify the causes of GWI, the Research Advisory Committee (RAC) on 
GW Veterans’ Illness concluded that the key contributors to GWI etiology included 
combined war-time exposure of the prophylactic anti-nerve gas pill pyridostigmine 
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bromide (PB) and pesticides which were also used prophylactically to protect against 
insect-borne diseases 197,221,233. The many pesticides used during the GW included 
irreversible and reversible acetylcholinesterase inhibitors (AChEi) including 
organophosphate (OP) and carbamate pesticides 197,221. Other commonly used pesticides 
included pyrethroids, such as permethrin (PER), the insect repellant N, N-diethyl-m-
toluamide (DEET) and organophosphates such as diisopropyl fluorophosphate (DFP) 
197,210,366,367,369–373. OP exposures from low-level sarin nerve agent exposure also has 
occurred in many GW veterans and has been modeled in animal studies with the sarin 
surrogate DFP. Results of these studies showed a chronic neuroinflammatory phenotype 
as a result of this sarin-surrogate exposure, particularly when in conjunction with a 
physical stressor 374. 
The complex clinical presentation of GWI suggests that various biological and 
metabolic processes might be altered in GW veterans. For example, impaired immune 
responses have been observed in veterans with GWI 221. Veterans with GWI showed 
altered expression in pro-and anti-inflammatory cytokines on their peripheral immune 
cells, and immune system irregularities were especially pronounced in GWI patients 
compared to controls during exercise challenge, such as increased IL-6, IL-10, and TNF-
α levels, as well as a Th1/Th17 immune polarization 223–227.  
Phospholipids (PL) are critical components of most cellular membranes, including 
mitochondrial membranes, and their metabolism generates bioactive lipids that can 
modulate inflammatory pathways 290.  In particular, phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) serve as a reservoir for ω-3 docosahexaenoic acid (DHA) 
and ω-6 arachidonic acid (AA), metabolism of which generates bioactive lipid, which can 
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alter the immune/inflammatory responses in both the central and the peripheral nervous 
system. For instance, DHA is a precursor of the anti-inflammatory mediators, resolvins 
and neuroprotectins, whereas AA is a precursor of pro-inflammatory lipid mediators, 
such as prostaglandins and leukotrienes 319,320. Preclinical studies have shown that 
exposure to GW agents can affect the brain phosphocholine levels 229, which is a 
metabolite of PC required for the endogenous synthesis of acetylcholine (ACh) 375. In 
addition, mitochondrial dysfunction is thought to underlie the clinical features of GWI 
230,231. Furthermore, mitochondria also contain PL, of which PC and PE make up 
approximately 75% of PL and phosphatidylinositol (PI) constitute 10% 376. 
Our group previously established several mouse models using exposures to 
combinations of these GW agents in order to investigate the complex underlying GWI 
pathology, which presumably involves multiple physiological and biochemical 
mechanisms.  We previously showed that PB+PER co-administration in a CD1 mouse 
model daily for 10 consecutive days, led to observed anxiety 30 days post exposure and 
delayed cognitive impairment 5 months post exposure 367. Additionally, at 5 months post 
exposure, astrogliosis was observed in exposed mice. Proteomic analyses revealed 
alteration of multiple biological systems, such as endocrine function, immune and 
inflammatory pathways, as well as disturbances in lipid metabolism 367. For example, the 
fatty acid-binding protein 3 (FABP3) was reduced in the brain of exposed animals. This 
protein plays an important role in the uptake of AA in the brain 377.  We subsequently 
translated the PB+PER exposure model to the more commonly used C57BL6/J strain of 
mice, again showing cognitive deficits associated with increased astrogliosis, as well as 
reduction of synaptophysin staining in the hippocampi and cerebral cortices at 5 months 
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post exposure 378. Since the neurobehavioral features we observed in our mouse model 
correlate with symptoms that are relevant to the clinical presentation of GWI, it is 
possible that identified pathologies in these animals are also present in human GWI 
patients 200,379. We have also reported elevated ether and diacyl PC species in the brains 
of these mice 229.  
The insect repellant DEET has also been named one of the key contributors to 
GWI, and it has been suggested that stress modulates GWI symptoms in humans 201,379. 
Addressing these additional exposures, Shetty and colleagues developed and 
characterized a rat model of GWI using a PB+PER+DEET exposure paradigm, along 
with 5 min of restraint stress to mimic war related stress 210,380,381. Their rat GWI model 
showed memory and mood dysfunction evident by deficits in spatial memory and 
increased depressive behavior 380. They also observed some loss of glutamatergic 
neurons, activated microglia, hypertrophy of astrocytes, reduced neurogenesis 380 and loss 
of certain subpopulations of gamma-amino butyric acid-ergic (GABA-ergic) interneurons 
in the hippocampus 382.  
These mouse and rat studies have been critical for advancing our understanding of the 
different facets of GWI pathology and for characterizing the underlying biological 
features.  However, translational studies between different animal models and human 
patients are currently lacking. Furthermore, there remains a need for identifying novel 
biomarkers, which can assist with diagnosing GWI and may also help link preclinical and 
clinical studies aimed at developing therapies. Taking into account the role of lipid 
disturbances detected in preclinical rodent models of GWI and the need for translational 
validation studies, we performed lipidomic analysis in the plasma of the two different 
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rodent models described above, which we then compared to results from plasma analysis 
of a cohort of GW veterans with and without GWI.  
 
5.2 Materials & Methods 
 
Animals 
GWI mouse model:  
All mouse experiments were conducted at the Roskamp Institute in Sarasota, 
Florida and were approved by the Roskamp Institute’s Institutional Animal Care and Use 
Committee and conducted in accordance with the Office of Laboratory Animal Welfare 
and the Association for the Assessment and Accreditation of Laboratory Animal Care. 
Mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and each mouse 
was individually housed in a controlled environment (regulated 14-h day/10-h night 
cycle) and maintained on a standard diet. The exposure paradigm has been previously 
described 378,383. Male C57BL6/J mice (12 weeks of age) were co-administered with 
either a 50µl total volume of GW agents to a final dose of 0.7 mg/kg of PB (Fisher 
Scientific (Hanover Park, IL)) and 200 mg/kg of PER (Sigma Aldrich (St. Louis, MO)) in 
100% dimethyl sulfoxide (DMSO) [exposed mice; n = 4], or a 50µl volume of vehicle 
(100% DMSO) [sham mice; n = 4] via intraperitoneal injection (IP) injection daily, for 10 
days. Six months post exposure, mice were euthanized, and plasma was collected. Mice 
were exsanguinated via cardiac puncture using an 18 gauge wide-bore needle to prevent 
hemolysis of red blood cells (RBC) during blood collection. Blood samples were 
collected into a 1.5 ml Eppendorf tube containing 10 units of heparin and a protease 
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inhibitor cocktail (Roche, NJ) to a final concentration of 1x. Samples were immediately 
centrifuged at 3000 x g for 5 min and the plasma was transferred to a new 1.5 ml 
Eppendorf tube and snap frozen in liquid nitrogen. Plasma samples were stored at -80C° 
until further biochemical studies. 
 
GWI rat model:  
All rat studies were conducted at the Central Texas Veterans Healthcare System 
in Temple, TX. Specifically, Sprague-Dawley rats were exposed to PB, DEET, PER and 
Stress using previously described procedures developed by Shetty et al. 380,381. 
Experiments were in compliance with the National Institutes of Health guidelines for care 
and use of animals and in accordance with the animal protocol approved by the animal 
care and use committee of the Central Texas Veterans Health Care System, Temple TX. 
Three-month-old male rats were obtained from Harlan (Indianapolis, IN) and housed for 
2 weeks before being exposed to GW agents. The exposure paradigm included PB (1.3 
mg/kg; Sigma, St. Louis, MO), PER (200 µl, 0.13 mg/kg in 70% alcohol; Chem. Service 
Inc., West Chester, PA), DEET (200 µl containing 40mg/kg in 70% alcohol; Chem. 
Service Inc., West Chester, PA), as well as 5 min of daily restraint stress, via a rat 
restrainer for 4 weeks (exposed rats n=5). PB was administered through oral gavage, 
whereas PER and DEET solutions were applied to shaved skin areas located on the back 
of neck. Non-exposed sham rats, were naïve controls (n=6). Plasma samples were 
collected 6 months post-exposure to GW agents and stress, and were sent to the Roskamp 
Institute investigators on dry ice via express delivery.  
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Human subjects 
Plasma samples from veterans, deployed to the 1990-1991 GW, were provided by 
the Boston University and the Nova Southeastern University investigators from an 
established biorepository of GW veterans, who agreed to share their blood samples from 
prior studies. This includes the Boston Gulf War Illness Consortium (GWIC) and the 
Dynamic Modeling of GWI study from Nova Southeastern University and the CDMRP 
funded study to the South Florida Veterans Affairs Foundation for Research and 
Education, Inc. The GWI biorepository is approved by the IRBs from Boston University, 
Nova Southeastern University and the Miami VAMC. Samples from the GWI 
biorepository were all collected from the Boston and Miami areas using the same 
standard operating procedures for phlebotomy, plasma separation and aliquoting. All 
samples were stored at -80oC and were not previously thawed and refrozen. GW veteran 
participants were consented into their respective studies using ICH GCP guidelines. The 
Kansas GWI criteria 200 were used to determine cases of GWI and controls. The Kansas 
GWI criteria require that GW veterans endorse symptoms in at least 3 of 6 symptom 
domains (fatigue/sleep problems, pain, neurological/cognitive/mood symptoms, 
respiratory complaints, gastrointestinal problems or skin symptoms). Controls were 
deployed veterans from the 1991 GW who did not meet the Kansas GWI criteria. 
Subjects also completed demographics and health symptom questionnaires including the 
Pittsburgh Sleep Quality Index (PSQI), Visual Analog Scale (VAS) for pain, Multi-
dimensional Fatigue Inventory (MFI-20) questionnaire, MOS Short Form 36-veteran 
version (SF-36V), and Profile of Mood States (POMS). Questionnaires can be found in 
the appendix, chapter 5; section 1. Study participants were excluded if they reported 
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being diagnosed with another medical condition that could explain the above mentioned 
symptoms according to the Kansas GWI case definition exclusions, including veterans 
with a history of prior central nervous system or major psychiatric disorders that may 
affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, 
Parkinson’s Disease, Alzheimer’s disease, schizophrenia). Control veterans (n=11) and 
veterans with GWI (n=22) were matched for age, gender and ethnicity. Due to low 
numbers in the different ethnic groups, we dichotomized the ethnicity into Caucasian 
(n=17) vs. non-Caucasian (n=16) in order to study ethnicity effect on PL levels in the 
entire cohort population independently of diagnosis. The non-Caucasian group included 
African American (n=8), Hispanic (n=4), Asians (n=2) and others (n=2). Baseline 
demographics can be found in Table 1. 
 
Lipidomic and Statistical Analyses were performed as previously described in 
Chapter 3. 
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5.3 Results 
 
Our aim was to first establish a plasma PL profile that could distinguish veterans 
with GWI from deployed controls. We examined changes in total PL levels, (PC, PE, PI, 
LPC and LPE), as well as the degree of unsaturation of PL class, ether content and ω-3 
and ω-6 fatty acid (FA) composition. We then investigated the association of individual 
PL molecular species with the diagnosis of GWI. Finally, we examined these species in 
rodent models of GWI in order to be able to validate these preclinical models. Our 
hypothesis is that if blood changes in the mouse models correlate with GWI-dependent 
plasma profiles in humans, then we may be able to extrapolate from plasma to brain, 
mouse to human for potentially pathogenic mechanism.  Specifically, although ambitious, 
we suggest correlation of our findings in human plasma to mouse plasma, and correlation 
of these plasma changes with changes we observe in the mouse brain; and we 
hypothesize that such GW-agent dependent changes in the mouse brain, correlating with 
mouse exposure/human GWI -dependent plasma changes, may thus reflect changes in the 
human GWI patient brain.    
  
 
Comparison of total phospholipid classes in GWI patients and GW deployed 
controls 
Our case control cohort included a total of 33 veterans who were deployed to the 
GW region during 1990-1991; 11 were classified as controls and 22 veterans were 
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diagnosed with GWI. In comparing baseline characteristics, control and GWI veterans 
were similar for gender, ethnicity and age (see Table 5-1).  
 
 
  Control GWI 
N total 11 22 
Age 
(Mean±Stdev) 48.5±7.7 48.4±6.3 
Male (%) 9 (81.9%) 17 (77.3%) 
Ethnicity 
  Caucasian 5 12 
African American 3 5 
Hispanic 2 2 
Asian 0 2 
Other 1 1 
 
Table 5-1 Baseline demographics of the Gulf War Veterans cohort. 
 
In order to determine if gender, age and ethnicity could potentially be 
confounding factors on the relationship between GWI and PL, we examined their 
influence on PL levels in the entire cohorts (combined controls and GWI). A gender 
effect was only observed for total PE (p=0.004) levels. There was no significant influence 
of ethnicity for any of the PL classes. There was a significant correlation of age with LPC 
(r=0.49; p<0.001) and PI (r=0.27; p=0.005).   
We investigated changes in total PL levels for GWI cases compared to controls, 
presented as a percentage of control and shown in Figure 5-1. For all subsequent 
analyses, we used gender as a covariate for all analyses pertaining to PE and age as a 
covariate for PI and LPC in order adjust for their potential confounding effects on 
relevant PL class. There were no significant differences for total PC, PE, LPE and PI 
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between the two comparison groups (p>0.05). However, for total LPC post-hoc analysis 
revealed a significant increase of 15% for GWI patients versus controls (p=0.020).  
 
 
 
Figure 5-1 Changes in total plasma phospholipid levels in GWI subjects and controls, 
represented by the mean ± SD as a percentage of control. Individual molecular species for 
each PL class identified by LC/MS were summed to calculate total PL levels within each 
class. * p < 0.05; MLM regression with post hoc analysis. Total LPC was significantly 
increased in GWI subjects (brick bars) compared to GW controls (solid bars). 
 
Analysis of the degree of unsaturation of PL classes in human subjects 
 It has been shown that the brain can synthesize SFA and MUFA, however most 
essential PUFA are acquired through the periphery due to the low capacity of the brain to 
synthesize these de novo. In order to investigate if GWI diagnosis influences unsaturation 
status of different PL classes, we examined SFA, MUFA and PUFA containing PL in 
human subjects. Figure 5-2 shows SFA, MUFA and PUFA containing species of PC, 
LPC, PE, LPE and PI in GWI subjects as a percentage of controls. For PI, no SFA-
containing species were found. 
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There were no differences between veterans with GWI and controls for the degree of 
unsaturation for PE and PI even after adjusting for potential confounding by gender and 
age, respectively.  However, SFA containing PC species were reduced by 22% in GWI 
patients compared to controls (p=0.024). No changes were seen in MUFA and PUFA 
containing PC species. In addition, the LPC, SFA, MUFA, and PUFA containing species 
were significantly elevated in GWI compared to controls by 16%, 15% and 23%, 
respectively, and remained significant after adjusting for age (p < 0.05). For LPE, PUFA 
containing species showed an increase of 50% in GWI compared to controls (p<0.001), 
whereas SFA and MUFA containing LPE species did not differ between the two groups.  
 
 
Figure 5-2 Degree of unsaturation of PL classes in plasma of GWI patients compared to 
controls, represented by mean ± SD as a percentage of control. For PC, SFA containing 
PC species were decreased in GWI patients, whereas for LPC and LPE, PUFA containing 
species were elevated compared to control subjects. No differences in the degree of 
unsaturation were observed for LPC and PE. For PI, no SFA containing species were 
identified (SFA: solid bars, MUFA: stripped bars, PUFA: brick bars). *p<0.05; MLM 
regression with post hoc analysis. 
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Examination of ether lipids in plasma of GWI subjects compared to controls 
Ether PL are dependent upon peroxisomes for their synthesis. Therefore, we 
grouped ether PL within each class. Figure 5-3 shows levels of ether PC, LPC, PE and 
LPE in GWI subjects compared to controls. No differences were observed for ePC, eLPC 
and ePE between GWI and control subjects. However, eLPE levels were increased in 
GWI veterans by 43% relative to controls (p<0.001).  
 
 
Figure 5-3 Ether lipid changes in plasma of GWI patients and compared to controls, 
represented by mean ± SD as a percentage of control. Levels of eLPE were 
significantly elevated in GWI patients (brick bars) compared to healthy GW controls 
(solid bars). No differences were observed for ePC, eLPC and ePE. p*<0.05; MLM 
regression with post hoc analysis. 
 
 
Profiling of AA- and DHA-containing phospholipid species in GWI patients 
Arachidonic acid (ω-6) and DHA (ω -3) containing fatty acids play a potential 
role in modulating inflammatory responses. Thus, we combined all AA and DHA 
containing species and AA/DHA ratios within each class for separate investigation.  
Figure 5-4 shows AA containing PL species of PC, LPC, PE, LPE and PI. No differences 
were observed for AA containing PC, PE and PI between the two groups. Compared to 
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controls, AA species within LPC and LPE were increased by 22% (p=0.023) and 40% 
(p=0.005; for LPC the p value was adjusted for potential confounding by age) in GWI 
compared to control subjects, respectively. For LPE, age was not detected as a 
cofounding factor. Figure 5-5 shows individual DHA containing PL species in the plasma 
of GWI subjects compared to controls. There were no differences between the two groups 
for DHA containing PE and PI species. However, DHA species of PC were 18% higher 
in GWI patients compared to controls (p=0.0013). Furthermore, within LPC and LPE, 
DHA containing species were increased in GWI compared to controls by 42% (p=0.001) 
and 91% (p<0.001), respectively (p values for PE (gender), LPC and PI (age) were 
adjusted as before). 
 
 
 
Figure 5-4 AA containing phospholipid species in plasma of GWI patients compared 
to controls, represented by mean ± SD as a percentage of control.  Within GWI 
patients (brick bars), AA containing LPC and LPE species were significantly elevated 
compared to controls. No differences were observed within PC, PE and PI. *p<0.05; 
MLM regression with post hoc analysis. 
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Figure 5-5 DHA containing phospholipid species in plasma of GWI patients compared 
to controls, represented by mean ± SD as a percentage of control.  Within GWI patients 
(brick bars), DHA containing PC, LPC and LPE species were significantly elevated 
compared to controls (solid bars). No differences were observed within DHA containing PE 
and PI species. *p<0.05; MLM regression with post hoc analysis. 
 
 
Comparison of individual molecular PL species across GWI rodent models and a 
GW veteran cohort. 
In order to examine the value of the described rodent models, we investigated 
individual PL molecular species in the plasma of these previously published animal 
models of GWI (rat model: PB+PER+DEET and stress exposure, mouse model: PB+PER 
exposure) and compared them with the clinical findings. Total PL, degree of saturation, 
ether and AA and DHA content PL data for both models can be found in the Appendix, 
Chapter 5, Section 2 Supplement tables 1-4. For the comparison of individual molecular 
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species we included PL in our analysis that showed a >1.1 fold change in humans for all 
PL classes and examined those in the rodent GWI models.   
Individual molecular species of PC that were significant for at least one model or 
the human subject cohort, are shown in Figure 5-6. Human GWI subjects showed 
significant increases in 7 out of the 10 shown individual PC species. The highest changes 
were observed for PC(40:6) and PC(40:7) (p<0.05). Increases ranged from 12% to 28%. 
Although the remaining 3 species showed increased levels in GWI patients, significance 
was not achieved.  For C57Bl6/J mice PC species ePC(38:1), PC(36:1) and PC(38:3) 
were non significantly elevated in exposed compared to controls (p>0.05). As with GWI 
subjects, exposed rats showed significant increase of the above-mentioned PC species, as 
well as the remaining 3 species compared to controls (p < 0.05). 
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Figure 5-6 Individual molecular species of PC are elevated in plasma from veterans 
with GWI, rodent model and mouse model of GWI. Blue:  Human GWI plasma values 
expressed as a percentage of control subjects ± SD (n = 11 controls, 22 GWI) showing 
elevated PC species in GWI subjects compared to controls. Green:  PB+PER exposed mice 
values expressed as a percentage of unexposed mice values ± SEM (n = 4 per group) 
showing that most of these species were also elevated in exposed mice but did not reach 
statistical significance. Red:  GW agent exposed rat values expressed as a percentage of 
unexposed rat values ± SEM (n = 6 sham, n = 5 exposed rats) showing elevated PC species in 
exposed compared to control rats.  *p<0.05; MLM regression with post hoc analysis. 
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significantly increased levels for 7 out of the 9 shown molecular lipid species for the GWI 
patients compared to controls. Levels increased in the range of 19% (LPC(0-18:0) ) to 42% 
(LPC(22:6n3)). Although, the remaining two LPC species (LPC(18:2n6) and LPC(20:3)) did 
not reach significance, a trend (p = 0.06-0.07) for the elevation was observed. For the GWI 
mouse model, statistical significance was achieved for 6 out of 9 individual molecular LPC 
species, including LPC(18:2n6) and LPC(20:4n6) (p<0.05); The remaining 3 showed a trend 
toward increase in the PB+PER mouse group (LPC(22:6n3), p=0.069, LPC(0-18:0), 
p=0.071, LPC(22:5n3), p=0.063). The rat GWI model showed significant increase of all 
shown LPC species in the exposure group (p<0.05), with percent change ranging from 44% 
(LPC(18:0)) to 160% (LPC(22:5n3)).  
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Figure 5-7 Individual molecular species of LPC are elevated in plasma from veterans 
with GWI, rodent model and mouse model of GWI. Blue:  Human GWI plasma values 
expressed as a percentage of control subjects ± SD (n = 11 controls, 22 GWI) showing 
elevated LPC species in GWI subjects compared to controls. Green:  PB+PER exposed mice 
values expressed as a percentage of unexposed mice values ± SEM (n = 4 per group) 
showing that most of these species were also elevated in exposed mice. Red:  GW agent 
exposed rat values expressed as a percentage of unexposed rat values ± SEM (n = 6 sham, n 
= 5 exposed rats) showing elevated LPC species in exposed compared to control rats.  
*p<0.05; MLM regression with post hoc analysis. 
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Individual molecular species of PE that were significant for at least one model or the 
human subject cohort, are shown in Figure 5-8. For human subjects, although we observed 
tendencies of elevated PE levels in the GWI patient group, only two molecular species 
reached significance (p<0.05, ePE(36:3) and PE(42:2)). Ether PE(36:3) was elevated by 19% 
and PE(42:2) by 78%. P values were adjusted for gender effect. Within the mouse model 
variance was high and no molecular species was significant (p>0.05). PE species ePE(38:0) 
and PE(36:2) were non significantly elevated.  Exposed rats showed the strongest signal and 
significant increases compared to controls for all shown PE species except one (p>0.05; 
PE(42:2). 
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Figure 5-8 Individual molecular species of PE are elevated in plasma from veterans 
with GWI, rodent model and mouse model of GWI. Blue:  Human GWI plasma values 
expressed as a percentage of control subjects ± SD (n = 11 controls, 22 GWI) showing two 
elevated PE species in GWI subjects compared to controls. Green:  PB+PER exposed mice 
values expressed as a percentage of unexposed mice values ± SEM (n = 4 per group) 
showing no significant difference in PE in exposed mice. Red:  GW agent exposed rat values 
expressed as a percentage of unexposed rat values ± SEM (n = 6 sham, n = 5 exposed rats) 
showing elevated PE species in exposed compared to control rats.  *p<0.05; MLM regression 
with post hoc analysis. 
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species were significantly elevated in human GWI patients compared to control (p<0.05, 
LPE(0-16:1), LPE(18:0) and LPE(20:4)), with increases between 31% for LPE(0-16:1) and 
46% for LPE(18:0). The mouse model showed 2 species, which overlapped to humans that 
were elevated as well, namely for LPE(18:0) (9%) and LPE(20:4) (20%; p<0.05), whereas 
the rat model only showed a significant increase for LPE(0-16:1) by 63% (p<0.05). 
 
 
Figure 5-9 Individual molecular species of LPE are elevated in plasma from veterans 
with GWI, rodent model and mouse model of GWI. Blue:  Human GWI plasma values 
expressed as a percentage of control subjects ± SD (n = 11 controls, 22 GWI) showing 
elevated LPE species in GWI subjects compared to controls. Green:  PB+PER exposed mice 
values expressed as a percentage of unexposed mice values ± SEM (n = 4 per group) 
showing that two species were also elevated in exposed mice. Red:  GW agent exposed rat 
values expressed as a percentage of unexposed rat values ± SEM (n = 6 sham, n = 5 exposed 
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rats) showing one elevated LPE species in exposed compared to control rats.  *p<0.05; MLM 
regression with post hoc analysis. 
 
Individual molecular species of PI that were significant for at least one model or the 
human subject cohort, are shown in Figure 5-10. For PI, none of the shown individual 
molecular species were significantly different in human GWI patients compared to controls 
(p>0.05). The p value was adjusted for age effect. PB+PER mice showed increased levels for 
two out of the five PI species, PI(38:5) and PI(40:5) (p<0.05) by 20% and 13% respectively. 
Consistent with this, exposed rats showed a significant increase for all PI species ((PI38:4), 
PI(38:5), PI(40:5) and PI (40:6), with elevations ranging from 143% to 212%.  
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Figure 5-10 Individual molecular species of PI are elevated in plasma from veterans, 
rodent model and mouse model of GWI. Blue:  Human GWI plasma values expressed as a 
percentage of control subjects ± SD (n = 11 controls, 22 GWI) showing no differences in PI 
species in GWI subjects compared to controls. Green:  PB+PER exposed mice values 
expressed as a percentage of unexposed mice values ± SEM (n = 4 per group) showing that 
two of these species were elevated in exposed mice. Red:  GW agent exposed rat values 
expressed as a percentage of unexposed rat values ± SEM (n = 6 sham, n = 5 exposed rats) 
showing elevated PI species in exposed compared to control rats.  *p<0.05; MLM regression 
with post hoc analysis. 
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5.4 Discussion 
  
 Shortly after returning from the 1991 conflict, a large proportion of GW veterans 
presented with multiple symptoms, later defined as GWI. The heterogeneous clinical 
presentation has made it difficult to objectively diagnose GWI, identify underlying 
pathology and find effective treatments for this debilitating illness. Preclinical animal 
models play a critical role in developing therapeutic targets. The heterogeneity of human 
exposure during the conflict can be addressed to some extent by looking at animal models 
of different GW agent exposures. These laboratory animals are more genetically 
homogenous than humans and environmental effects are better controlled in laboratory 
settings. Therefore, they allow for a more controlled assessment of the impact of GW 
agent exposures on brain changes that might be relevant to GWI. Identification of 
overlapping changes in GWI rodent models and human patients will likely facilitate 
development of diagnostic and therapeutic approaches that are relevant to the underlying 
pathological features of GWI.  In this study, we performed PL profiling to identify areas 
of overlap between the clinical patient population and GWI mouse models.  
The PB+PER mouse model and the PB+PER+DEET and stress rat model utilized in this 
study have been well characterized with respect to neurobehavioral features that are 
similar to symptoms reported by GWI patients 205,378,380,383. In the PB+PER mouse model, 
this includes anxiety and cognitive deficits, which is accompanied by astroglial activation 
in the brains of exposed mice at 5, 16 and 22 months post exposure 378,383,384.The 
PB+PER+DEET+stress rat model characterized by Shetty and colleagues exhibits 
depressive and anxiety like behavior with spatial learning and memory deficits that are 
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evident at 3 months post exposure 380. Furthermore, this model shows hippocampal 
pathology accompanied by decreased neurogenesis, partial loss of glutamatergic and 
GABA-ergic neurons, astroglial hypertrophy, microglial activation and mild 
inflammation 380–382. As such, these rodent models are ideal candidates for translational 
studies aimed at examining long-term changes that are relevant to chronic features of 
GWI symptomatology. However, rodent physiology is different from human and don’t 
fully capture the their conditions. Yet, they can be useful even if they only address certain 
aspects of human disease.  In this case observed brain symptoms are well replicated in 
these rodent models, therefore we are interested in lipids in order determine if such 
models can provide an indication of biological changes that are relevant to the human 
condition.   
We evaluated total PL levels for each class in plasma from GWI and control GW 
veterans and the two rodent models of GWI described above.  We observed elevated 
plasma levels of total LPC in veterans with GWI compared to controls. Both mouse and 
rat models also showed significantly higher total LPC levels in exposed animals 
compared to controls. For total PC, PE and PI there were no significant differences 
between the groups for human and mouse studies.  However, exposed rats showed a 
particularly strong increase in these PL classes. Because rats were exposed to stress and 
DEET, in addition to PB+PER, future investigation in subtypes of exposure in relation to 
GWI severity and symptom profiles may provide insights into possible differential 
response to GW agents and PL profiles.  
We also examined the degree of unsaturation of different PL classes in the human 
cohort and in the rodent models. In general, there was a good overlap for the degree of 
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unsaturation of LPC, with all SFA, MUFA and PUFA being elevated in GWI patients and 
in the GWI animal models (see supplemental data). In particular, PUFA LPC species 
reached statistical significance in both rodent GWI models and in human GWI patients.  
There was also a significant increase in PUFA within LPE in GWI patients and although 
these levels were elevated in both rodent models, this difference did not reach statistical 
significance.  In humans, we observed that SFA-containing PC species were decreased 
whereas MUFA and PUFA were non-significantly elevated in GWI patients and controls. 
In mice, although SFA and PUFA containing PC species did not differ significantly, 
MUFA containing species were elevated in exposed compared to control mice. In rats 
however, significant increases were seen for SFA, MUFA and PUFA species. Similar 
differences were found for PE. No significance was observed in humans, however mice 
showed lower SFA and PUFA containing PE species, whereas rats had increased levels 
of saturated and unsaturated PE. For SFA, MUFA and PUFA containing PI no 
significance was detected in humans and mice, however rats showed increased levels. 
These studies suggest possible differences in PL profiles in response to different 
combinations of GW exposures and chronicity of illness, which warrant further 
investigation. As most of these PL in plasma are bound to various lipoproteins, known 
differences between human and rodent lipoprotein compositions could influence these 
findings 385. For example, in human plasma, initial uptake of cell cholesterol by HDL is 
subsequently followed by esterification through lecithin:cholesterol acyltransferase 
(LCAT). A portion of the HDL cholesteryl esters are then not delivered directly to the 
liver, but transferred by the cholesteryl ester transfer protein (CETP) to low and very 
low-density lipoprotein (LDL and VLDL). This is followed by a delivery of these 
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cholesteryl esters in the VLDL/LDL pool to the liver. Mice however, do not possess 
CETP. This results in the fact that while humans transport most of their plasma 
cholesterol in LDL, mice use HDL for this process 386. Furthermore, HDL particles, 
which contain PL, differ in humans and rodents in regard to their size patterns 387. 
Therefore, it may be helpful to further study the lipoprotein composition in rodents in 
order to understand the complexity of our findings. 
It is known that SFA and MUFA can be synthesized de novo within the brain, yet 
essential PUFA are mainly supplied from the periphery 318. For example, LPC (22:6n3) 
can be directly transported from plasma to the brain via the specialized mfsd2a receptor 
388. As such, increases in essential PUFA containing PL species could indicate transport 
deficiencies into various organs, including the brain. However, further investigation of 
the LPC and LPE content of the brain is necessary to fully understand the reasons behind 
those changes. Additionally, among PUFA, the shorter-chain ω3 and ω6 fatty acids 
alpha-linolenic acid (18:3n3) and linoleic acid (18:2n6) are obtained from the diet and, to 
some extent, can be used to synthesize their longer chain fatty acid counterparts, such as 
eicosatetraenoic acid (ETA 20:4n3), AA (20:4n6), eicosapentaenoic acid (EPA 20:5n3), 
docosapentaenoic acid (DPA 22:5n3) and DHA (22:6n3). Among these PUFA, AA and 
DHA containing lipid species are involved in regulating the intensity and duration of 
inflammatory responses 389 and possible changes in their levels could influence the 
immune/inflammatory imbalances observed in GWI 374. Our findings in relation to 
changes in PUFA, particularly AA and DHA containing PL, suggest examination of 
bioactive metabolites of AA and DHA in relation to GWI pathology in the future. Owing 
to the potential role of AA and DHA containing species in inflammation, we examined 
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PL containing these fatty acids and found that AA containing PL species increased for 
LPC in humans, mice and rats. For LPE only humans and the mouse model reached 
significance, although rats showed a trend in the same direction. DHA containing species 
of LPC, LPE and PC were higher in GWI subjects. The same was observed for PC and 
LPC in rats with no DHA containing LPE species being identified in this model. 
However, in mice significance for these three PL classes was not achieved.  For DHA 
containing PE and PI, no changes were observed in humans and mice, whereas levels in 
rats were elevated. Interestingly DHA and AA containing PC species were marginally 
increased in the brains of 5 month old PB+PER GWI mice 229. However, further studies 
investigating lipid enzymes, transport and metabolism are necessary to understand the 
relationship between brain and peripheral changes. Yet, this investigation and previous 
studies clearly underline the importance of lipid modulation in GWI pathology 
228,229,367,369. 
We also observed changes in ether lipids. Within all PL classes, only eLPE 
showed elevation in GWI patients compared to control. Although eLPC showed an 
increase, significance was not achieved, owing to high variance between the samples. As 
ether PL are dependent upon peroxisomes for their synthesis, examination of their 
functionality should be investigated in the future. However, in mice no ether lipid class 
was significantly changed, whereas rats showed significant increases for ePC, eLPC and 
ePE. Again, a possibility could be that the elevated stress dose in rats leads to changes in 
ether lipids, which are not observed in humans or mice. It is also interesting that eLPE is 
only differentially regulated in humans.  
We also compared individual molecular species of each PL class within rats and 
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mice to human plasma samples to identify species with diagnostic potential and to 
investigate overlap between the GWI models and veterans with this condition with the 
ultimate goal of facilitating future translational work aimed at developing therapies for 
treating GWI. Overall, we observed increases in all classes for overlapping molecular 
species. The most consistency was seen for several individual LPC species, such as 
LPC(16:0), LPC(18:0), LPC(18:1n9) and  LPC(20:4n6). 
Finally, the rat model showed the strongest signal with elevations reaching up to 
200% for all PL classes.  Compared to clinical samples, as well as the mouse model, rats 
received 5 minutes of restraint stress in addition to GW agents. Some epidemiological 
studies in GW veterans have shown that operational stress amplifies the effects of GW 
agents, leading to more severe symptom presentations of GWI 201,379. These findings have 
been supported by exercise challenges in humans showing exercise induced hyperalgesia 
in a GWI subpopulation as well as alterations in immune functioning, cognition and brain 
structure 390. Moreover animal studies have shown that combined GW agent and stress 
exposure induce long-term behavioral consequences as well as long-term learning 
dysfunction in a rat model of GWI 369,370. This could explain why changes in rats show 
the strongest increases among all studied groups. Because of this it would be interesting 
to include a stress paradigm in our mouse model as well as collect plasma samples of 
GWI veterans before and after exercise challenge to determine if lipid metabolism is 
further disturbed. It is also interesting to note that we observed the most significant 
changes for lyso PL, LPC and LPE, within the GWI patients compared to controls. Since 
LPE and LPC can be generated by phospholipase action on PC and fatty acyl CoA can 
reacylate lyso-PC to form PC future studies should examine enzyme activities involved in 
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PL metabolism and remodeling.  Furthermore, peripheral changes could reflect brain 
lipid changes, which would implement disturbances in lipid transport and therefore 
should be examined. Alternatively, if plasma lipid disturbances do not reflect brain 
changes, these abnormalities could reflect immune dysfunction in GWI (i.e. autoimmune 
responses, inflammation) and would be another area of interest to investigate. Finally, the 
study of lipoprotein content (HDL, VLDL etc.) could shed further light on the 
involvement of phospholipids in GWI.  
Although no differences in PC and PE concentration were observed in humans, 
increases in LPC and LPE could indicate increased phospholipase A2 (PLA2) activity. 
Furthermore, the acyltransferase activities (LPCAT3 and LPCAT4), which convert LPC 
and LPE to PC and PE respectively, could be affected. More investigation is needed to 
explain the observed changes. Finally, major PI species showed no effect in response to 
GW agent exposure in humans. 
As these were pilot studies, there are number of limitations present which do not fully 
allow us to assess potential use of lipid changes in diagnosing GWI. Our human sample 
size was small and therefore we were not able to fully assess the impact of gender and 
age on PL levels in this case control study, but instead we adjusted our statistical analyses 
to account for these confounding factors. Additionally, in order to assess diagnostic 
strength validation in another cohort is necessary. We are not yet able to generalize our 
findings to GWI in the veteran population with validation being required in a larger 
cohort to accomplish this. Validation studies using a larger cohort of GWI and control 
GW veterans will also allow us the opportunity to assess differential response to various 
combinations of exposure to GW agents and to investigate differences in lipid profiles 
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based on the severity of symptoms and different symptom clusters in order to identify 
subgroups of veterans with GWI.  This could ultimately improve our ability to provide an 
objective diagnosis and management of relevant symptoms in subgroups of ill veterans.  
 
5.5 Conclusion  
 
In this study, we identified significantly different overlapping phospholipid 
changes between two different rodent models of GWI and a clinical sample of veterans 
with GWI. These differences were particularly evident within the lysophospholipids. This 
first attempt at a pilot translational study using two different rodent models and a clinical 
cohort of veterans with GWI proved successful in suggesting strong potential avenues for 
further larger studies of phospholipid biomarkers of GWI. These results also provide 
evidence for further study of these models for therapeutic target discovery if validated in 
larger preclinical and clinical samples. 
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Chapter 6 Discussion 
6.1 Summary of thesis research 
 
Traumatic brain injury is a debilitating illness, affecting over 1.7 million people in 
the US per year, with 5.3 million experiencing long-term consequences. As most TBIs 
are categorized as mild (~80%), diagnosis, monitoring and treatment have been difficult. 
18,391. Furthermore, its high prelevance in the military together with its comorbidity with 
PTSD has made it clear that an objective measure is needed that can address exposure 
and symptom heterogeneity. In the case of GWI it has been almost 25 years since the 
Persian Gulf War and the veterans’ exposure to Gulf War agents. Although symptom 
categories and clusters are used to identify veterans with GWI, there are no available 
biomarkers to assist with diagnosis. The self-report system of GWI comes with a large 
reporting bias, given the many years, which have elapsed since the exposure, and the lack 
of objective data on the use of PB, PER and DEET, which has made it difficult to pin 
point the origin of this debilitating disease. Therefore, many GW veterans exhibit GWI 
symptoms but lack a formal diagnosis due to the absence of an objective measure. 
Therefore in order to objectively diagnose veterans with any of these conditions, 
biomarkers (or panels of biomarkers) are needed. 
  Protein biomarkers have been widely studied, especially in TBI, yet 
mostly at acute and sub-acute phases post injury. These biomarkers have shown great 
value at immediate hospital admissions. For soldiers that are deployed acute care is 
available, however acute diagnostics and the ability to evaluate biomarkers might not be 
accessible, especially in cases of mTBI. Furthermore, for illnesses such as PTSD it is 
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crucial to develop a measurement that can diagnose the illness without self-reporting 
bias. Thus, in this thesis I first and foremost investigated plasma samples from 120 
human active-duty soldiers with a history of TBI (mTBI), PTSD and/or both compared to 
control individuals in order to identify chronic peripheral changes of these conditions 
(Chapter 2 & Chapter 3). Assessments were made via patient reported outcomes (PRO). 
Whilst clinician-reported outcomes are important and are often used in in clinical trials, 
in which a physician or clinician records observer outcomes-related data, based on their 
interpretation of the treatment’s efficacy. This can include for examples results on brain 
imaging, drug measurements in blood or tumor size in cancer patients. However this 
approach fails to take into account patient reported outcomes. The U.S. Food & Drug 
Administration defines PROs as “Any report coming directly from patients… about a 
health condition and its treatment.392” Relying on clinician reported outcomes alone, 
results are only seen as in trial participants as a groups. Yet, individual PRO can help to 
develop personalized treatment, which might differ among subjects due to similar but 
varying underlying biology of their condition. 
 
6.1.1 Proteomic studies 
In chapter 2 we focused our investigation on global protein profiling via liquid 
chromatography mass spectrometry to detect changes in protein content. Although none 
of the 3 identified proteins, for which there was evidence of differential expression, 
passed multiple test correction threshold, the validation experiment demonstrated a 
significant increase in the TBI+PTSD population compared to controls. Although, mostly 
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known to be differently expressed in certain cancer types, LRG1 expression was found to 
be induced in a mice and model 283.  
This is of interest as comorbidity of TBI and PTSD has been under recent focus. 
For example a study by Haarbauer-Krupa et. al. investigated the occurrence of PTSD 6 
months post mTBI in a civilian population. They observed that the incidence of PTSD 
after 6 months was 27% for mTBI subjects who had screened negative for PTSD at the 
time of injury assessment 393. In military personnel that have a history of TBI the PTSD 
incidence numbers are even higher. It has been estimated that PTSD develops following 
mTBI in 32-66% of military cases 28. Therefore we believe that LRG1 could be of value 
in clinical assessment and could be used as a potential diagnostic tool for the 
identification of TBI and PTSD comorbidity at chronic stages.  
Furthermore, we used a CHI single mTBI mouse model to see if similar changes 
occurred in the plasma of these animals. Although we did not observe significant 
differences in LRG1 concentrations at the acute 24hrs timepoint post injury, we were able 
to see a non-significant trend (p=0.06) for increased LRG1 concentrations in mTBI mice 
compared to controls at 3 months post injury. At 6 months post injury LRG1 levels were 
significantly elevated in mTBI animals.  At the later timepoints of 12 and 24 months post 
injury levels of injured mice stayed elevated, however LRG1 was also increased in 
control animals. Therefore the effect of age on LRG1 levels meant significance was lost.  
How LRG1 contributes to TBI and PTSD pathology is unclear. However, it has 
been shown that increased LRG1 expression promotes angiogenesis via TGFβ1 
endothelial cell signaling 359. Multiple studies have observed that angiogenesis plays an 
important role in mediating functional recovery after TBI (reviewed by 360). Furthermore, 
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if LRG1 influences TGFβ1 signaling, the protein could have influence on a variety of 
TGFβ1 effector responses, such as inflammation 394. Although major regulators of 
angiogenesis such as CD34+ EPCs and VGFR have been shown to return to baseline days 
after TBI, LRG1 responses could be continuing as a secondary mechanism. In fact, our 
clinical cohort was comprised of individuals who had sustained a mild TBI and PTSD, 
but showed good recovery, as their participation in our study was during their preparation 
for their upcoming deployment.  Thus, it is possible that LRG1 is a positive indicator for 
outcome in these conditions. Therefore further studies should include subjects with poor 
outcome after injury to investigate if their LRG1 levels are unchanged. If that is the case 
then future studies could investigate LRG1 as a potential drug target to induce 
angiogenesis and possible other responses. Furthermore, inhibition of LRG1 or LRG1 
knockout mice could be used in a model of TBI and/or PTSD to investigate outcome 
compared to control or wild type animals respectively. 
In conclusion, although more investigation is needed on how LRG1 is connected 
to TBI, we believe that LRG1 holds an interesting potential for the detection of TBI and 
PTSD at chronic timepoints after injury. 
After performing global proteomics, and targeted protein analysis of LRG1, our next 
interest was to see if the investigated conditions would have long-term effects on 
peripheral lipid levels. 
 
6.1.2 Lipidomic studies 
In the past decade lipids have become a focal point for more attention in 
conjunction with TBI, as well as PTSD and GWI, due to their high abundance in the 
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brain and the fact that they can cross the blood-brain barrier more readily than proteins 
322.  
Altered lipid metabolism has been shown to contribute to CNS injury 298 and 
abnormal phospholipid (PL) profiles have been reported in the CSF of patients with TBI 
299. Studies on PTSD patients showed increases in cholesterol, low-density lipoproteins, 
triglycerides, and a reduction of high-density lipoproteins in blood 300–303. Thus, in 
chapter 3 we continued our investigation on the same military cohort by examining 
plasma lipid abnormalities. Additionally, soldiers were genotyped for apolipoprotein E 
(APOE) due to the connection between the ApoE protein, lipid transport and TBI. We 
observed changes in concentration of 6 major PL classes. Those classes (PC, LPC, PE, 
LPE, PI and SM) were significantly decreased in TBI, PTSD and TBI+PTSD compared 
to controls, with signal strength (least to strongest decrease) in the following order 
PTSD<TBI<TBI+PTSD compared to controls. We examined degree of saturation and 
showed that MUFA containing PC and PI species were lower in the TBI and TBI+PTSD 
groups. However these PLs were unaltered among PTSD subjects compared to controls. 
Similarly, ether PC levels were lower in PTSD and TBI+PTSD subjects relative to 
controls. Ratios of AA to DHA containing species were significantly decreased within 
PC and PE classes. APOE ε4 (+) subjects exhibited higher PL levels than their APOE ε4 
(-) counterparts within the same diagnostic groups.  Lastly, PTSD severity analysis 
revealed that significant PL decreases were primarily restricted to the moderate-to-severe 
PTSD group.  
We created a ROC curve for each diagnostic stemming from multiple individual 
lipid species, determining their sensitivity and specificity. It is important to mention that 
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the changes observed in peripheral lipids were relatively small, although significant. For 
total lipids changes ranged in the order PTSD (10~20%) <TBI (20~30%) <TBI+PTSD 
(25~40%). These rather small changes are not unusual for lipids in disease, as shown by 
other groups in the field of lipidomics 395,396. We recommend that findings should be 
replicated in a larger cohort.  
Although findings of our lipidomic findings need to be validated, we have shown that PL 
alterations are evident in individuals with chronic mild TBI and PTSD.  
After the discovery of lipid involvement at chronic stages post-TBI in our 
population, we investigated plasma lipid content of those mentioned phospholipid classes 
in one of our well characterized mouse models of mTBI.(Mouzon et al. 2012; Mouzon et 
al. 2014; Mouzon pers. comm.) (Chapter 4) to determine if our clinical cohort findings 
could be replicated preclinically. As animal samples were collected at an acute time point 
(24 hrs post-injury) and at several chronic stages (3, 6, 12 and 24 months post-injury) 
from injured mice and sham controls we were able to perform plasma phospholipid 
profiling over this 2-year period post-injury. Overall, statistical analysis extending over 
multiple timepoints revealed that lipid levels were not different at 24hrs post injury but 
changed over the next 3 months as indicated by the decrease in mTBI versus control at 
the 3 months timepoint. We then observed a possible recovery phase around the 6 months 
timepoint, where PL levels returned to those of control animals. Finally, lipid levels 
dropped again at the chronic 12- and 24 months timepoints post injury. The reason 
behind these changes could be increased oxidation of phospholipids. At the moment we 
are in the process of developing an MS method to measure these oxidative lipids, but 
were not able to implementing this approach for this work. Therefore, we performed a 
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standard lipid peroxidation assay that showed significantly increased oxidation in TBI 
animals at 3months compared to 24hrs, where no difference between control and TBI 
mice was observed. Once our oxidative lipid MS assay is ready we hope to perform 
measurements not only on the animal cohort but on human subjects as well. 
 
In correlation to the military cohort, we were able to reproduce our findings in the 
animal model showing that at chronic time points lower levels of several major PL 
classes in mTBI mice compared to controls were observed. We further showed that 
certain lipid species are affected by age more than others. For example, SFA, MUFA and 
PUFA fatty acids were differentially regulated over time.  Ether containing PE species 
were elevated at 24 hrs post-injury and decreased relative to controls at chronic stages. 
Arachidonic acid (AA) and docosahexaenoic acid (DHA) containing species were 
significantly decreased within all PL classes at the chronic stages. We are aware that the 
military cohort is a cross-sectional analysis, whereas lipid levels were measured at 
several timepoints post injury in mice. Therefore, we hope to use a similar approach in 
human cohorts in the near future as we did in animals to see how lipid levels behave over 
a time course of acute to subacute and chronic injury phases.  
As we were able to show that a lipidomic platform has great potential for the 
investigation of biomarker profiles we used this approach for another debilitating disease, 
namely Gulf War Illness. Furthermore, previous global proteomics by our group in a 
mouse model of GWI had revealed alteration in lipid metabolism 367. 
In chapter 5 we included healthy Gulf War Veterans and veterans with GWI and 
compared their lipid profiles to mouse and rat models of GWI. We observed increases of 
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multiple phospholipid (PL) species across all studied cohorts. Furthermore, our data 
suggested dysfunction within ether -and DHA and AA-containing PL species, supporting 
the proposed role for immune and inflammatory balance with veterans with GWI. 
Although the animal models were able to reproduce lipid observation in humans it was 
interesting to observe the different levels of changes in lipid signals between the models. 
This emphasizes the need for more comparative studies among models. Whereas the 
mouse model and human samples showed similar levels of increases (1.2~1.5 fold) in 
lipid levels for GWI, the rat model exceeded these elevated values in some cases by 2-3 
fold. It is of note that the rat samples provided by Dr. Shetty also included, besides 
PB+PER exposure (also used in mice) a stress paradigm and use of DEET in the model.  
Furthermore, our sample size for this human cohort was small (N=33). Therefore our 
findings need to be replicated in other cohorts.  
 
6.2 Limitations and future directions 
Human samples are influenced by various factors that are not typically found in 
corresponding animal models. In humans the severity of injury or trauma varies due to 
different exposures. In the case of TBI, injury can vary in impact strength, type of impact 
(blast/penetrating) and brain area of impact between individuals. Additionally, gender, 
age and ethnic background all have been shown to influence biological signals as well as 
disease progression and outcome. Although age and gender matched groups are routinely 
compared, ethnicity is often overlooked and ethnic groups are frequently not equally 
represented. Furthermore, others and we have shown that genetic variants, such as those 
encoded by the APOE gene, can influence experimental data and therefore need to be 
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accounted for.  In this study we stratified our analysis by APOE ε4carrier and non-carrier, 
due to the involvement of the protein in lipid transport and its known influence on TBI 
outcome, but other genes could also influence our outcome measures, such as genes 
innvolved in the HPA axis stress response. It would be therefore beneficial for future 
analysis to include relevant genetic polymorphisms as cofactors. Because of the 
heterogeneity of the TBI/PTSD cohort a higher number of individuals should be sampled. 
Furthermore lifestyle habits, including diet, smoking, alcohol consumption and exercise 
regime can all influence biological outcome measurements and many of these factors rely 
on self-report. Although it is almost impossible to control perfectly for all these factors, 
active duty military personnel stationed at Fort Riley and Camp Shelby received similar 
diets (plus samples were collected during fasting) and have comparable fitness levels. 
Moreover, use of medication in patients at the time of sample collection can interfere 
with scientific findings, especially in cases where severe symptoms are present and need 
to be treated. In our study use of medication was reduced to a minimum, as active duty 
soldiers were getting ready for a one-year deployment, therefore passing medical 
examination. Furthermore, for the majority of subjects the upcoming deployment was 
their first military assignment, therefore individuals with TBI and/or PTSD received these 
exposures in a non combat environment, mostly during training. Together all described 
factors add to the heterogeneity of samples, making validation across clinical cohorts 
difficult and we suggest validation of our findings in multiple larger and diverse cohorts.  
Currently, our scientists at the Roskamp Institute are working with the Tampa VA 
and collecting blood samples from subjects with mild TBI. Additionally, at the moment 
we are working on collaborations with the Boston and Bronx VA, where we expect to 
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receive a high number of samples from veterans with GWI and relevant controls. We 
hope to use those samples once collection is complete to target the same protein/lipids 
observed in this study.  
Furthermore, whilst the assessment of levels of molecules is a good way to gain 
information about the association of such molecules in a disease state, other approaches 
should be used in the future to understand the underlying mechanism that connects the 
molecular changes with the condition. One concept could investigate enzymatic activity 
in relations to the investigated molecule. Additionally, the location of the molecule could 
contribute to its role in the disease; therefore studying certain regions (e.g. brain regions) 
and specific cell types can share light on the function of this molecule. Moreover, 
solubility (membrane bound or not) of a molecule can be important. Finally, 
posttranslational modification (PTM), reversible or irreversible chemical alterations of a 
protein after its translation, play a great role in protein function. Examples of protein 
modification include chemical groups (e.g. phosphoryl), lipids (e.g. palmitic acid), 
carbohydrates (e.g. glucose) or even entire proteins (e.g. ubiquitin) to amino acid side 
chains, as well as the enzymatic cleavage of peptide bonds 397. Most PTM occur at side 
chains that can act as either strong (C, M, S, T, Y, K, H, R, D, E) or weak (N, Q) 
nucleophiles, leading to changes in protein dynamics, binding affinity and structure 
which can affect protein function. Therefore, future studies should investigate changes in 
regards to these mechanisms to understand why certain biomarkers are found in the 
mentioned conditions. 
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Some of the mentioned confounding factors can be avoided in animal models. 
Controlled standard diet, age and gender matched cloned lines of mice together with 
identical housing conditions allow researchers to minimize variables. Moreover, 
genetically manipulated mice or rats afford the opportunity to explore the influence of 
genetic risk factors. Animal studies also allow easier implementation longitudinal study 
paradigms (as shown in Chapter 4). The animal model we used for comparison with our 
TBI military cohort is a single mTBI model. Our Institute is also working with a 
repetitive mTBI (r-mTBI) model. At the moment a r-mTBI + PTSD (and PTSD alone) 
model is being developed by Ph.D. student Moustafa Algamal, who will compare our 
existing r-mTBI model with the r-mTBI +PTSD and PTSD mice in regards to behavior, 
pathology, proteomics and lipidomics analyses. 
The measured plasma lipid concentrations observed in the aforementioned 
conditions, as well as LRG1, serve as the basis for a panel of objective biomarkers; 
therefore they do not necessarily reflect the pathological underlying mechanism. 
However, animal models could be used in the future to link the observed changes to 
alterations of specific biological mechanisms.  
Given the complexity and diversity of lipids, which has started recently to receive 
much attention, different approaches are needed to fully investigate variations in the 
biological responses within different lipid classes. Approaches for the measurement of 
lipids includes two major categories: LC- based or shotgun MS. In our studies, we used 
LC-based MS due to the complexity of lipids and their highly dynamic range in plasma. 
Our LC-based lipidomic approach reduces the complexity of PL, by allowing each class 
of lipid to elute based on the polarity of the head group and chain length of fatty acids 
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within each class. This achieves enrichment of low abundance species and the 
identification of many individual species. Whilst shotgun lipidomics is a high-throughput 
approach it comes at the expense preserving the complexity of a lipid extract due to the 
absence of pre-chromatographic separation 398. 
Our lipidomics studies indicate peripheral chronic lipid disturbances for the investigated 
conditions (overall decreases in TBI/PTSD and increases in GWI). However, it should be 
noted that PL only represent a subclass class of lipids. Therefore future investigations 
need to extend these analyses and also examine other classes such as sterols, 
sphingolipids including cardiolipin and cholesterol. Furthermore, we need to understand 
the pathological role of lipids, therefore in is crucial to examine their relevance in relation 
to their metabolites, such as the PUFA’s eicosanoids, including prostaglandins, 
thromboxanes and leukotrienes. Furthermore, as mentioned previously, PUFAs are prone 
to oxidations; therefore measurement of oxidative lipids is necessary and will be done in 
the near future. 
Another approach should investigate the state of PLs in plasma. It is known that 
PE, PI, and SM are only present bound to lipoproteins, whereas PC and LPC can be 
found on both lipoproteins and plasma lipoprotein free fraction (PLFF)399. Furthermore, 
apolipoproteins are associated with very low-density lipoproteins (VLDL), intermediate 
density lipoproteins, chylomicron remnants, and certain subclasses of high-density 
lipoproteins (HDL). It has been shown that in terms of the distribution of apoE among the 
various plasma lipoproteins, apoE4 has a preference for large, triglyceride-rich VLDL 
particles, whereas apoE3 and apoE2 associate with the small, phospholipid- rich HDL. 
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As a result lipoprotein fraction should be investigated to gain deeper understanding about 
PL metabolism in our cohorts. Similar, plasma exosomes, which are bioactive vesicles 
originating from multivesicular bodies, have shown to contain high levels of PC (59%), 
SM (21%) and PE (9%)400. Playing an important role in communication between cells, 
exosomes transport lipids and lipolytic enzymes. They are of specific interest as 
therapeutic drugs could be conveyed by encapsulation into these liposomes. It has been 
suggested that exosomes and the knowledge of their lipid composition/organization could 
be used as the first “therapeutic vehicles” in order to treat various diseases401. Therefore, 
future lipidomics studies should investigate exosomes in the plasma of our patient 
groups, as well as their phospholipid composition to possibly find a link between the 
physiology of PL and lipoprotein/vesicle bodies presentation. 
 
In order to establish our observed lipid changes as a biomarker more work is 
needed. The biomarker needs to be shown to be valid and reliable under clinical trial 
conditions and has to show a strong relationship to clinical outcome. Therefore, our 
findings need to be repeated in other cohorts. Finally, once a biomarker is established 
targeted data analysis or exploration of other approaches is necessary to improve 
throughput, suitable for routine clinical work. 
DHA is known to promote hippocampal neurogenesis in the adult brain 402,403, 
modulate signal transduction molecules and receptor affinity 404 and plays a role in the 
support of mitochondrial functioning 405. Furthermore, DHA is known to reduce 
inflammatory cytokines (interleukin IL-1, tumor necrosis factor, TNF) 406 and reactive 
oxygen species 407, as well as exhibit anti-inflammatory properties (see discussion 
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Chapter 3-5) 319.Evidence for the beneficial effects of DHA supplementation in TBI 
comes from various preclinical studies, which have been extensively reviewed 408. It has 
been shown that long chain PUFA supplementation before or after TBI in mice protect 
the brain by restoring the expression of specific protective mediators, limiting structural 
damage to the axon and events such as neuronal apoptosis, and diminishing TBI induced 
cognitive dysfunction 408. As both animal models and human studies investigating lipid 
involvement in TBI suggest that n-3 supplementation would be beneficial two new 
clinical trials are currently recruiting (https://clinicaltrials.gov/). Miller et al. at the 
University of Texas Southwestern Medical Center aim to use 2g of DHA treatment daily 
for 3 month in patients with concussion due to sports-related injury (mTBI) 
(https://clinicaltrials.gov/ct2/show/NCT01903525). Another new study by Bica et al. at 
East Carolina University aims to investigate concussion outcome after treatment with 
high dose of n-3 fatty acid containing 2200mg of DHA for 30 days after onset of 
concussion symptoms (https://clinicaltrials.gov/ct2/show/NCT01814527). 
Due to the fact that DHA has been linked with hippocampal neurogenesis, it has been 
suggested that n-3 supplementation during the early post-trauma period could facilitate 
the clearance of fear memory from the hippocampus and consequently minimize PTSD 
symptoms 409. Clinical studies have supported this hypothesis, as PTSD symptoms were 
shown to be lower in DHA treated PTSD injured patients compared to placebos 410. 
Furthermore, a clinical trial investigating PTSD symptoms in female rescue workers who 
were deployed during the acute disaster phase of the Great East Japan Earthquake 
showed attenuated PTSD symptoms 411. Although not all trials were able to confirm these 
positive findings, higher n-3 intake has been linked to other mood disorders, such as 
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major depressive disorder and bipolar disorder 412–414 and thus the importance of lipid 
homeostasis in these conditions cannot be ignored.  
As more evidence arises for the involvement of lipid dysfunction in Gulf War 
Illness it is only a matter of time until investigation of long-chain PUFA supplementation 
in Gulf War veterans move into clinical trials. Furthermore, GWI has been linked with 
mitochondrial dysfunction 230. The connection of mitochondria and lipid homeostasis has 
been extensively reviewed 415 and thus, looking forward, investigation of isolated 
mitochondria and changes in their lipid content could add to the understanding of the 
underlying pathology of GWI.  
 
Statistics 
Data generated by Mass Spectrometry leads to the problem of multicollinearity during 
analysis, meaning in a multiple regression model two or more predictor variables are 
highly correlated and they can be linearly predicted from the others with a great degree of 
accuracy. Multicollinearity in big data analytics can lead to biased estimation and 
variance inflation. In order to address this problem, different statistical approaches can be 
used, including avoiding multiple comparisons via univariant analysis with relaxed p 
values followed by confirmation set (used for our proteomic data set), or multiple 
comparisons via bootstrapping methods, PCA (used for our lipidomic data set) and 
machine learning methods such as random forest/trees tests. 
 
One of the most common ways to deal with multicollinearity is Principal 
Component Analysis. In PCA, orthogonal transformations are used to remove correlations 
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variables into an output set of values of linearly uncorrelated variables (named principal 
components). Although the technique is sensitive to hypothesis testing, missing data, 
outliners, transformations, inaccuracy if out outcome variables were greater than our 
sample size as well as its assumption of normal distribution of data, PCA is robust when 
used for description, meaning high in accuracy as long as data is continuous, does not 
have to many outliners and is not strongly skewed416. 
The bootstrapping method relies on resampling sample data. In general, random 
samples are drawn from a full sample set and estimates of the standard errors are 
computed for each. After that an average of all the bootstrap samples is computed. The 
jackknifing approach is similar to the bootstrapping method, but making use of 
recomputing the standard error, each time eliminating one case. Then, an average of the 
standard errors is used. Although this method is relatively simply using standard errors 
and confidence intervals, checks for stability of data it does not well deal with the issue 
of multicollinearity nor allows the reduction of the dimensions of our dataset, as 
assumptions are being made in this statistical methods (such as independence of 
samples)416. 
Machine learning is a concept of computer science and artificial intelligence. It 
aims to build systems (algorithms), which learn from data, in contrast to programming 
instructions. Random forest/trees tests are an example of machine learning approaches, 
where random subsets of variables for each tree are chosen and the most frequent tree 
output is used as the overall classification. Random forest itself does not remove 
multicollineraity, but works well if the prediction with a validation and predicting set has 
the same of collinearity. Therefore, this approach is often used discovery and validation 
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sets. Since we are in the discovery phase of this project, this statistical method will be of 
value in the future, when we validate our findings416. 
Multicollinearity can be avoided by only observing one variable at a time 
(univariant analysis), therefore not making multiple comparisons. Since all our data set 
contained multiple variables we chose to use mixed model ANOVA for our independent 
proteomic data. 
 Overall different approaches can be used for statistical evaluation of our 
generated data sets. The used tests in this thesis have proven strong analytical strength by 
other groups in the field, as well as our groups at Roskamp Institute. 
 
The work described in this thesis represents a new approach in the field of 
biomarker discovery. It extends the existing literature with a focus on biomarkers in TBI 
to chronic phases of injury, indicating that even in mild TBI secondary injury 
mechanisms persist over a long period of time. Our findings that show proteomic and 
lipid abnormalities at these late timepoints could facilitate development of diagnostics 
especially for the military, where immediate admission to a well equipped hospital might 
not always be possible.  Furthermore, the chronic and heterogenic illnesses PTSD and 
GWI, where diagnosis relies heavily on self-report are in dire need for an objective panel 
of biomarkers. Additionally, a biomarker panel could be used for personalized care and 
help monitor illness development and treatment response. This thesis is the first step in 
such a direction. Findings in our animal models show that they are well fitted for further 
characterization and expansion of TBI, PTSD and GWI research areas. Our studies 
provide information on biochemical abnormalities that persist long after the initial 
 228 
injury/trauma event and exposure to chemical reagents; these abnormalities may provide 
useful insight into the continuing pathogenesis and serve as preliminary data for the 
development of diagnostic markers or drug targets for these diseases.  
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Chapter 2 
Section 1  
Chapter 2 Table 1: Mass Spectrometry approaches 
Approach Description Benefits Limitations 
1.Stable Isotope-
Labeling 
Peptide sequence is labeled with chemically equivalent mass tag; Label 
keeps biochemical/ analytical properties of the peptide but changes its 
mass. Thus, can be used as a relative reference, as different samples can 
be combined but is still distinguishable in MS analysis. 
1.1 Metabolic 
labeling: Stable 
isotope labeling 
with amino acids in 
cell culture 
(SILAC) (Ong et 
al., 2002) 
Heavy isotopes (2H, 13C or 15N) 
are introduced to a cell culture; 
cell turnover incorporates them 
only into newly synthesized 
proteins 
Use of cell or 
organism; no limits 
of amount of sample 
to be labeled  
Expensive, no 
analysis of 
human 
samples 
possible, the 
labeled 
arginine can 
become a 
proline 
1.2 Chemical 
labeling 
Isotopes are introduced chemically at protein/peptide level 
Dimethyl labeling 
(Boearseman 2009) 
Tryptic digests are labeled with 
sodium cyanoborohydride 
(NaBH3CN) to generate  “light” 
label (+28 Da per primary amine) 
and sodium cyanoborodeuteride 
(NaBD3CN) to methylate amines 
to generate  “heavy” label (+36 
Da per primary amine).  
 Cost-effective,  
fast reaction, can be 
used for a varieties 
of biological 
samples; can work 
with small amounts 
of sample  (µg - mg 
range), reliable;  
Small isotope 
effect during 
LC separation 
due to 
deuterated 
labels. 
18O labeling (1951 
by Sprinson and 
Rittenberg) 
Protease (e.g. trypsin) catalyzes  
exchange of two 16O atoms for 
two 18O atoms at the C-terminal 
carboxyl group of proteolytic 
peptides; results  in mass shift of 
4 Da between differently labeled 
peptides 
Simple, low cost  Occurrence of 
incomplete 
incorporation 
of two 18O 
atoms into 
peptide leads to 
difficulties in 
data analysis  
Isotope-coded 
affinity tags (ICAT) 
(Gygi et al., 1999) 
Stable isotope-bearing chemical 
reagents are introduced to 
reactive sites (cysteine) on 
protein/peptide. Reagent consists 
of a reactive group that is 
cysteine-directed, a polyether 
linker region with 8 deuteriums 
and a biotin group that allows 
purification of labeled peptides. 
Denaturation and reduction of 
Limited peptide 
mixture complexity 
(only cysteine-
containing peptides 
are isolated),  
which can enable 
identification of 
lower abundant 
proteins 
Proteins could 
contain no 
cysteines or 
only in single 
peptide; large  
biotin tag 
increases 
fragmentation 
complexity of 
spectra 
 3 
two pools of proteins results in 
derivatization of cysteine residues 
with either the ‘heavy’ or ‘light’ 
ICAT reagent. 
Isobaric tags for 
relative and 
absolute 
quantitation 
(iTRAQ) (Ross et 
al., 2004) 
Labeling of N-termini and lysine 
side chains with different isobaric 
mass reagent; Different mass tags 
only distinguishable after peptide 
fragmentation; Each tag adds the 
same total mass to a given peptide 
results in each peptide species 
producing a single peak during 
LC 
Analysis of any 
sample possible; 
Multiplexing of up 
to 8 samples 
without increased 
complexity at MS 
analysis 
Expensive, 
unstable 
chemical 
reagents; 
Introduction of 
isotope label at 
peptide level; 
MS with low 
m/z measuring 
capabilities 
necessary; 
peptide 
quantification 
depends on a 
single tandem 
mass spectrum 
Isobaric labeling 
(tandem mass tags 
(TMT)  (Thompson 
et al., 2003) 
Analysis of any 
sample possible; 
Multiplexing of up 
to 10 samples 
without increased 
complexity at MS 
analysis 
2. Label-free 
quantification 
Direct analysis of protiens in 
samples, no mixing of samples, 
comparison after analysis 
High coverage of 
proteome; no limit 
to  number of 
experiments  
Lack of a 
formal 
internal 
standard, 
leads to  error 
in individual 
datasets  
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Section 2 - Neurocognitive Measures 
PTSD Checklist-Military Version (PCL-M)  
 
 
 
 
 
 
Life Events Checklist 
 5 
 
 
 
 
 
 
 
 6 
 
Brief Traumatic Brain Injury Screen (BTBIS) 
 
 
 
 7 
 
Zung Depression Scale (ZDS) 
 
 8 
 
Zung Anxiety Scale (ZAS) 
 
 
 
 
 
 9 
 
 
Alcohol Use Identification Test (Audit) 
  
 10 
Epworth Sleepiness Scale 
 
 
 
 11 
Pittsburgh Sleep Quality Index (PSQI) 
 
 
 
 12 
 
 13 
 
 
 
 14 
 
 
 15 
 
 
 16 
 
 
 
 
 17 
Central Nervous System Vital Signs® (CNS VS) 
CNS Vital Signs is comprised of eight common neuropsychological measures. The 
battery generates 15 primary scores, which are used to calculate 5 domain (index) scores 
(Memory, Psychomotor Speed, Reaction Time, Cognitive Flexibility, and Complex 
Attention).  
Descriptions of the CNS Vital Signs measures. 
Measure Description 
Verbal Memory Measure: How well subject can recognize, remember, and 
retrieve words e.g. exploit or attend literal representations or 
attribute. 
Relevance: Remembering, turning off the stove, recalling an 
appointment or rehabilitation information, taking medications, 
and attending class. 
Visual Memory Measure: How well subject can recognize, remember and 
retrieve geometric figures e.g. exploit or attend symbolic or 
spatial representations.  
Relevance: Remembering graphic instructions, navigating, 
operating machines, recalling images, remember a calendar of 
events, and using a graphical user interface. 
Composite Memory 
 
Measure: How well subject is able to recognize, remember and 
retrieve words and geometric figures. Identify problems with the 
storage, manipulation, and retrieval of information.  
Relevance: Remembering and learning new information, 
turning off the stove, recalling an appointment or rehabilitation 
information, taking medications, attending class, inability to 
navigate in familiar places, recalling images, etc. 
Processing Speed 
 
Measure: How well a subject can automatically and fluently 
perform relatively easy or over‐learned cognitive tasks, 
especially when high mental efficiency is required i.e. attention 
and focused concentration.  
Relevance: Medication effect, ability to respond/react to threats, 
take evasive action or see possible danger/risk signs, or issues 
with accuracy and detail. 
Executive Function 
 
 
 
 
 
 
 
Psychomotor Speed 
 
 
Measure: How well a subject recognizes set shifting (mental 
flexibility) and abstraction (rules, categories) and manages 
multiple tasks simultaneously.  
Relevance: Ability to sequence tasks and manage multiple tasks 
simultaneously, flexibility required for self‐correction, tracking 
and responding to a set of simple instructions. 
Measure: How well a subject recognizes and processes 
information i.e., perceiving, attending/responding to incoming 
information, motor speed, fine motor coordination, and visual‐
perceptual ability.  
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Measure Description 
 
 
 
 
 
 
Reaction Time 
 
 
 
 
 
Complex Attention 
 
 
 
 
 
 
Cognitive 
Flexibility 
Relevance: Distractibility, fitness‐to‐drive, occupation issues, 
obsessive concern with accuracy and detail. May be a result of: 
medication effects, anxiety, learning disabilities, visual 
perceptual problems, working under time pressure, typing and 
machine operation. 
Measure: How fast the subject can react, in milliseconds, to a 
simple and increasingly complex direction set. 
Relevance: Driving a car, attending to conversation, tracking 
and responding to a set of simple instructions, taking longer to 
decide what response to make. 
Measure: How well the subject can maintain focus and perform 
quickly and accurately e.g. problem attending to multiple stimuli 
at the same time. Ability to track and respond to information 
over brief or lengthy periods of time and/or performs mental 
tasks quickly and accurately requiring vigilance.  
Relevance: Self‐regulation, learning, productivity, and 
behavioral control. 
Measure: How well subject is able to adapt to rapidly changing 
and increasingly complex set of directions and/or to manipulate 
the information.  
Relevance: Reasoning, switching tasks, decision‐making, 
impulse control, strategy formation, attending to conversation. 
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Section 3 
Chapter 2: Tables 2 - 5: ROC tables, containing all values for sensitivity and 1-specificity 
TBI 
X Prob 1-
Specificity 
Sensitivity Sens-      
(1-Spec) 
True 
Pos 
True 
Neg 
False 
Pos 
False Neg 
  0 0 0 0 52 0 21 
77.336 0.9541 0 0.0476 0.0476 1 52 0 20 
75.60559 0.9441 0 0.0952 0.0952 2 52 0 19 
75.60278 0.9441 0 0.1429 0.1429 3 52 0 18 
71.2181 0.9088 0 0.1905 0.1905 4 52 0 17 
71.008 0.9067 0 0.2381 0.2381 5 52 0 16 
70.3535 0.8998 0 0.2857 0.2857 6 52 0 15 
69.84545 0.8941 0 0.3333 0.3333 7 52 0 14 
64.8725 0.8227 0 0.381 0.381 8 52 0 13 
62.79685 0.7833 0 0.4286 0.4286 9 52 0 12 
61.30013 0.7511 0 0.4762 0.4762 10 52 0 11 
61.0575 0.7456 0 0.5238 0.5238 11 52 0 10 
57.62667 0.6598 0 0.5714 0.5714 12 52 0 9 
57.5785 0.6585 0 0.619 0.619* 13 52 0 8 
56.6405 0.6327 0.0385 0.619 0.5806 13 50 2 8 
56.158 0.6191 0.0577 0.619 0.5614 13 49 3 8 
53.83586 0.5513 0.0769 0.619 0.5421 13 48 4 8 
52.94684 0.5247 0.0769 0.6667 0.5897 14 48 4 7 
52.579 0.5137 0.0962 0.6667 0.5705 14 47 5 7 
52.08271 0.4987 0.1154 0.6667 0.5513 14 46 6 7 
50.8274 0.461 0.1346 0.6667 0.5321 14 45 7 7 
47.79394 0.3725 0.1346 0.7143 0.5797 15 45 7 6 
47.70158 0.3699 0.1538 0.7143 0.5604 15 44 8 6 
46.21511 0.3293 0.1538 0.7619 0.6081 16 44 8 5 
43.64446 0.2648 0.1731 0.7619 0.5888 16 43 9 5 
42.6081 0.2413 0.2115 0.7619 0.5504 16 41 11 5 
42.224 0.2329 0.2115 0.8095 0.598 17 41 11 4 
41.643 0.2207 0.2308 0.8095 0.5788 17 40 12 4 
40.9645 0.2069 0.25 0.8095 0.5595 17 39 13 4 
40.64873 0.2008 0.2692 0.8095 0.5403 17 38 14 4 
40.33297 0.1947 0.2885 0.8095 0.5211 17 37 15 4 
39.438 0.1784 0.3077 0.8095 0.5018 17 36 16 4 
39.11849 0.1728 0.3269 0.8095 0.4826 17 35 17 4 
38.402 0.1608 0.3462 0.8095 0.4634 17 34 18 4 
38.15 0.1568 0.3654 0.8095 0.4441 17 33 19 4 
 20 
36.218 0.1284 0.3846 0.8095 0.4249 17 32 20 4 
35.78863 0.1227 0.3846 0.8571 0.4725 18 32 20 3 
35.3115 0.1167 0.3846 0.9048 0.5201 19 32 20 2 
34.65 0.1087 0.4038 0.9048 0.5009 19 31 21 2 
34.4365 0.1063 0.4231 0.9048 0.4817 19 30 22 2 
33.803 0.0992 0.4423 0.9048 0.4625 19 29 23 2 
33.56425 0.0967 0.4615 0.9048 0.4432 19 28 24 2 
33.0987 0.0919 0.4808 0.9048 0.424 19 27 25 2 
32.41859 0.0853 0.5 0.9048 0.4048 19 26 26 2 
32.1965 0.0832 0.5192 0.9048 0.3855 19 25 27 2 
31.68133 0.0786 0.5192 0.9524 0.4332 20 25 27 1 
31.54416 0.0774 0.5192 1 0.4808 21 25 27 0 
31.29016 0.0753 0.5385 1 0.4615 21 24 28 0 
31.2515 0.075 0.5577 1 0.4423 21 23 29 0 
29.90461 0.0645 0.5769 1 0.4231 21 22 30 0 
29.316 0.0603 0.5962 1 0.4038 21 21 31 0 
28.20838 0.0532 0.6154 1 0.3846 21 20 32 0 
27.9332 0.0515 0.6346 1 0.3654 21 19 33 0 
27.61315 0.0497 0.6538 1 0.3462 21 18 34 0 
27.30021 0.0479 0.6731 1 0.3269 21 17 35 0 
26.48787 0.0437 0.7115 1 0.2885 21 15 37 0 
25.84419 0.0405 0.7308 1 0.2692 21 14 38 0 
24.241 0.0337 0.75 1 0.25 21 13 39 0 
24.04282 0.0329 0.7692 1 0.2308 21 12 40 0 
22.96182 0.029 0.7885 1 0.2115 21 11 41 0 
22.82823 0.0286 0.8077 1 0.1923 21 10 42 0 
22.1886 0.0265 0.8269 1 0.1731 21 9 43 0 
22.00162 0.0259 0.8462 1 0.1538 21 8 44 0 
21.89138 0.0256 0.8654 1 0.1346 21 7 45 0 
21.82021 0.0254 0.8846 1 0.1154 21 6 46 0 
21.8155 0.0254 0.9038 1 0.0962 21 5 47 0 
21.707 0.025 0.9423 1 0.0577 21 3 49 0 
21.22106 0.0236 0.9615 1 0.0385 21 2 50 0 
16.674 0.0138 0.9808 1 0.0192 21 1 51 0 
12.51322 0.0084 1 1 0 21 0 52 0 
12.51322 0.0084 1 1 0 21 0 52 0 
Chapter 2 Table 2. 
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PTSD 
X Prob 1-
Specificity 
Sensitivity Sens- 
(1-Spec) 
True 
Pos 
True 
Neg 
False 
Pos 
False Neg 
  0 0 0 0 52 0 34 
67.2245 0.822 0 0.0294 0.0294 1 52 0 33 
66.58806 0.8156 0 0.0588 0.0588 2 52 0 32 
61.58237 0.7591 0 0.0882 0.0882 3 52 0 31 
60.40432 0.7443 0 0.1176 0.1176 4 52 0 30 
59.031 0.7262 0 0.1471 0.1471 5 52 0 29 
56.6405 0.6929 0.0385 0.1471 0.1086 5 50 2 29 
56.158 0.6859 0.0577 0.1765 0.1188 6 49 3 28 
54.397 0.6597 0.0577 0.2059 0.1482 7 49 3 27 
53.963 0.6531 0.0577 0.2353 0.1776 8 49 3 26 
53.83586 0.6511 0.0769 0.2353 0.1584 8 48 4 26 
52.94684 0.6373 0.0769 0.2647 0.1878 9 48 4 25 
52.6995 0.6334 0.0769 0.2941 0.2172 10 48 4 24 
52.579 0.6315 0.0962 0.2941 0.198 10 47 5 24 
52.51299 0.6305 0.0962 0.3235 0.2274 11 47 5 23 
52.08271 0.6237 0.1154 0.3235 0.2081 11 46 6 23 
50.8274 0.6036 0.1346 0.3235 0.1889 11 45 7 23 
48.61169 0.5672 0.1346 0.3529 0.2183 12 45 7 22 
47.70158 0.552 0.1538 0.3529 0.1991 12 44 8 22 
45.99 0.5233 0.1538 0.3824 0.2285 13 44 8 21 
45.89864 0.5217 0.1538 0.4118 0.2579 14 44 8 20 
45.3285 0.5121 0.1538 0.4706 0.3167 16 44 8 18 
45.003 0.5066 0.1538 0.5 0.3462* 17 44 8 17 
43.64446 0.4836 0.1731 0.5 0.3269 17 43 9 17 
42.6081 0.4661 0.2115 0.5 0.2885 17 41 11 17 
41.94013 0.4549 0.2115 0.5294 0.3179 18 41 11 16 
41.643 0.4499 0.2308 0.5294 0.2986 18 40 12 16 
40.9645 0.4386 0.25 0.5294 0.2794 18 39 13 16 
40.796 0.4358 0.25 0.5588 0.3088 19 39 13 15 
40.64873 0.4333 0.2692 0.5588 0.2896 19 38 14 15 
40.33297 0.4281 0.2885 0.5588 0.2704 19 37 15 15 
39.438 0.4133 0.3077 0.5588 0.2511 19 36 16 15 
39.1755 0.409 0.3077 0.5882 0.2805 20 36 16 14 
39.11849 0.4081 0.3269 0.5882 0.2613 20 35 17 14 
38.82555 0.4033 0.3269 0.6176 0.2907 21 35 17 13 
38.402 0.3965 0.3462 0.6176 0.2715 21 34 18 13 
38.15 0.3924 0.3654 0.6176 0.2523 21 33 19 13 
37.95663 0.3893 0.3654 0.6471 0.2817 22 33 19 12 
36.218 0.3617 0.3846 0.6471 0.2624 22 32 20 12 
 22 
35.78676 0.355 0.3846 0.6765 0.2919 23 32 20 11 
34.65 0.3376 0.4038 0.7353 0.3314 25 31 21 9 
34.4365 0.3344 0.4231 0.7353 0.3122 25 30 22 9 
33.803 0.3249 0.4423 0.7353 0.293 25 29 23 9 
33.56425 0.3214 0.4615 0.7353 0.2738 25 28 24 9 
33.0987 0.3145 0.4808 0.7353 0.2545 25 27 25 9 
32.7845 0.31 0.4808 0.7647 0.2839 26 27 25 8 
32.41859 0.3047 0.5 0.7647 0.2647 26 26 26 8 
32.1965 0.3015 0.5192 0.7647 0.2455 26 25 27 8 
31.29016 0.2888 0.5385 0.7941 0.2557 27 24 28 7 
31.2515 0.2882 0.5577 0.8529 0.2952 29 23 29 5 
31.066 0.2857 0.5577 0.8824 0.3247 30 23 29 4 
29.90461 0.2699 0.5769 0.8824 0.3054 30 22 30 4 
29.316 0.2621 0.5962 0.8824 0.2862 30 21 31 4 
28.20838 0.2479 0.6154 0.8824 0.267 30 20 32 4 
27.9332 0.2444 0.6346 0.8824 0.2477 30 19 33 4 
27.61315 0.2405 0.6538 0.8824 0.2285 30 18 34 4 
27.30021 0.2366 0.6731 0.8824 0.2093 30 17 35 4 
26.68501 0.2292 0.6731 0.9118 0.2387 31 17 35 3 
26.48787 0.2268 0.7115 0.9118 0.2002 31 15 37 3 
26.164 0.223 0.7115 0.9412 0.2296 32 15 37 2 
25.84419 0.2193 0.7308 0.9706 0.2398 33 14 38 1 
24.241 0.2013 0.75 0.9706 0.2206 33 13 39 1 
24.04282 0.1991 0.7692 0.9706 0.2014 33 12 40 1 
22.96182 0.1877 0.7885 0.9706 0.1821 33 11 41 1 
22.82823 0.1864 0.8077 0.9706 0.1629 33 10 42 1 
22.1886 0.1799 0.8269 0.9706 0.1437 33 9 43 1 
22.00162 0.178 0.8462 0.9706 0.1244 33 8 44 1 
21.89138 0.1769 0.8654 0.9706 0.1052 33 7 45 1 
21.82021 0.1762 0.8846 0.9706 0.086 33 6 46 1 
21.8155 0.1762 0.9038 0.9706 0.0667 33 5 47 1 
21.707 0.1751 0.9423 0.9706 0.0283 33 3 49 1 
21.22106 0.1704 0.9615 0.9706 0.009 33 2 50 1 
19.77987 0.1571 0.9615 1 0.0385 34 2 50 0 
16.674 0.1312 0.9808 1 0.0192 34 1 51 0 
12.51322 0.1023 1 1 0 34 0 52 0 
12.51322 0.1023 1 1 0 34 0 52 0 
Chapter 2 Table 3. 
 
 
 23 
TBI+PTSD 
X Prob 1-
Specificity 
Sensitivity Sens- 
(1-Spec) 
True 
Pos 
True 
Neg 
False 
Pos 
False Neg 
  0 0 0 0 52 0 13 
76.5905 1 0 1 1* 13 52 0 0 
12.51322 0 1 1 0 13 0 52 0 
12.51322 0 1 1 0 13 0 52 0 
Chapter 2 Table 4. 
PTSD/TBI 
X Prob 1-
Specificity 
Sensitivity Sens- 
(1-Spec) 
True 
Pos 
True 
Neg 
False 
Pos 
False 
Neg 
  0 0 0 0 21 0 34 
1.296224 0.967 0 0.0294 0.0294 1 21 0 33 
1.412363 0.9248 0 0.0588 0.0588 2 21 0 32 
1.417704 0.922 0 0.0882 0.0882 3 21 0 31 
1.426267 0.9172 0 0.1176 0.1176 4 21 0 30 
1.492285 0.8712 0 0.1471 0.1471 5 21 0 29 
1.494871 0.869 0 0.2059 0.2059 7 21 0 27 
1.495408 0.8685 0 0.2353 0.2353 8 21 0 26 
1.498919 0.8655 0.0476 0.2353 0.1877 8 20 1 26 
1.500803 0.8639 0.0952 0.2353 0.1401 8 19 2 26 
1.515669 0.8502 0.0952 0.2647 0.1695 9 19 2 25 
1.539703 0.8259 0.0952 0.3235 0.2283 11 19 2 23 
1.547916 0.8169 0.1429 0.3235 0.1807 11 18 3 23 
1.553722 0.8103 0.1429 0.3529 0.2101 12 18 3 22 
1.553745 0.8102 0.1905 0.3529 0.1625 12 17 4 22 
1.579288 0.7791 0.1905 0.3824 0.1919 13 17 4 21 
1.589118 0.7662 0.1905 0.4118 0.2213 14 17 4 20 
1.593015 0.7609 0.1905 0.4412 0.2507 15 17 4 19 
1.610618 0.7362 0.1905 0.4706 0.2801 16 17 4 18 
1.62263 0.7183 0.1905 0.5 0.3095 17 17 4 17 
1.625559 0.7139 0.2381 0.5 0.2619 17 16 5 17 
1.653241 0.6698 0.2381 0.5294 0.2913 18 16 5 16 
1.656371 0.6646 0.2381 0.5882 0.3501 20 16 5 14 
1.6618 0.6554 0.2381 0.6176 0.3796 21 16 5 13 
1.662663 0.654 0.2381 0.6471 0.409 22 16 5 12 
1.664784 0.6504 0.2857 0.6471 0.3613 22 15 6 12 
1.679373 0.6252 0.3333 0.6471 0.3137 22 14 7 12 
1.686741 0.6122 0.3333 0.6765 0.3431 23 14 7 11 
1.720267 0.5512 0.3333 0.7059 0.3725 24 14 7 10 
1.721806 0.5484 0.3333 0.7353 0.402 25 14 7 9 
 24 
1.72384 0.5446 0.381 0.7647 0.3838 26 13 8 8 
1.732096 0.5292 0.381 0.7941 0.4132 27 13 8 7 
1.735575 0.5227 0.381 0.8235 0.4426 28 13 8 6 
1.749412 0.4969 0.381 0.8529 0.472* 29 13 8 5 
1.76026 0.4766 0.4286 0.8529 0.4244 29 12 9 5 
1.760624 0.4759 0.4762 0.8529 0.3768 29 11 10 5 
1.77108 0.4564 0.4762 0.8824 0.4062 30 11 10 4 
1.781068 0.438 0.4762 0.9118 0.4356 31 11 10 3 
1.785739 0.4294 0.5238 0.9118 0.388 31 10 11 3 
1.787461 0.4262 0.5714 0.9118 0.3403 31 9 12 3 
1.789456 0.4226 0.5714 0.9412 0.3697 32 9 12 2 
1.797938 0.4072 0.619 0.9412 0.3221 32 8 13 2 
1.812061 0.3819 0.6667 0.9412 0.2745 32 7 14 2 
1.823396 0.3621 0.6667 0.9706 0.3039 33 7 14 1 
1.827528 0.355 0.6667 1 0.3333 34 7 14 0 
1.844138 0.3271 0.7143 1 0.2857 34 6 15 0 
1.847286 0.3219 0.7619 1 0.2381 34 5 16 0 
1.851307 0.3154 0.8095 1 0.1905 34 4 17 0 
1.85259 0.3133 0.8571 1 0.1429 34 3 18 0 
1.878538 0.2731 0.9048 1 0.0952 34 2 19 0 
1.878554 0.2731 0.9524 1 0.0476 34 1 20 0 
1.888382 0.2588 1 1 0 34 0 21 0 
1.888382 0.2588 1 1 0 34 0 21 0 
Chapter 2 Table 5. 
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Chapter 3 
Section 1 
Plasma profiling of individual molecular species of PC, LPC, SM, PE, LPE, and PI in 
plasma of TBI, PTSD, and TBI+PTSD subjects 
Chapter 3 Tables 1–6 show values of PL molecular species in plasma within each PL 
class identified by PCA to be significantly associated with the different diagnostic groups 
and the control group, as PCA also allows us to distinguish diagnostic groups, not only 
from control subjects but also from each other (TBI, compared with PTSD/TBI+PTSD 
and vice versa; see online supplementary material at www.liebertpub.com). For PC, 
multivariate PCA of the plasma data showed that component 1 explained 66% of the 
variance in the dataset and was associated with PTSD and TBI+PTSD (p = 0.04). 
Component 4 (p = 0.007), associated with TBI and TBI+PTSD, and component 5 (p = 
0.01), associated with TBI+PTSD, each explained 3% of variance in the dataset. 
Supplementary Table 1 shows individual PC species and those that were specific to PCA 
components 1, 4, and 5 after post hoc adjustments. For LPC component 1 of the PCA, 
there was significance for TBI and TBI+PTSD, which explained 84% of the total 
variance in the dataset (p < 0.001). Supplementary Table 2 shows all individual LPC 
species that were identified to be significant by PCA in component 1. For PE, 
multivariate PCA of the plasma data showed that component 1 explained 79% of 
variance in the dataset and was associated with TBI+PTSD (p = 0.05). Component 2 
explained 6% of variance in the dataset and was associated with TBI (p = 0.03). 
Supplementary Table 3 shows individual PE species, identified by components 1, 2, and 
3. For LPE, component 1 of the PCA explained 62% of the total variance in the dataset 
(F3, 351 = 8.2, p < 0.001), and was significantly associated with TBI (p = 0.007), PTSD 
(p = 0.01), and TBI+PTSD (p < 0.001). Supplementary Table 4 shows individual LPE 
species that were specific to PCA component 1. For PI, component 1 explained 89% of 
the total variance (p < 0.001) and was associated with TBI (p = 0.2) and TBI+PTSD (p < 
0.001). Supplementary Table 5 shows individual PI species in plasma with significant 
changes. For SM, component 2 explained 22% of the total variance (p < 0.001) and was 
significantly associated with TBI (p = 0.001), PTSD (p = 0.05), and TBI+PTSD (p < 
0.001). Supplementary Table 6 shows individual significant SM species that were 
specifically significant with PCA component 2. 
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Table 1-6. Plasma levels of phosphatidylcholine (PC), lysophosphatidylcholines 
(LPC), phosphatidylethanolamine (PE), lysophosphatidylethanolamide (LPE), 
phosphatidylinositol (PI), and sphingomyelin (SM) molecular species quantified by 
liquid chromatography/mass spectrometry (LC/MS) analyses. Phospholipids 
presented in each table are those that were associated with principal component analysis 
component within each class that was significantly associated with traumatic brain injury 
(TBI), post-traumatic stress disorder (PTSD), and/or TBI+PTSD. Individual species for 
all lipid classes that are significant different, compared with controls, are indicated with * 
for p < 0.05. Values are represented in µM – standard error of the mean.  
Chapter 3 Table 1. Individual PC Species 
Phosphatidylcholine 
 
Control TBI PTSD TBI+PTSD 
ePC(32:0) 4.71 ± 0.09 4.17 ± 0.14* 4.26 ± 0.13* 3.86 ± 0.16* 
PC(32:2) 5.34 ± 0.20 4.53 ± 0.29 4.85 ± 0.27 3.42 ± 0.27*#$ 
PC(32:0) 19.26 ± 0.43 16.48 ± 0.61* 17.59 ± 0.52* 16.76 ± 1.24* 
ePC(34:3) 10.30 ± 0.32 8.64 ± 0.43 9.06 ± 0.31* 7.95 ± 0.27* 
ePC(34:2) 12.03 ± 0.42 10.35 ± 0.50 10.44 ± 0.41* 9.30 ± 0.39* 
ePC(34:1) 10.55 ± 0.22 9.06 ± 0.32* 9.56 ± 0.27* 8.20 ± 0.33*#$ 
ePC(34:0) 5.27 ± 0.14 4.42 ± 0.18* 4.69 ± 0.16* 3.88 ± 0.12*$ 
PC(34:3) 14.28 ± 0.81 11.61 ± 0.83 12.28 ± 0.88 10.97 ± 0.77* 
PC(34:2) 630.71 ± 19.69 488.47 ± 22.00* 543.91 ± 19.57* 465.35 ± 16.40* 
PC(34:1) 188.48 ± 5.79 155.16 ± 7.39* 169.31 ± 6.03 143.97 ± 6.63* 
PC(34:0) 9.95 ± 0.29 8.22 ± 0.38 8.87 ± 0.28 7.96 ± 0.54* 
ePC(36:5) 18.01 ± 0.48 15.92 ± 0.73 16.38 ± 0.50 14.76 ± 0.42* 
ePC(36:4) 18.89 ± 0.49 16.79 ± 0.65 16.40 ± 0.46* 14.82 ± 0.46*# 
ePC(36:3) 8.48 ± 0.23 7.00 ± 0.31* 7.39 ± 0.23* 6.18 ± 0.27*#$ 
ePC(36:2) 17.06 ± 0.50 13.63 ± 0.59* 14.70 ± 0.54* 12.03 ± 0.34*$ 
ePC(36:1) 9.02 ± 0.29 7.10 ± 0.38* 8.00 ± 0.35 6.06 ± 0.19*$ 
PC(36:4) 297.71 ± 8.26 256.01 ± 11.33 267.46 ± 10.33 237.52 ± 9.71* 
PC(36:3) 164.83 ± 4.84 124.12 ± 5.91* 143.97 ± 4.82* 122.40 ± 8.08*$ 
PC(36:2) 269.71 ± 7.45 206.73 ± 9.73* 236.14 ± 8.06* 192.75 ± 10.27*$ 
PC(36:1) 42.69 ± 1.68 29.62 ± 2.10* 37.91 ± 2.07 26.43 ± 2.28*$ 
ePC(38:6) 8.80 ± 0.21 7.79 ± 0.30 7.87 ± 0.23* 7.55 ± 0.30* 
ePC(38:5) 20.78 ± 0.51 18.27 ± 0.72 18.15 ± 0.51* 16.64 ± 0.51*# 
ePC(38:4) 18.32 ± 0.46 16.12 ± 0.63 15.85 ± 0.47* 14.47 ± 0.45*# 
ePC(38:3) 6.99 ± 0.24 5.46 ± 0.30* 5.99 ± 0.27* 4.60 ± 0.20*$ 
ePC(38:0) 2.94 ± 0.08 2.54 ± 0.11 2.60 ± 0.10 2.31 ± 0.10* 
PC(38:6) 73.10 ± 2.07 64.36 ± 2.76 63.89 ± 2.44* 65.01 ± 3.11 
PC(38:5) 77.24 ± 2.08 65.05 ± 2.73 67.54 ± 2.32* 61.55 ± 3.02* 
PC(38:4) 178.52 ± 4.95 151.08 ± 7.04 160.03 ± 5.90 140.15 ± 7.48* 
PC(38:3) 66.77 ± 2.56 48.92 ± 3.35* 57.62 ± 2.95 41.73 ± 3.89*$ 
PC(38:2) 6.42 ± 0.39 4.30 ± 0.37* 6.00 ± 0.70 3.17 ± 0.16*$ 
ePC(40:6) 5.59 ± 0.15 4.91 ± 0.20 4.77 ± 0.17* 4.79 ± 0.14* 
ePC(40:5) 4.90 ± 0.18 4.68 ± 0.20 4.54 ± 0.16* 4.61 ± 0.14 
PC(40:8) 4.19 ± 0.12 3.49 ± 0.16 3.73 ± 0.14 2.99 ± 0.09*#$ 
PC(40:7) 8.41 ± 0.23 7.25 ± 0.31 7.35 ± 0.25* 7.18 ± 0.31* 
PC(40:6) 27.37 ± 0.77 24.07 ± 1.05 24.32 ± 0.89* 24.20 ± 1.31 
PC(40:3) 1.70 ± 0.08 1.33 ± 0.09 1.48 ± 0.09 1.16 ± 0.04* 
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For PC, significant differences were observed to the control group (*p < 0.05), to the TBI group (#p < 0.05; 
PC[32:2], ePC[34:1], ePC[36:4], ePC[36:3], ePC[38:5], ePC[38:4], and PC[40:8]), and with the PTSD 
groups ($p < 0.05; PC[32:2], ePC[34:1], ePC[34:0] ePC[36:3], ePC[36:2], ePC[36:1], PC[36:3], 
PC[36:31], PC[36:1], ePC[38:3], PC[38:3], PC[38:2] and PC[40:8]. ePC, ether phosphatidylcholine.  
Chapter 3 Table 2. LPC Significance 
 
 
For LPC, significance was observed in TBI+PTSD subjects for LPC species, LPC(0-16:0), LPC(16:1), 
LPC(0-18:0), and LPC(18:3). LPC(20:3) was significantly different between PTSD and TBI subjects. 
TBI+PTSD subjects showed significant differences, compared with PTSD ($p < 0.05), for lipid species 
LPC(0-16:0), LPC(16:1), LPC(16:0), LPC(0-18:0), LPC(18:3), LPC(18:1), LPC(18:0), and LPC(20:2). 
 
 
 
 
 
 
 
 
 
 
 
Lysophosphatidylcholine 
 
Control TBI PTSD TBI+PTSD 
LPC(0-16:0) 4.27 ± 0.12 3.46 ± 0.17* 3.73 ± 0.15*# 2.63 ± 0.10*#$ 
LPC(16:1) 8.35 ± 0.27 6.56 ± 0.35* 7.11 ± 0.30*# 5.19 ± 0.18*#$ 
LPC(16:0) 240.78 ± 7.40 188.18 ± 8.97* 196.57 ± 7.71* 159.45 ± 5.13*$ 
LPC(0-18:0) 7.76 ± 0.24 5.98 ± 0.27* 6.37 ± 0.25*# 5.10 ± 0.16*#$ 
LPC(18:3) 2.92 ± 0.09 2.28 ± 0.11* 2.65 ± 0.12 1.86 ± 0.06*#$ 
LPC(18:2) 138.39 ± 4.97 98.40 ± 5.21* 115.26 ± 4.26* 97.78 ± 4.29* 
LPC(18:1) 57.04 ± 1.88 43.53 ± 2.39* 48.39 ± 1.88* 39.49 ± 1.45*$ 
LPC(18:0) 82.62 ± 2.75 63.09 ± 3.29* 67.59 ± 3.13* 54.83 ± 2.70*$ 
LPC(20:5) 2.26 ± 0.10 1.99 ± 0.10* 2.11 ± 0.13* 1.75 ± 0.06 
LPC(20:4) 26.56 ± 0.95 21.58 ± 1.04* 23.03 ± 1.10* 20.21 ± 0.87 
LPC(20:3) 9.30 ± 0.33 6.63 ± 0.38* 8.28 ± 0.42# 6.30 ± 0.36*$ 
LPC(20:2) 2.41 ± 0.08 1.81 ± 0.10* 2.00 ± 0.08* 1.61 ± 0.06*$ 
LPC(22:6) 4.92 ± 0.17 3.92 ± 0.20* 4.26 ± 0.20* 4.06 ± 0.16 
LPC(22:5) 3.14 ± 0.11 2.42 ± 0.13* 2.71 ± 0.12* 2.22 ± 0.09* 
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Chapter 3 Table 3. PE Significance 
Phosphatidylethanolamine 
 
Control TBI PTSD TBI+PTSD 
ePE(34:3) 4.66 ± 0.18 3.43 ± 0.21 4.08 ± 0.15 2.88 ± 0.17*#$ 
ePE(34:2) 4.57 ± 0.25 3.21 ± 0.30 3.69 ± 0.24 3.33 ± 0.75* 
ePE(34:1) 2.81 ± 0.04 2.61 ± 0.06 2.65 ± 0.05 2.48 ± 0.08*$ 
ePE(34:0) 0.50 ± 0.02 0.41 ± 0.02* 0.44 ± 0.02 0.34 ± 0.01*#$ 
PE(34:4) 0.54 ± 0.02 0.43 ± 0.02* 0.47 ± 0.02* 0.34 ± 0.01*#$ 
PE(34:2) 5.35 ± 0.24 3.70 ± 0.26* 4.13 ± 0.16* 3.64 ± 0.45*#$ 
PE(34:1) 3.47 ± 0.15 2.45 ± 0.15* 2.92 ± 0.12 2.40 ± 0.29*$ 
ePE(36:5) 21.70 ± 0.87 16.63 ± 0.97* 18.65 ± 0.72* 13.18 ± 0.76*#$ 
ePE(36:4) 5.86 ± 0.23 4.33 ± 0.27* 5.04 ± 0.17 3.70 ± 0.23*#$ 
ePE(36:3) 10.63 ± 0.56 7.10 ± 0.60* 8.55 ± 0.46 7.57 ± 1.43* 
ePE(36:2) 4.12 ± 0.20 2.85 ± 0.24* 3.30 ± 0.19 2.83 ± 0.51* 
PE(36:5) 2.72 ± 0.09 2.14 ± 0.11* 2.26 ± 0.07* 1.76 ± 0.08*#$ 
PE(36:4) 6.39 ± 0.23 4.84 ± 0.31* 5.25 ± 0.19* 4.29 ± 0.45*$ 
PE(36:3) 5.83 ± 0.27 3.71 ± 0.27* 4.35 ± 0.16* 4.06 ± 0.44* 
PE(36:2) 14.63 ± 0.69 9.30 ± 0.73* 10.87 ± 0.45* 10.50 ± 1.52* 
ePE(38:6) 21.56 ± 0.85 16.31 ± 0.99* 18.26 ± 0.68 14.06 ± 0.90*$ 
ePE(38:5) 35.24 ± 1.47 26.22 ± 1.70* 29.22 ± 1.15* 22.20 ± 1.40*$ 
ePE(38:4) 5.13 ± 0.21 3.62 ± 0.21* 4.14 ± 0.14* 3.33 ± 0.29*$ 
ePE(38:3) 2.22 ± 0.10 1.67 ± 0.14 1.82 ± 0.10 1.62 ± 0.30* 
PE(38:6) 4.74 ± 0.19 3.83 ± 0.19* 3.86 ± 0.17* 3.45 ± 0.43* 
PE(38:5) 8.13 ± 0.31 6.12 ± 0.34* 6.64 ± 0.26* 5.25 ± 0.43*$ 
PE(38:4) 25.88 ± 1.15 19.15 ± 1.20* 21.21 ± 0.92* 16.12 ± 1.68*$ 
PE(38:3) 3.31 ± 0.13 2.39 ± 0.16* 2.73 ± 0.12* 2.21 ± 0.30*$ 
PE(38:1) 3.28 ± 0.13 2.61 ± 0.13 2.79 ± 0.11 2.52 ± 0.15* 
PE(38:0) 8.04 ± 0.32 6.03 ± 0.33* 6.49 ± 0.26* 5.95 ± 0.47* 
ePE(40:6) 8.61 ± 0.37 6.45 ± 0.40* 7.16 ± 0.31 5.55 ± 0.46*$ 
ePE(40:5) 8.20 ± 0.42 6.34 ± 0.45 6.88 ± 0.34 5.06 ± 0.48*$ 
ePE(40:4) 2.43 ± 0.06 1.98 ± 0.08* 2.15 ± 0.06* 1.78 ± 0.12*#$ 
ePE(40:3) 1.80 ± 0.06 1.42 ± 0.07* 1.54 ± 0.06* 1.35 ± 0.14*$ 
PE(40:6) 5.23 ± 0.21 3.96 ± 0.24* 4.29 ± 0.21 4.08 ± 0.73* 
PE(40:5) 4.06 ± 0.17 3.01 ± 0.20* 3.32 ± 0.15* 2.71 ± 0.40*$ 
PE(42:7) 1.94 ± 0.06 1.53 ± 0.07* 1.72 ± 0.06 1.25 ± 0.05*#$ 
PE(42:6) 2.73 ± 0.09 2.11 ± 0.11* 2.36 ± 0.08* 1.72 ± 0.08*#$ 
For PE, ePE(34:3), ePE(34:0), PE(34:4), PE(34:2), ePE(36:5), ePE(36:4), PE(36:5), ePE(40:4), PE(42:7), 
and PE(42:6) were significantly different in TBI+PTSD, compared with TBI subjects (#p<0.05). Compared 
with the PTSD group, there were significant differences ($p<0.05) in TBI+PTSD subjects for lipid species 
ePE(34:3), ePE(34:1), ePE(34:0), PE(34:4), PE(34:2), PE(34:1), ePE(36:5), ePE(36:4), PE(36:5), PE(36:4), 
ePE(38:6), ePE(38:5), ePE(38:4), PE(38:5), PE(38:4), PE(38:3), ePE(40:6), ePE(40:5), ePE(40:4), 
ePE(40:3), PE(40:5), PE(42:7), and PE(42:6). ePE, ether phosphatidylethanolamine  
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Chapter 3 Table 4. LPE Significance 
Lysophosphatidylethanolamine 
 
Control TBI PTSD TBI+PTSD 
LPE(o-16:1) 1.71 ± 0.05 1.31 ± 0.06* 1.43 ± 0.05* 1.14 ± 0.05*$ 
LPE(16:0) 3.44 ± 0.16 2.90 ± 0.18* 2.92 ± 0.15* 2.68 ± 0.12* 
LPE(o-18:2) 0.82 ± 0.05 0.66 ± 0.05* 0.65 ± 0.04* 0.71 ± 0.07 
LPE(o-18:1) 1.53 ± 0.08 1.30 ± 0.07* 1.31 ± 0.06* 1.20 ± 0.07* 
LPE(18:3) 0.93 ± 0.03 0.72 ± 0.04* 0.80 ± 0.03* 0.57 ± 0.03*$ 
LPE(18:2) 13.89 ± 0.61 9.01 ± 0.62* 10.88 ± 0.45* 9.32 ± 0.69* 
LPE(18:1) 6.11 ± 0.30 3.88 ± 0.27* 5.14 ± 0.27*# 4.80 ± 0.35 
LPE(18:0) 4.35 ± 0.24 3.48 ± 0.23* 3.54 ± 0.21* 3.27 ± 0.21* 
LPE(o-20:1) 4.29 ± 0.08 4.16 ± 0.11 4.11 ± 0.10 3.66 ± 0.14*# 
LPE(20:4) 8.38 ± 0.29 6.45 ± 0.36* 7.05 ± 0.34* 6.16 ± 0.41* 
LPE(22:6) 4.12 ± 0.13 3.40 ± 0.18* 3.50 ± 0.17* 3.14 ± 0.18* 
LPE(22:5) 1.72 ± 0.07 1.35 ± 0.08* 1.46 ± 0.07* 1.24 ± 0.08* 
 
For LPE, compared with the TBI group (#p < 0.05), LPE (0–20:1) in PTSD subjects and LPE(18:1) in 
TBI+PTSD subjects were significantly different. Differences in LPE(0–16:1) and LPE(18:3) were 
significant in TBI+PTSD subjects, compared with in PTSD subjects ($p < 0.05). 
 
Chapter 3 Table 5. PI Significance 
Phosphatidylinositol 
 
Control TBI PTSD TBI+PTSD 
PI(34:2) 9.79 ± 0.46 6.49 ± 0.53* 8.12 ± 0.43* 5.50 ± 0.21*$ 
PI(34:1) 7.89 ± 0.36 5.23 ± 0.45* 6.92 ± 0.35 4.56 ± 0.21*$ 
PI(34:0) 0.99 ± 0.04 0.69 ± 0.05* 0.84 ± 0.05 0.59 ± 0.03*$ 
PI(36:4) 11.79 ± 0.50 8.62 ± 0.70* 9.70 ± 0.58* 7.13 ± 0.43*$ 
PI(36:3) 8.80 ± 0.43 5.51 ± 0.44* 7.02 ± 0.39* 5.03 ± 0.34*$ 
PI(36:2) 29.69 ± 1.36 18.97 ± 1.45* 24.21 ± 1.21* 16.96 ± 0.65*$ 
PI(36:1) 8.98 ± 0.40 5.85 ± 0.51* 7.84 ± 0.39 5.10 ± 0.20*$ 
PI(36:0) 0.76 ± 0.03 0.55 ± 0.04* 0.66 ± 0.03* 0.49 ± 0.03*$ 
PI(37:4) 3.66 ± 0.16 2.56 ± 0.23 2.97 ± 0.18* 2.21 ± 0.39*#$ 
PI(38:6) 1.58 ± 0.07 1.24 ± 0.09 1.28 ± 0.06* 1.06 ± 0.05* 
PI(38:5) 10.38 ± 0.53 7.33 ± 0.61 8.35 ± 0.49 5.97 ± 0.40*#$ 
PI(38:4) 124.11 ± 5.62 90.86 ± 6.85* 98.75 ± 5.75* 76.49 ± 3.30*$ 
PI(38:3) 19.96 ± 0.95 13.15 ± 1.00* 16.07 ± 0.98* 12.05 ± 0.99*$ 
PI(38:2) 2.34 ± 0.11 1.51 ± 0.11* 1.84 ± 0.10* 1.39 ± 0.10*$ 
PI(40:6) 3.62 ± 0.14 2.83 ± 0.20* 2.93 ± 0.15* 2.49 ± 0.12* 
PI(40:5) 3.78 ± 0.15 2.75 ± 0.20* 3.10 ± 0.16* 2.30 ± 0.12*$ 
PI(40:4) 2.17 ± 0.10 1.55 ± 0.12* 1.70 ± 0.09* 1.25 ± 0.07*$ 
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For PI, significant differences in TBI+PTSD subjects, compared with the PTSD group, were observed for 
all individual PI species, except PI(38:6) and PI(40:6), which were significant, compared to controls. 
PI(37:4) and PI(38:5) showed significant difference between TBI+PTSD and TBI subjects. 
 
Chapter 3 Table 6. SM Significance 
Sphingomyelin 
 
Control TBI PTSD TBI+PTSD 
SM(16:1) 36.73 ± 1.22 29.58 ± 1.63* 32.62 ± 1.39*# 24.59 ± 0.87*$ 
SM(16:0) 225.10 ± 6.40 191.86 ± 10.91* 195.94 ± 6.06* 164.93 ± 10.19* 
DSM(16:0) 24.59 ± 13.66 8.23 ± 0.30* 9.89 ± 0.43*# 7.69 ± 0.27*$ 
SM(18:1) 22.68 ± 0.77 18.71 ± 0.98* 20.08 ± 0.77* 16.47 ± 0.85* 
SM(18:0) 47.01 ± 2.87 37.46 ± 2.09* 40.76 ± 1.61 33.42 ± 2.25* 
DSM(18:0) 14.52 ± 4.27 7.52 ± 0.46* 9.27 ± 0.49* 6.84 ± 0.64* 
SM(22:0) 96.51 ± 13.62 62.96 ± 2.81* 76.43 ± 3.38*# 57.56 ± 4.81*$ 
DSM(22:0) 11.34 ± 5.16 4.70 ± 0.21* 5.92 ± 0.24# 4.91 ± 0.53 
SM(24:1) 95.66 ± 5.45 77.26 ± 3.46* 82.07 ± 3.87* 66.90 ± 3.64* 
SM(24:0) 44.96 ± 7.10 32.24 ± 1.65* 35.62 ± 2.02 28.53 ± 1.99* 
DSM(24:0) 6.35 ± 3.87 2.16 ± 0.14* 2.22 ± 0.13* 2.14 ± 0.31 
 
For SM, PTSD was significantly different from TBI (#p < 0.05) for individual species SM(16:1), 
DSM(16:0), SM(22:0), and DSM(22:0). TBI+PTSD showed significant differences, compared with PTSD 
subjects ($p < 0.05), for species SM(16:1), DSM(16:0), and SM(22:0). 
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Section 2 
Chapter 4 Table 1. Model for TBI/Control 
TBI/Control 
Positive if Greater Than or 
Equal Toa 
Sensitivity 1 - Specificity 
0 1 1 
0.0003201 1 0.98 
0.000728 1 0.959 
0.0009059 1 0.939 
0.0010088 1 0.918 
0.0010308 1 0.898 
0.0023843 1 0.878 
0.0039458 1 0.857 
0.0078302 1 0.837 
0.0143355 1 0.816 
0.018829 1 0.796 
0.0216165 1 0.776 
0.0229153 1 0.755 
0.023284 1 0.735 
0.0258332 1 0.714 
0.0295138 1 0.694 
0.0319376 1 0.673 
0.0331461 1 0.653 
0.0333842 1 0.633 
0.0348726 1 0.612 
0.0436122 1 0.592 
0.0523973 1 0.571 
0.0541673 1 0.551 
0.0560511 1 0.531 
0.0653177 1 0.51 
0.0741049 1 0.49 
0.0758687 1 0.469 
0.0782528 1 0.449 
0.0933067 1 0.429 
0.1170664 1 0.408 
0.1281328 1 0.388 
0.1363335 1 0.367 
0.1521556 1 0.347 
0.1610514 0.952 0.347 
0.1708775 0.952 0.327 
 32 
0.2027056 0.905 0.327 
0.2275636 0.905 0.306 
0.2309259 0.857 0.306 
0.2404489 0.81 0.306 
0.2506981 0.81 0.286 
0.2539207 0.81 0.265 
0.264218 0.81 0.245 
0.2731101 0.81 0.224 
0.2886595 0.81 0.204 
0.3091372 0.81 0.184 
0.3154035 0.762 0.184 
0.3595685 0.714 0.184 
0.4050152 0.714 0.163 
0.4128655 0.667 0.163 
0.4314235 0.619 0.163 
0.4493595 0.619 0.143 
0.4616927 0.619 0.122 
0.4858942 0.619 0.102 
0.5278696 0.571 0.102 
0.581578 0.524 0.102 
0.6310951 0.524 0.082 
0.6777047 0.524 0.061 
0.7033585 0.524 0.041 
0.7162581 0.476 0.041 
0.7337488 0.429 0.041 
0.7519871 0.429 0.02 
0.7745748 0.429 0 
0.7929965 0.381 0 
0.8023577 0.333 0 
0.8172826 0.286 0 
0.8320203 0.238 0 
0.8453654 0.19 0 
0.8617333 0.143 0 
0.9015343 0.095 0 
0.9442715 0.048 0 
1 0 0 
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PTSD/Control 
Positive if Greater Than or 
Equal Toa 
Sensitivity 1 - Specificity 
0 1 1 
0.0794584 1 0.98 
0.0898444 1 0.961 
0.1168506 1 0.941 
0.1425846 1 0.922 
0.159953 1 0.902 
0.1757084 1 0.882 
0.1780795 1 0.863 
0.1896353 1 0.843 
0.2003984 1 0.824 
0.2027674 1 0.804 
0.21145 1 0.784 
0.2217499 1 0.765 
0.2243891 0.971 0.765 
0.2252604 0.971 0.745 
0.2303867 0.943 0.745 
0.2369179 0.943 0.725 
0.2394072 0.943 0.706 
0.2399753 0.943 0.686 
0.2404916 0.914 0.686 
0.2409993 0.914 0.667 
0.2453073 0.914 0.647 
0.2626892 0.886 0.647 
0.2855862 0.886 0.627 
0.2956931 0.886 0.608 
0.2990594 0.886 0.588 
0.3032657 0.857 0.588 
0.3135079 0.829 0.588 
0.3232387 0.829 0.569 
0.3260206 0.829 0.549 
0.3319038 0.829 0.529 
0.33647 0.829 0.51 
0.3380085 0.829 0.49 
0.3391003 0.8 0.49 
0.3452105 0.771 0.49 
0.3511471 0.771 0.471 
0.3564882 0.743 0.471 
0.3639014 0.743 0.451 
 34 
0.3705299 0.714 0.451 
0.3755812 0.714 0.431 
0.3775026 0.686 0.431 
0.3896955 0.686 0.412 
0.4008059 0.686 0.392 
0.4038276 0.657 0.392 
0.4087202 0.629 0.392 
0.4145029 0.629 0.373 
0.4211236 0.6 0.373 
0.4266404 0.6 0.353 
0.4293396 0.571 0.353 
0.4302646 0.543 0.353 
0.4315886 0.543 0.333 
0.4361004 0.543 0.314 
0.4416025 0.543 0.294 
0.4500837 0.543 0.275 
0.4587867 0.514 0.275 
0.4670146 0.514 0.255 
0.4783581 0.514 0.235 
0.4894846 0.514 0.216 
0.4959783 0.486 0.216 
0.502472 0.486 0.196 
0.5105237 0.457 0.196 
0.5176489 0.429 0.196 
0.5305112 0.4 0.196 
0.5385555 0.4 0.176 
0.5423254 0.371 0.176 
0.5489329 0.343 0.176 
0.5647867 0.343 0.157 
0.5786658 0.314 0.157 
0.5843426 0.286 0.157 
0.5888753 0.286 0.137 
0.5924966 0.257 0.137 
0.6002557 0.257 0.118 
0.6055955 0.229 0.118 
0.6069177 0.2 0.118 
0.60739 0.2 0.098 
0.6141478 0.171 0.098 
0.6346784 0.171 0.078 
0.6490615 0.171 0.059 
0.6513235 0.171 0.039 
 35 
0.6533999 0.143 0.039 
0.6580722 0.114 0.039 
0.6639494 0.086 0.039 
0.6664918 0.086 0.02 
0.6802207 0.057 0.02 
0.7061777 0.029 0.02 
0.7327367 0 0.02 
1 0 0 
 
 
 
TBI+PTSD/Control 
Positive if Greater Than or 
Equal Toa 
Sensitivity 1 - Specificity 
0 1 1 
0.0001423 1 0.98 
0.0003207 1 0.96 
0.0004986 1 0.94 
0.0006301 1 0.92 
0.0008564 1 0.9 
0.0010359 1 0.88 
0.0010977 1 0.86 
0.0015192 1 0.84 
0.0019413 1 0.82 
0.0027029 1 0.8 
0.0044212 1 0.78 
0.0079791 1 0.76 
0.0105961 1 0.74 
0.0109267 1 0.72 
0.0127811 1 0.7 
0.0143509 1 0.68 
0.0160561 1 0.66 
0.0215753 1 0.64 
0.0263522 1 0.62 
0.0281165 1 0.6 
0.0297569 1 0.58 
0.0309859 1 0.56 
0.0337609 1 0.54 
0.040487 1 0.52 
0.0452289 1 0.5 
 36 
0.0486148 0.909 0.5 
0.0533577 0.909 0.48 
0.0552101 0.909 0.46 
0.0555933 0.909 0.44 
0.0653878 0.909 0.42 
0.0785234 0.909 0.4 
0.089107 0.909 0.38 
0.110792 0.909 0.36 
0.1400743 0.818 0.36 
0.1553989 0.818 0.34 
0.1709385 0.818 0.32 
0.1918754 0.818 0.3 
0.2072906 0.818 0.28 
0.2227882 0.818 0.26 
0.2353613 0.818 0.24 
0.2448624 0.818 0.22 
0.2628385 0.818 0.2 
0.2776911 0.818 0.18 
0.2948441 0.727 0.18 
0.3282904 0.636 0.18 
0.3482269 0.636 0.16 
0.3546619 0.636 0.14 
0.3585686 0.636 0.12 
0.3663632 0.636 0.1 
0.3741141 0.545 0.1 
0.3965565 0.545 0.08 
0.4231576 0.455 0.08 
0.4306512 0.455 0.06 
0.4502956 0.364 0.06 
0.4724377 0.273 0.06 
0.5055574 0.273 0.04 
0.5391119 0.273 0.02 
0.5497214 0.273 0 
0.64593 0.182 0 
0.7600091 0.091 0 
1 0 0 
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Chapter 4 
Section 1  
Chapter 4 table 1: Total plasma levels of PC, LPC, PE, LPE, PI and SM quantified by LC/MS 
analyses (µM± SEM). Individual molecular species of each class were quantified by LC/MS and summed 
after lipidomeDB analyses to generate total lipid levels. *denotes significant p values for all timepoints. 
  Control mTBI 
PC       
24h 1205.31 ± 137.34 1140.15 ± 38.82 
3mo 1333.05 ± 91.35 1071.09 ± 63.22* 
6mo 1409.66 ± 142.51 1221.99 ± 96.03 
12mo 1463.37 ± 53.10 1114.72 ± 41.80* 
24mo 519.72 ± 49.31 408.83 ± 31.44* 
LPC       
24h 558.63 ± 64.48 524.95 ± 20.78 
3mo 715.59 ± 53.35 498.91 ± 27.52* 
6mo 761.90 ± 91.89 598.23 ± 61.14 
12mo 660.39 ± 38.03 571.40 ± 27.72 
24mo 585.54 ± 79.58 432.14 ± 38.16* 
PE       
24h 52.07 ± 6.61 59.62 ± 3.61 
3mo 60.53 ± 4.39 45.07 ± 2.59* 
6mo 59.58 ± 6.89 54.20 ± 3.16 
12mo 63.27 ± 3.43 46.08 ± 3.18* 
24mo 24.73 ± 2.18 21.56 ± 0.62* 
LPE       
24h 37.63 ± 5.40 38.59 ± 3.26 
3mo 47.47 ± 4.93 34.17 ± 4.19* 
6mo 41.28 ± 5.70 32.81 ± 4.15 
12mo 39.26 ± 3.17 33.98 ± 2.38 
24mo 33.59 ± 3.92 25.19 ± 1.47* 
PI       
24h 191.61 ± 7.95 174.70 ± 11.66 
3mo 231.73 ± 19.07 170.28 ± 19.17* 
6mo 220.67 ± 19.81 193.07 ± 19.46 
12mo 267.47 ± 30.50 189.67 ± 28.59* 
24mo 114.43 ± 12.51 85.04 ± 7.83* 
SM       
24h 46.17 ± 4.95 51.04 ± 2.16 
3mo 44.14 ± 4.96 39.71 ± 2.54 
6mo 58.24 ± 4.69 47.98 ± 4.39 
12mo 50.10 ± 4.52 42.20 ± 1.63 
24mo 17.97 ± 2.34 15.47 ± 0.89* 
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Chapter 4 table 2: Plasma levels of PC molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints. 
Time-post injury PC Species Control mTBI mTBI/Control ratios 
24h ePC(38:6) 0.72 ± 0.14 1.07 ± 0.10 1.49 
24h PC(32:2) 0.94 ± 0.13 0.66 ± 0.10 0.70 
24h PC(34:3) 14.58 ± 1.22 10.81 ± 0.70 0.74 
24h PC(36:5) 7.31 ± 0.64 5.64 ± 0.28 0.77 
24h PC(40:4) 2.95 ± 0.35 2.02 ± 0.08 0.68 
24h PC(42:6) 0.94 ± 0.17 0.59 ± 0.06 0.63 
3mo ePC(34:2) 2.25 ± 0.21 1.71 ± 0.16 0.76 
3mo ePC(36:2) 5.93 ± 0.41 4.82 ± 0.41 0.81 
3mo ePC(36:4) 1.64 ± 0.13 1.14 ± 0.11 0.70 
3mo ePC(38:5) 1.89 ± 0.14 1.38 ± 0.13 0.73 
3mo PC(32:0) 11.21 ± 0.77 9.07 ± 0.87 0.81 
3mo PC(34:2) 359.17 ± 23.82 288.48 ± 19.96 0.80 
3mo PC(36:2) 160.36 ± 12.30 126.30 ± 9.67 0.79 
3mo PC(36:3) 76.53 ± 5.40 62.04 ± 4.19 0.81 
3mo PC(36:4) 187.98 ± 11.27 149.62 ± 7.79 0.80 
3mo PC(38:5) 48.32 ± 3.22 38.90 ± 1.84 0.81 
6mo PC(32:0) 12.51 ± 1.35 9.44 ± 0.79 0.75 
12mo ePC(34:1) 5.30 ± 0.48 4.67 ± 0.42 0.88 
12mo ePC(38:0) 3.98 ± 0.21 2.74 ± 0.29 0.69 
12mo ePC(38:4) 3.82 ± 0.15 3.08 ± 0.16 0.81 
12mo ePC(38:6) 1.10 ± 0.07 0.77 ± 0.12 0.70 
12mo ePC(40:6) 1.63 ± 0.10 1.01 ± 0.10 0.62 
12mo PC(32:0) 14.61 ± 1.01 10.24 ± 0.53 0.70 
12mo PC(34:0) 5.46 ± 0.15 3.74 ± 0.08 0.69 
12mo PC(34:3) 16.55 ± 1.01 11.11 ± 0.65 0.67 
12mo PC(36:5) 8.08 ± 0.39 5.95 ± 0.37 0.74 
12mo PC(40:5) 8.00 ± 0.48 6.18 ± 0.38 0.77 
12mo PC(40:7) 18.92 ± 0.89 13.76 ± 1.08 0.73 
12mo PC(34:1) 99.13 ± 6.93 77.16 ± 7.69 0.78 
12mo PC(34:2) 409.14 ± 13.01 307.73 ± 11.62 0.75 
12mo PC(36:2) 169.98 ± 6.73 133.94 ± 5.78 0.79 
12mo PC(36:3) 78.69 ± 3.82 65.02 ± 3.93 0.83 
12mo PC(36:4) 209.58 ± 7.19 162.76 ± 5.78 0.78 
12mo PC(38:4) 125.04 ± 4.82 96.45 ± 6.23 0.77 
12mo PC(38:5) 48.04 ± 2.35 39.36 ± 1.39 0.82 
12mo PC(38:6) 141.46 ± 5.19 95.52 ± 7.17 0.68 
12mo PC(40:6) 42.15 ± 1.19 29.45 ± 2.79 0.70 
24mo ePC(34:2) 0.14 ± 0.05 0.47 ± 0.06 3.24 
24mo ePC(36:1) 0.70 ± 0.06 0.56 ± 0.03 0.80 
24mo ePC(38:0) 1.48 ± 0.17 0.86 ± 0.12 0.58 
24mo PC(32:1) 2.75 ± 0.33 1.44 ± 0.24 0.52 
24mo PC(32:2) 0.50 ± 0.09 0.23 ± 0.05 0.46 
24mo PC(34:3) 5.12 ± 0.64 3.41 ± 0.40 0.67 
24mo PC(36:1) 9.19 ± 0.78 6.41 ± 0.69 0.70 
24mo PC(36:5) 2.94 ± 0.31 1.85 ± 0.24 0.63 
24mo PC(40:4) 0.88 ± 0.11 0.63 ± 0.04 0.72 
24mo PC(40:5) 3.76 ± 0.38 2.94 ± 0.25 0.78 
24mo PC(40:7) 9.78 ± 0.98 6.34 ± 0.62 0.65 
24mo PC(40:8) 2.75 ± 0.28 1.83 ± 0.22 0.67 
24mo PC(34:1) 48.24 ± 4.69 31.75 ± 5.15 0.66 
24mo PC(34:2) 122.13 ± 14.06 96.28 ± 7.33 0.79 
24mo PC(36:3) 36.53 ± 4.61 25.47 ± 2.11 0.70 
24mo PC(38:5) 23.96 ± 2.14 16.74 ± 1.73 0.70 
24mo PC(38:6) 42.90 ± 3.67 34.05 ± 3.14 0.79 
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Chapter 4 table 3: Plasma levels of LPC molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints. 
Time-post injury LPC species Control mTBI mTBI/Control ratios 
24h LPC(16:1) 5.36 ± 0.49 3.65 ± 0.74 0.68 
3mo LPC(0-20:0) 1.89 ± 0.17 1.07 ± 0.24 0.57 
3mo LPC(16:1) 7.82 ± 0.55 6.12 ± 0.26 0.78 
3mo LPC(16:0) 239.39 ± 13.87 167.44 ± 8.63 0.70 
3mo LPC(18:0) 118.91 ± 9.34 85.15 ± 8.32 0.72 
3mo LPC(18:1) 71.42 ± 6.57 50.26 ± 2.87 0.70 
3mo LPC(18:2) 164.71 ± 12.90 112.02 ± 7.42 0.68 
3mo LPC(20:4) 65.65 ± 6.83 42.45 ± 2.23 0.65 
3mo LPC(22:6) 25.66 ± 2.85 17.44 ± 1.16 0.68 
6mo LPC(16:1) 8.43 ± 1.09 6.16 ± 0.75 0.73 
6mo LPC(22:6) 28.44 ± 4.69 18.84 ± 2.99 0.66 
24mo LPC(0-16:0) 1.44 ± 0.26 0.78 ± 0.15 0.54 
24mo LPC(16:1) 8.31 ± 1.47 4.07 ± 0.57 0.49 
24mo LPC(20:3) 9.59 ± 1.42 5.95 ± 0.98 0.62 
24mo LPC(16:0) 180.70 ± 24.32 131.93 ± 12.37 0.73 
24mo LPC(18:1) 84.68 ± 12.89 52.47 ± 8.10 0.62 
24mo LPC(18:2) 124.21 ± 21.50 86.35 ± 7.54 0.70 
 
 
Chapter 4 table 4: Plasma levels of PE molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints. 
Time-post injury PE species Control mTBI mTBI/Control ratios 
24h ePE(38:4) 1.12 ± 0.17 1.65 ± 0.09 1.48 
24h ePE(38:5) 1.60 ± 0.20 2.29 ± 0.12 1.43 
24h ePE(38:6) 1.79 ± 0.20 2.64 ± 0.18 1.48 
24h ePE(40:5) 0.75 ± 0.10 1.04 ± 0.07 1.40 
24h ePE(40:6) 2.31 ± 0.30 3.49 ± 0.27 1.51 
24h PE(38:0) 2.24 ± 0.28 3.14 ± 0.17 1.40 
3mo ePE(36:2) 1.18 ± 0.11 0.83 ± 0.05 0.70 
3mo ePE(36:4) 1.58 ± 0.24 1.00 ± 0.12 0.63 
3mo ePE(38:4) 1.73 ± 0.16 1.20 ± 0.04 0.70 
3mo ePE(38:5) 2.42 ± 0.21 1.70 ± 0.08 0.70 
3mo ePE(40:4) 2.23 ± 0.17 1.76 ± 0.10 0.79 
3mo ePE(40:5) 1.21 ± 0.11 0.87 ± 0.06 0.72 
3mo ePE(40:6) 2.99 ± 0.27 2.29 ± 0.11 0.77 
3mo PE(34:1) 0.26 ± 0.06 0.15 ± 0.04 0.56 
3mo PE(34:2) 1.64 ± 0.14 1.05 ± 0.14 0.64 
3mo PE(36:2) 3.35 ± 0.31 2.31 ± 0.27 0.69 
3mo PE(36:3) 1.59 ± 0.12 1.08 ± 0.13 0.68 
3mo PE(36:4) 2.90 ± 0.19 2.02 ± 0.17 0.70 
3mo PE(38:0) 3.21 ± 0.30 2.19 ± 0.10 0.68 
3mo PE(38:1) 0.66 ± 0.07 0.45 ± 0.04 0.68 
3mo PE(38:3) 0.45 ± 0.04 0.31 ± 0.03 0.69 
3mo PE(38:4) 5.10 ± 0.34 3.73 ± 0.19 0.73 
3mo PE(38:5) 3.69 ± 0.33 2.86 ± 0.20 0.77 
3mo PE(38:6) 6.00 ± 0.45 4.50 ± 0.23 0.75 
3mo PE(40:5) 1.01 ± 0.12 0.64 ± 0.08 0.63 
3mo PE(40:6) 1.89 ± 0.19 1.35 ± 0.07 0.72 
3mo PE(42:6) 0.38 ± 0.03 0.23 ± 0.03 0.60 
12mo ePE(36:2) 1.28 ± 0.09 0.93 ± 0.10 0.72 
12mo ePE(38:4) 2.07 ± 0.11 1.32 ± 0.13 0.64 
12mo ePE(38:5) 2.70 ± 0.15 2.02 ± 0.17 0.75 
 40 
12mo ePE(38:6) 2.23 ± 0.10 1.58 ± 0.13 0.71 
12mo ePE(40:4) 2.46 ± 0.21 1.86 ± 0.21 0.75 
12mo ePE(40:5) 1.39 ± 0.10 1.00 ± 0.10 0.72 
12mo ePE(40:6) 3.21 ± 0.15 2.34 ± 0.22 0.73 
12mo PE(34:2) 1.70 ± 0.11 1.25 ± 0.15 0.74 
12mo PE(36:2) 3.66 ± 0.26 2.85 ± 0.33 0.78 
12mo PE(36:4) 2.73 ± 0.20 1.94 ± 0.13 0.71 
12mo PE(38:0) 3.49 ± 0.14 2.59 ± 0.20 0.74 
12mo PE(38:1) 0.84 ± 0.07 0.49 ± 0.05 0.58 
12mo PE(38:3) 0.45 ± 0.03 0.33 ± 0.03 0.74 
12mo PE(38:4) 5.50 ± 0.36 3.65 ± 0.32 0.66 
12mo PE(38:5) 3.58 ± 0.27 2.51 ± 0.21 0.70 
12mo PE(38:6) 5.96 ± 0.42 3.35 ± 0.41 0.56 
12mo PE(40:6) 2.03 ± 0.13 1.24 ± 0.13 0.61 
12mo PE(40:7) 1.62 ± 0.16 0.90 ± 0.11 0.56 
12mo PE(42:5) 0.33 ± 0.05 0.22 ± 0.02 0.65 
12mo PE(42:6) 0.46 ± 0.03 0.33 ± 0.03 0.71 
24mo ePE(40:4) 1.06 ± 0.11 0.87 ± 0.06 0.81 
24mo ePE(40:5) 0.44 ± 0.07 0.32 ± 0.01 0.72 
24mo PE(38:5) 1.36 ± 0.14 1.06 ± 0.05 0.79 
24mo PE(38:6) 1.61 ± 0.13 1.21 ± 0.07 0.75 
 
 
Chapter 4 table 5: Plasma levels of LPE molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints. 
Time-post injury LPE species Control mTBI mTBI/Control ratios 
3mo LPE(16:0) 8.83 ± 0.70 4.79 ± 0.61 0.54 
3mo LPE(18:1) 3.05 ± 0.37 2.01 ± 0.29 0.66 
6mo LPE(16:0) 7.64 ± 0.87 4.28 ± 1.05 0.56 
12mo LPE(22:6) 6.95 ± 0.51 4.36 ± 0.34 0.63 
24mo LPE(18:1) 2.45 ± 0.39 1.82 ± 0.20 0.74 
24mo LPE(18:2) 4.57 ± 0.81 2.76 ± 0.26 0.60 
24mo LPE(18:3) 0.09 ± 0.03 0.03 ± 0.02 0.39 
24mo LPE(20:4) 6.19 ± 0.80 3.62 ± 0.33 0.59 
24mo LPE(22:6) 5.57 ± 0.67 3.15 ± 0.27 0.57 
 
 
 
Chapter 4 table 6: Plasma levels of PI molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints. 
Time-post injury PI species Control mTBI mTBI/Control ratios 
24h PI(34:2) 8.12 ± 0.57 5.83 ± 0.61 0.72 
24h PI(36:3) 6.15 ± 0.38 4.82 ± 0.34 0.78 
24h PI(36:4) 18.97 ± 1.05 13.18 ± 1.06 0.69 
3mo PI(36:3) 7.18 ± 0.52 5.22 ± 0.51 0.73 
3mo PI(38:4) 136.92 ± 12.69 98.62 ± 13.21 0.72 
3mo PI(38:5) 12.50 ± 1.24 8.72 ± 0.84 0.70 
3mo PI(37:4) 1.52 ± 0.08 1.08 ± 0.09 0.71 
3mo PI(38:2) 1.00 ± 0.07 0.69 ± 0.08 0.69 
3mo PI(38:6) 1.71 ± 0.10 1.27 ± 0.12 0.74 
3mo PI(40:7) 0.50 ± 0.02 0.38 ± 0.03 0.75 
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3mo PI(42:3) 2.94 ± 0.39 1.98 ± 0.27 0.67 
12mo PI(34:2) 8.99 ± 1.04 6.07 ± 0.63 0.68 
12mo PI(36:2) 17.30 ± 1.84 11.58 ± 0.98 0.67 
12mo PI(36:3) 7.93 ± 0.96 5.54 ± 0.61 0.70 
12mo PI(38:3) 18.97 ± 2.55 12.49 ± 2.31 0.66 
12mo PI(38:4) 160.53 ± 18.35 110.95 ± 18.61 0.69 
12mo PI(38:2) 1.36 ± 0.12 0.92 ± 0.13 0.68 
12mo PI(40:5) 2.63 ± 0.34 1.90 ± 0.26 0.72 
12mo PI(40:6) 4.03 ± 0.43 2.97 ± 0.31 0.74 
24mo PI(36:4) 8.17 ± 0.89 5.78 ± 0.47 0.71 
24mo PI(38:3) 8.65 ± 1.25 5.11 ± 0.62 0.59 
24mo PI(38:4) 64.19 ± 6.38 48.38 ± 5.19 0.75 
24mo PI(38:5) 8.89 ± 1.08 5.91 ± 0.63 0.66 
24mo PI(36:6) 1.86 ± 0.22 1.20 ± 0.18 0.64 
24mo PI(38:2) 0.58 ± 0.11 0.39 ± 0.04 0.67 
24mo PI(38:6) 0.86 ± 0.11 0.66 ± 0.07 0.76 
24mo PI(40:4) 1.46 ± 0.20 0.75 ± 0.07 0.51 
24mo PI(40:5) 1.46 ± 0.22 1.04 ± 0.10 0.71 
 
Chapter 4 table 7: Plasma levels of SM molecular species quantified by LC/MS analyses (µM± SEM). 
Phospholipids presented in each table are those that were significantly associated with PCA component within each 
class that was significantly associated with mTBI at given timepoints 
 
Time-post injury SM species Control mTBI mTBI/Control ratios 
6mo DSM(16:0) 0.65 ± 0.06 0.36 ± 0.02 0.56 
6mo DSM(18:0) 0.79 ± 0.09 0.37 ± 0.08 0.46 
6mo SM(18:0) 5.59 ± 0.64 0.64 ± 0.34 0.12 
24mo DSM(16:0) 0.19 ± 0.05 0.25 ± 0.02 1.36 
24mo DSM(18:0) 0.15 ± 0.04 0.20 ± 0.01 1.36 
24mo SM(18:0) 1.84 ± 0.24 1.25 ± 0.08 0.68 
24mo SM(22:1) 2.76 ± 0.35 2.15 ± 0.12 0.78 
24mo SM(24:0) 2.97 ± 0.45 1.79 ± 0.17 0.60 
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Chapter 5 
Section 1 – Neurocognitive Measures 
Visual Analog Scale (VAS) 
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Multi-dimensional Fatigue Inventory (MFI-20) 
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MOS Short Form 36-veteran version (SF-36V) 
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Profile of Mood States (POMS) 
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Section 2 – Supplemental tables 
Chapter 5 table 1: Total plasma levels for mice and rat model of PC, LPC, PE, LPE, PI and SM quantified by 
LC/MS analyses (Percentage of control± SEM). Individual molecular species of each class were quantified by 
LC/MS and summed after lipidomeDB analyses to generate total lipid levels. *denotes significant p values for p<0.05. 
 
 Mouse model Rat model 
 Control PB+PER exposed Control PB+PER+DEET+Stress 
total PC 100 ± 3.35 101.71 ± 5.92 100 ± 4.84 230.44 ± 11.94* 
total LPC 100 ± 2.92 121.48 ± 4.09* 100 ± 6.04 160.84 ± 6.91* 
total PE 100 ± 4.73 97.13 ± 5.43 100 ± 3.38 142.82 ± 5.63* 
total LPE 100 ± 2.77 112.12 ± 5.57* 100 ± 2.15 94.87 ± 2.26 
total PI 100 ± 2.60 106.33 ± 3.19 100 ± 4.96 239.53 ± 10.84* 
total SM 100 ± 2.58 104.05 ± 2.94 100 ± 5.66 184.15 ± 7.56 
 
 
Chapter 5 table 2: Plasma levels for mice and rat model of SFA, MUFA and PUFA containing PC, LPC, PE, 
LPE and PI species quantified by LC/MS analyses (Percentage of control± SEM). *denotes significant p values for 
p<0.05. 
  Mouse model Rat model 
  Control PB+PER  Control PB+PER+DEET+Stress  
PC SFA 100 ± 4.43 99.45 ± 7.31 100 ± 2.18 219.45 ± 9.63* 
 MUFA 100 ± 5.05 121.45 ± 12.81 100 ± 4.02 222.58 ± 12.22* 
 PUFA 100 ± 3.95 97.44 ± 6.08 100 ± 5.99 236.86 ± 15.09* 
LPC SFA 100 ± 3.12 115.89 ± 3.55* 100 ± 6.39 147.57 ± 6.63* 
 MUFA 100 ± 3.34 135.39 ± 10.24* 100 ± 4.64 172.86 ± 6.45* 
 PUFA 100 ± 4.14 127.21 ± 4.58* 100 ± 6.05 184.28 ± 8.65* 
PE SFA 100 ± 5.80 94.04 ± 4.47* 100 ± 5.88 161.83 ± 7.62* 
 MUFA 100 ± 3.25 103.91 ± 7.26 100 ± 3.49 128.50 ± 3.55* 
 PUFA 100 ± 5.01 95.75 ± 5.20* 100 ± 3.38 143.03 ± 6.55* 
LPE SFA 100 ± 4.78 105.08 ± 4.75 100 ± 11.16 50.42 ± 20.60* 
 MUFA 100 ± 4.26 105.10 ± 6.87 100 ± 1.74 96.11 ± 1.90 
 PUFA 100 ± 3.20 116.46 ± 7.08 100 ± 11.83 105.98 ± 19.89 
PI SFA 100 ± 13.77 113.27 ± 14.56 100 ± 12.32 129.48 ± 6.89* 
 MUFA 100 ± 4.99 113.60 ± 5.72 100 ± 12.37 36.37 ± 1.78* 
 PUFA 100 ± 2.47 105.84 ± 3.45 100 ± 5.31 241.51 ± 11.38* 
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Chapter 5 table 3: Plasma levels for mice and rat model of ether containing PC, LPC, PE and LPE  species 
quantified by LC/MS analyses (Percentage of control± SEM) *denotes significant p values for p<0.05. 
 
 Mouse model  Rat model 
 Control   PB+PER    Control   PB+PER+DEET+Stress  
ePC 100 4.98 ± 96.80 ± 8.90 100 ± 5.37 226.37 ± 11.92* 
eLPC 100 5.14 ± 100.61 ± 6.86 100 ± 4.36 144.96 ± 4.04* 
ePE 100 4.05 ± 96.56 ± 4.26 100 ± 7.19 129.74 ± 4.91* 
eLPE 100 4.64 ± 104.87 ± 7.42 100 ± 1.74 96.11 ± 1.90 
 
Chapter 5 table 4: Plasma levels for mice and rat model of AA, DHA and AAtoDHA ratios containing PC, LPC, 
PE and LPE species quantified by LC/MS analyses (Percentage of control± SEM). No DHA containing LPE 
species were identified for the rat model, therefore ratio for AAtoDHA containing LPE species could not be 
determined.*denotes significant p values for p<0.05. 
  Mouse model Rat model 
  Control PB+PER Control PB+PER+DEET+Stress 
PC DHA 100 ± 4.53 89.36 ± 5.73 100 ± 6.75 274.99 ± 26.61* 
 AA 100 ± 4.11 97.15 ± 5.40 100 ± 6.04 225.09 ± 12.75* 
LPC DHA 100 ± 5.16 115.56 ± 7.92 100 ± 11.04 230.95 ± 23.45* 
 AA 100 ± 3.88 128.34 ± 4.59* 100 ± 6.77 180.23 ± 11.26* 
PE DHA 100 ± 5.65 89.27 ± 3.99 100 ± 4.97 198.35 ± 14.97* 
 AA 100 ± 5.17 94.32 ± 5.28 100 ± 5.66 160.76 ± 11.38* 
LPE DHA 100 ± 2.89 116.71 ±  8.11 N/A 
 AA 100 ± 3.47 119.89 ± 8.60* 100 ± 31.43 144.36 ± 36.57 
PI DHA 100 ± 2.57 102.78 ± 3.01 100 ± 7.60 286.61 ± 28.20* 
 AA 100 ± 2.19 102.60 ± 3.02 100 ± 6.16 245.68 ± 11.53* 
 
 
 
